0001144204-17-026909.txt : 20170512 0001144204-17-026909.hdr.sgml : 20170512 20170512161759 ACCESSION NUMBER: 0001144204-17-026909 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170512 DATE AS OF CHANGE: 20170512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACURA PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0000786947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 110853640 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-10113 FILM NUMBER: 17838878 BUSINESS ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 CITY: PALATINE STATE: IL ZIP: 60067 BUSINESS PHONE: 847-705-7709 MAIL ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 STREET 2: . CITY: PALATINE STATE: IL ZIP: 60067 FORMER COMPANY: FORMER CONFORMED NAME: HALSEY DRUG CO INC/NEW DATE OF NAME CHANGE: 19920703 10-Q 1 v464992_10q.htm FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20649

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2017

TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________________ to_______________________

Commission File Number 1-10113

Acura Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

New York		11-0853640
(State or other Jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

616 N. North Court, Suite 120
Palatine, Illinois		60067
(Address of Principal Executive Offices)		(Zip Code)

847 705 7709

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 S-T (§232.405 of this charter) during the preceding 12 months (or to such shorter period that the registrant was required to submit and post such files).

Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large” filer, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨		Accelerated filer ¨
Non-accelerated filer ¨		Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

As of May 5, 2017 the registrant had 11,883,339 shares of common stock, $.01 par value, outstanding.

ACURA PHARMACEUTICALS, INC. AND SUBSIDIARY

TABLE OF CONTENTS

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2017

		Page No.

Part 1. FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements:

	Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016 (unaudited)	2

	Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three months Ended March 31, 2017 and March 31, 2016 (unaudited)	3

	Consolidated Statement of Stockholders’ Equity for the Three months Ended March 31, 2017 (unaudited)	4

	Consolidated Statements of Cash Flows for the Three months Ended March 31, 2017 and March 31, 2016 (unaudited)	5

	Notes to Consolidated Financial Statements (unaudited)	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	24

Item 4.	Controls and Procedures	44

Part II. OTHER INFORMATION

Item 1.	Legal Proceedings	44

Item 1A.	Risk Factors	44

Item 6.	Exhibits	45

Signatures		46

Item 1. Financial Statements

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited; in thousands except par value)

	March 31, 2017			December 31, 2016

Assets:
Cash and cash equivalents	$	3,843		$	2,681
Restricted cash equivalents (Note 9)		2,500			2,500
Trade accounts receivable (net of allowances of $27 and $7)		6			23
Collaboration revenue receivable		36			79
Royalty receivable		52			50
Inventories (net of allowances of $- and $32) (Note 6)		-			309
Prepaid expenses and other current assets		301			268

Total current assets		6,738			5,910
Property, plant and equipment, net (Note 7)		739			867
Intangible asset, net of accumulated amortization of $621 and $569 (Note 4)		1,379			1,431

Total assets	$	8,856		$	8,208

Liabilities:
Accounts payable	$	209		$	77
Accrued expenses (Note 8)		1,040			703
Accrued interest		35			-
Other current liabilities		19			27
Sales returns liability		302			304
Debt - current (Note 9)		2,798			2,376

Total current liabilities		4,403			3,487
Debt – non-current portion, net of discounts (Note 9)		2,142			2,979
Accrued interest – non-current portion		598			559

Total liabilities		7,143			7,025

Commitments and contingencies (Note 14)

Stockholders’ equity:
Common stock - $.01 par value per share; 100,000 shares authorized, 11,883 and 11,834 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively		119			118
Additional paid-in capital		375,887			375,763
Accumulated deficit		(374,293	)		(374,698	)

Total stockholders’ equity		1,713			1,183

Total liabilities and stockholders’ equity	$	8,856		$	8,208

See accompanying Notes to Consolidated Financial Statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited; in thousands except per share amounts)

	Three months Ended March 31,
	2017			2016
Revenues:
License fee revenue	$	2,500		$	-
Collaboration revenue		36			100
Royalty revenue		74			17
Product sales, net		107			107
Total revenues, net		2,717			224

Cost and expenses:
Cost of sales		128			102
Research and development		711			1,014
Sales, marketing, general and administrative		1,296			2,246
Total costs and expenses		2,135			3,362

Operating income (loss)		582			(3,138	)

Non-Operating income (expense):
Investment income		1			27
Interest expense (Note 9)		(178	)		(249	)
Other expense		-			(24	)
Total other expense, net		(177	)		(246	)

Income (loss) before provision for income taxes		405			(3,384	)
Provision for income taxes		-			-
Net income (loss)	$	405		$	(3,384	)

Other comprehensive income:
Unrealized gains on securities		-			70
Comprehensive income (loss)	$	405		$	(3,314	)

Income (loss) per share:
Basic	$	0.03		$	(0.28	)
Diluted	$	0.03		$	(0.28	)
Weighted average shares outstanding:
Basic		11,907			11,837
Diluted		12,083			11,837

See accompanying Notes to Consolidated Financial Statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

(Unaudited; in thousands)

					Additional
	Common Stock				Paid-in		Accumulated
	Shares		Par Value		Capital		Deficit			Total
Balance at January 1, 2017		11,834	$	118	$	375,763	$	(374,698	)	$	1,183

Net income		-		-		-		405			405

Share-based compensation		-		-		117		-			117

Net distribution of common stock pursuant to restricted stock unit award plan		49		1		7		-			8

Balance at March 31, 2017		11,883	$	119	$	375,887	$	(374,293	)	$	1,713

See accompanying Notes to Consolidated Financial Statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in thousands)

	Three months Ended March 31,
	2017			2016
Cash Flows from Operating Activities:
Net income (loss)	$	405		$	(3,384	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation		25			34
Provision for sales returns		49			39
Share-based compensation		117			150
Amortization of debt discount and deferred debt issue costs		30			40
Amortization of bond premium in marketable securities		-			19
Amortization of intangible asset		52			52
Loss on sales of marketable securities		-			24
Change in assets and liabilities:
Trade accounts receivable		17			(57	)
Collaboration revenue receivable		43			-
Royalty receivable		(2	)		-
Accrued investment income		-			12
Inventories		103			74
Prepaid expenses and other current assets		(33	)		121
Accounts payable		132			265
Accrued expenses		337			591
Accrued interest		74			99
Other current liabilities		-			1
Sales returns liability		(51	)		(2	)
Net cash provided by (used in) operating activities		1,298			(1,922	)
Cash Flows from Investing Activities:
Proceeds from sales and maturities of marketable securities		-			3,177
Proceeds from transfer of equipment to licensee		103			-
Proceeds from transfer of inventory to licensee		206			-
Capital expenditures		-			(49	)
Net cash provided by investing activities		309			3,128
Cash Flows from Financing Activities:
Principal payments on debt		(445	)		(409	)
Net cash (used in) financing activities		(445	)		(409	)
Net increase in cash, cash equivalents, and restricted cash		1,162			797
Cash, cash equivalents, and restricted cash at beginning of period		5,181			2,485
Cash, cash equivalents, and restricted cash at end of period	$	6,343		$	3,282

Supplemental disclosure of cash flow information:
Cash paid during the year for:
Interest	$	75		$	110
Income taxes	$	-		$	-

See accompanying Notes to Consolidated Financial Statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(Unaudited; in thousands)

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statements of cash flows:

	March 31, 2017		March 31, 2016
	(in thousands)
Cash and cash equivalents	$	3,843	$	782
Restricted cash equivalents		2,500		2,500
Total cash, cash equivalents and restricted cash show in the consolidated statements of cash flows	$	6,343	$	3,282

See accompanying Notes to Consolidated Financial Statements.

ACURA PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2017 AND MARCH 31, 2016

NOTE 1 – OPERATIONS

Principal Operations

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® and Limitx™ Technologies are intended to address methods of product tampering associated with opioid abuse while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine.

Oxaydo® Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first and only approved immediate-release oxycodone product in the United States with abuse deterrent labeling. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo®. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. (see Note 4).

Nexafed® Tablets (30mg pseudoephedrine) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine and acetaminophen), utilizing the Impede Technology, were launched by us into the United States market in December 2012 and February 2015, respectively. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC entered into a License and Development Agreement pursuant to which we granted Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine – containing product and providing for the joint development of such product using our Impede Technology for the U.S. market. On March 16, 2017, we and MainPointe Pharmaceuticals, LLC (“MainPointe”), entered into a License, Commercialization and Option Agreement (“MainPointe Agreement”), pursuant to which we granted MainPointe an exclusive license to our Impede technology in the United States and Canada to commercialize our Nexafed products. The MainPointe Agreement also grants MainPointe the option to expand the licensed territory to the European Union, Japan and South Korea and to add additional pseudoephedrine-containing products utilizing our Impede technology. (see Note 4).

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The going concern basis of presentation assumes that we will continue in operation for the next twelve months and will be able to realize our assets and discharge our liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. At March 31, 2017, we had unrestricted cash and cash equivalents of $3.8 million, working capital deficit of $0.2 million and an accumulated deficit of $374.3 million. Though we had income from operations of $0.6 million and net income of $0.4 million for the three months ended March 31, 2017, we have suffered annual losses from operations in prior years and have not generated or have generated limited annual positive cash flows from operations. Our current unrestricted cash and cash equivalents will not be sufficient to fund the development of our products and our related operating expenses beyond mid-2017 while maintaining compliance with the $2.5 million compensating balance requirement under our term loan with Oxford Finance LLC or Oxford.

In addition to our $2.5 million cash reserve requirement, our term loan agreement with Oxford contains customary affirmative and negative covenants. One such covenant is that the Company must submit on an annual basis to Oxford, within 120 days after the end of its fiscal year, audited consolidated financial statements, together with an unqualified audit opinion from an independent registered public accounting firm, or the Unqualified Audit Opinion Covenant. Per the term loan agreement an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business (the “going concern opinion”) is deemed to violate the Unqualified Audit Opinion Covenant. Failure to comply with the Unqualified Audit Opinion Covenant is a breach of the term loan agreement and unless such covenant or breach is waived, Oxford would have the option of accelerating the debt under the term loan agreement and initiating enforcement collection actions, foreclosing on collateral (which includes most assets of the Company) and, among other things, preventing the Company from using any funds in its bank or securities accounts. On March 16, 2017, we and Oxford entered into a third amendment to the Loan Agreement, or the Third Amendment. Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement.

However, these factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. To fund further operations and product development activities beyond mid-2017, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. The Company intends to explore a variety of capital raising and other transactions to provide additional funding to continue operations. These include a registered public offering of the Company’s common stock, for which the Company filed a registration statement on Form S-1 with the SEC on February 3, 2017, and potential private offerings of common stock to institutional investors. The Company is also actively seeking a licensing partner for its Limitx Technology, with the objective of receiving an upfront license fee, development milestone payments and royalties on the net sales of products utilizing the Limitx Technology, similar to the Egalet and Bayer Agreements. The Company is also exploring licensing or selling select assets and intellectual property in an effort to raise capital and reduce operating expenses. Finally, the Company is evaluating the potential for a strategic transaction which may involve the Company being acquired in a merger or asset purchase transaction. No assurance can be given that we will be successful in completing any one or more of such transactions on acceptable terms, if at all, or if completed, that such transactions will provide payments to the Company sufficient to fund continued operations. In the absence of the Company’s completion of one or more of such transactions, there will be substantial doubt about the Company’s ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations.

In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS

Revenue from Contracts with Customers

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and related disclosures and have not yet determined the transition method we will utilize to adopt the standard for use in 2018.

Inventories

In July 2015, the FASB issued ASU No. 2015-11, which amended Accounting Standards Codification (“ASC”) Topic 330 Inventory. The amendment simplifies the measurement of inventory, applying to inventories for which cost is determined by methods other than last-in first-out (LIFO) and the retail inventory method (RIM), specifying that an entity should measure inventory at the lower of cost and net realizable value instead of at the lower of cost or market. The amendments in this ASU were effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016. The Company adopted the guidance of the standard in the first quarter of 2017 which did not have a material impact on the Company’s consolidated financial statements.

Leases

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018 but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements and related footnote disclosures, and has not yet determined what effect, if any, the impact of adoption will be.

Employee Share-Based

In March 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting, which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 is to be applied either prospectively, retrospectively or using a modified retrospective transition approach depending on the area covered in this update. The new standard was effective for annual and interim periods, within those fiscal years, beginning after December 15, 2016. The Company adopted the guidance in the first quarter of 2017 which did not have a material impact on the Company’s consolidated financial statements.

Intra-Entity Transfers of Assets Other Than Inventory

In October 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 eliminates from Topic 740, Income Taxes, the recognition exception for intra-entity asset transfers other than inventory so that an entity’s consolidated financial statements reflect the current and deferred tax consequences of those intra-entity asset transfers when they occur. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements and related footnote disclosures, and has not yet determined what effect, if any, the impact of adoption will be.

Statement of Cash Flows - Restricted Cash

In November 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-18, Statements of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that at statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2017 but early adoption is permitted. The Company early adopted the guidance in the first quarter of 2017 which did not have a material impact on the Company’s consolidated financial statements or related footnote disclosures.

NOTE 3 – LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

MainPointe Agreement

On March 16, 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement.

On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million plus approximately $309 thousand for inventories and equipment being transferred to them. They also paid us $117 thousand for Nexafed inventory under manufacture by one of our contract manufacturing organizations. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country.

MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing pseudoephedrine (“PSE”) and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.

The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura.

KemPharm Agreement

On October 13, 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities.

Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free.

The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm.

Bayer Agreement

On June 15, 2015, we and Bayer entered into a License and Development Agreement (the “Bayer Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine–containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Bayer Agreement also grants Bayer first right to negotiate a license to the Impede Technology for certain other products.

We and Bayer have formed a joint development committee to coordinate development of the Bayer Licensed Product. We are eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed Product in countries with patent coverage and a reduced royalty elsewhere.

The term of the Bayer Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Bayer Agreement in its entirety if the other party materially breaches the Bayer Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Bayer Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Bayer Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time.

Egalet Agreement

On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.

Egalet paid us a $5.0 million license fee upon signing of the Egalet Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.

Terminated Pfizer Agreement

In 2007, we entered into License, Development and Commercialization Agreement for Oxaydo (named Oxecta™ under a Pfizer trademark) and other Aversion opioid development products with King Pharmaceuticals Research and Development, Inc., which became a subsidiary of Pfizer in 2011 (the “Pfizer Agreement”). In April 2014, we entered into two letter agreements with Pfizer providing for the termination of the Pfizer Agreement and the return to us of Oxaydo and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our consolidated financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Oxaydo, which is 9.7 years. During each of the three months ended March 31, 2017 and 2016, we recorded amortization expense of $52 thousand. Annual amortization of the patent for years 2017 through 2021 is expected to approximate $207 thousand.

NOTE 4 – REVENUE RECOGNITION

License Fee Revenue

On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The payment was non-refundable and non-creditable when made and we had no further requirements to earn the payment. The amount was recognized as revenue when received (see Note 3).

Milestone Revenue

Milestone revenue is contingent upon the achievement of certain pre-defined events in the development agreements. Milestone payments are recognized as revenue upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to that milestone. Milestone payments are triggered either by the results of our research and development efforts or by events external to us, such as regulatory approval to market a product. As such, the milestones are substantially at risk at the inception of an agreement, and the amounts of the payments assigned thereto are commensurate with the milestone achieved. In addition, upon the achievement of a milestone event, we have no future performance obligations related to that milestone payment. Each milestone payment is non-refundable and non-creditable when made and is recognized as revenue when received.

Collaboration Revenue

Collaboration revenue is derived from research and development services we provide, such as under our agreement with Bayer, and are recognized when those services are incurred pursuant to the agreements. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the service’s hourly rates pursuant to the collaboration agreement. We recognized $36 thousand and $100 thousand of collaboration revenue during the three months ended March 31, 2017 and 2016, respectively.

Royalty Revenue

In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year over the term of the agreement (excluding net sales resulting from any co-promotion efforts by us). We recognize royalty revenue each calendar quarter based on net sales reported to us by Egalet in accordance with the agreement. We have recorded royalties of $72 thousand and $17 thousand on net sales for the three months ended March 31, 2017 and 2016, respectively. (see Note 3).

In connection with our License, Commercialization and Option Agreement with MainPointe, which occurred on March 16, 2017, we will receive a royalty of 7.5% on net sales of the licensed products over the term of the agreement. Such royalty shall be payable for sales made during each calendar quarter and payment will be remitted within forty-five (45) days after the end of the quarter to which it relates. We have recorded royalties of $2 thousand on net sales for the three months ended March 31, 2017 (see Note 3).

Product Sales

Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. Prior to entering into the MainPointe Agreement, we sold our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products were sold subject to the right of return usually for a period of up to twelve months after the product expiration. Both products had an initial shelf life of twenty-four months from the date of manufacture, which shelf life had been extended to thirty-six months for Nexafed product supplied to us during 2016 from one of the Company’s contract manufacturers. Prior to entering into the MainPointe Agreement, we recognized revenue from our Nexafed product line sales when the price was fixed and determinable at the date of sale, title and risk of ownership were transferred to the customer, and returns could be reasonably estimated, which generally occurred at the time of product shipment.

Shipping and Handling Costs

We record shipping and handling costs in selling expenses. The amounts recorded to selling expenses from the shipments of the Nexafed product line during each of the three month periods ended March 31, 2017 and 2016 were not material. As of mid-March 2017 we no longer manufacture, distribute or sell the Nexafed product line as the Company granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada.

NOTE 5 – RESEARCH AND DEVELOPMENT ACTIVITIES

Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. During 2015, we entered into a cancelable arrangement for contract manufacturing services on a project to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablet while moving supply to an alternate contract manufacturer. Approximately $50 thousand was remaining under this agreement at both March 31, 2017 and December 31, 2016. At March 31, 2017 our remaining obligations under cancelable CRO arrangements were approximately $0.1 million, for services to be incurred as subjects are enrolled and progress through the studies and the final study reports are completed. We did not have prepaid CRO costs or prepaid clinical trial study expenses at either March 31, 2017 or December 31, 2016.

NOTE 6 – INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. We write down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.

Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.

Inventories at December 31, 2016 are summarized as follows:

	December 31,
	2016
	(in thousands)
Raw and packaging materials	$	98
Finished goods		243
Total		341
Less: reserve for finished goods		(32	)
Net inventories	$	309

NOTE 7 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at March 31, 2017 and December 31, 2016 are summarized as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Building and improvements	$	1,273		$	1,273
Scientific equipment		598			598
Computer hardware and software		109			109
Machinery and equipment		415			568
Land and improvements		162			162
Other personal property		70			70
Office equipment		27			27
Total		2,654			2,807
Less: impairment reserve		(82	)		(82	)
Less: accumulated depreciation		(1,833	)		(1,858	)
Net property, plant and equipment	$	739		$	867

The impairment reserve of $82 thousand is for our remaining Nexafed production machinery and other equipment which was not conveyed to MainPointe under the MainPointe Agreement. We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.

NOTE 8 – ACCRUED EXPENSES

Accrued expenses at March 31, 2017 and December 31, 2016 are summarized as follows:

	March 31,		December 31,
	2017		2016
	(in thousands)
Cost sharing expenses under license agreement	$	269	$	150
Advanced expense reimbursements under license agreements		209		-
Other fees and services		51		47
Payroll, payroll taxes and benefits		173		116
Professional services		173		232
Clinical, non-clinical and regulatory services		136		131
Marketing, advertising, and promotion		5		10
Property taxes		18		16
Franchise taxes		6		1
Total	$	1,040	$	703

NOTE 9 – DEBT

On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest−only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As security for its obligations under the initial Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after−acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the warrants was lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the warrant modification, (ii) we agreed to maintain $2.5 million cash reserves until such time as we have repaid $5.0 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.

On October 13, 2016, we and Oxford entered into a second amendment to the Loan Agreement (the “Second Amendment”). Pursuant to the Second Amendment, (i) the requirement that we maintain a $2.5 million cash balance reserve until such time as $5.0 million in principal was repaid under the Term Loan has been modified so that the $2.5 million cash balance reserve remains in place until we raise an additional $6.0 million (excluding payments received under the KemPharm Agreement) through the issuance of equity securities and from upfront payments under license, joint venture, collaboration or other partnering transactions, provided that at least $3.0 million of such amount must be raised through the issuance and sale of our equity securities, and (ii) the Lender consented to the terms of our Agreement with KemPharm.

On March 16, 2017, we and Oxford entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement. Under the Loan Agreement, an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business is deemed to violate the Unqualified Audit Opinion Covenant.

The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 1% of the principal prepaid. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We are accruing additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate. As of March 31, 2017 and December 31, 2016, we have accumulated and accrued $598 thousand and $559 thousand, respectively, of additional interest.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate of 10.16%.

The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non−payment defaults, covenant defaults (including breach of the Unqualified Audit Opinion Covenant), a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.

Our debt at March 31, 2017 is summarized below (in thousands):

Current Debt	Current			Long-term			Total
Balance at Jan. 1, 2017	$	2,521		$	2,979		$	5,500
Principal payments		(445	)		-			(445	)
Classification		722			(722	)		-
Balance at Mar. 31, 2017	$	2,798		$	2,257		$	5,055

Debt Discount	Current		Long-term			Total
Balance at Jan. 1, 2017	$	-	$	(98	)	$	(98	)
Amortization expense		-		20			20
Classification		-		-			-
Balance at Mar. 31, 2017	$	-	$	(78	)	$	(78	)

Deferred Debt Issuance Costs	Current		Long-term			Total
Balance at Jan. 1, 2017	$	-	$	(47	)	$	(47	)
Amortization expense		-		10			10
Classification		-		-			-
Balance at Mar. 31, 2017	$	-	$	(37	)	$	(37	)

Current Debt, net at Mar 31, 2017	$	2,798	$	2,142		$	4,940

Our interest expense for the three months ended March 31, 2017 and 2016 consisted of the following:

	March 31,		March 31,
	2017		2016
	(in thousands)
Term Loan	$	148	$	209
Debt discount		20		26
Debt issue costs		10		14
Total interest expense	$	178	$	249

The annual principal payments of the debt outstanding at March 31, 2017 are as follows:

	Annual Principal Payments
Year	(in thousands)
2017	$	2,077
2018		2,978
Total	$	5,055

NOTE 10 – COMMON STOCK WARRANTS

At both March 31, 2017 and 2016, we have outstanding common stock purchase warrants (“warrants”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. See Note 9 for a discussion of the reduction of the exercise price of these warrants to $2.52 per share which were originally issued to the Lender in connection with the issuance of the $10.0 million secured promissory notes in December 2013. The warrants contain a cashless exercise feature.

NOTE 11 – SHARE-BASED COMPENSATION

Share-based Compensation

We have four share-based compensation plans covering stock options and RSUs for our employees and directors.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations from all types of issued instruments comprised the following (in thousands):

	Three Months Ended March 31,
	2017		2016
Research and development expense:
Stock options	$	34	$	43
Restricted stock units		-		-
Subtotal	$	34	$	43

General and administrative expense:
Stock options		53		77
Restricted stock units		30		30
Subtotal	$	83	$	107
Total	$	117	$	150

Stock Option Award Plans

We maintain various stock option plans. A summary of our stock option plan activity during the three month periods ending March 31, 2017 and 2016 is shown below:

	Three Months Ended March 31,
	2017						2016
	Number of Options (000’s)			Weighted Average Exercise Price			Number of Options (000’s)		Weighted Average Exercise Price
Outstanding, Jan. 1		1,397		$	13.57			1,198	$	15.67
Granted		-			-					--
Exercised		(1	)		(0.92	)				--
Forfeited or expired		-			-					--
Outstanding, Mar. 31		1,396		$	13.58			1,198	$	15.67
Options exercisable		1,125		$	16.52			876	$	20.64

The following table summarizes information about nonvested stock options outstanding at March 31, 2017 (in thousands except price data):

	Number of Options Not Exercisable			Weighted Average Fair Value

Outstanding, Jan. 1, 2017		335		$	1.18
Granted		-			-
Vested		(64	)		1.36
Forfeited		-			-
Outstanding, Mar. 31, 2017		271		$	1.14

We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date.

The assumptions used in the Black-Scholes model to determine fair value for the 2016 stock option grant were:

	2016
Expected dividend yield		0.0	%
Risk-free interest rates		2.3	%
Average expected volatility		85	%
Expected term (years)		10
Weighted average grant date fair value	$	0.77

The intrinsic value of the option awards which were vested and outstanding at March 31, 2017 and 2016 was $0 thousand and $70 thousand, respectively. The total remaining unrecognized compensation cost on unvested option awards outstanding at March 31, 2017 was $309 thousand, and is expected to be recognized in operating expense in varying amounts over the 20 months remaining in the requisite service period.

Restricted Stock Unit Award Plan

We have a Restricted Stock Unit Award Plan (the “2014 RSU Plan”) for our employees and non-employee directors. Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award.

A summary of the grants under the RSU Plans consisted of the following:

	Three months Ended March 31,
	2017						2016
	(in thousands)
	Number of RSUs			Number of Vested RSUs			Number of RSUs			Number of Vested RSUs
Outstanding, Jan. 1		91			91			45			45
Granted		238			-			88			-
Distributed		(67	)		(67	)		(42	)		(42	)
Vested		-			59			-			22
Forfeited or expired		-			-			-			-
Outstanding, Mar. 31		262			83			91			25

Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of March 31, 2017, three thousand shares are available for award under the 2014 RSU Plan.

Information about the awards under the 2014 RSU Plan is as follows:

On January 2, 2015, we awarded approximately 10 thousand RSUs to each of our four non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2015. The RSU awards subject to cash settlement are subject to marked-to market accounting. Distributions of stock under the January 2, 2015 award cannot be deferred until a later date and the stock under such awards were distributed on January 4, 2016.

On January 4, 2016, we awarded approximately 22 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2016. The portion of the RSU awards which are subject to cash settlement are also subject to marked-to market accounting and the liability recorded in the Company’s balance sheet as an estimate for such cash settlement was $27 thousand at December 31, 2016. Distributions of stock under the January 4, 2016 award are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.

On January 3, 2017, we awarded approximately 60 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2017. The portion of the RSU awards which are subject to cash settlement are also subject to marked-to market accounting and the liability recorded in the Company’s balance sheet as an estimate for such cash settlement was $19 thousand at March 31, 2017. Distributions of stock under the January 3, 2017 award are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.

Information about the distribution of shares under the 2014 RSU Plan is as follows:

On January 4, 2016, 1 thousand RSUs from the May 1, 2014 award and 41 thousand RSUs from the January 2, 2015 award were distributed. There are 2 thousand RSUs from the May 1, 2014 award which remain deferred until a future distribution date. Of the 42 thousand RSUs distributed, 33 thousand RSUs were distributed in common stock and 9 thousand RSUs were settled in cash.

On January 3, 2017, 1 thousand RSUs from the May 1, 2014 award and 66 thousand RSUs from the January 4, 2016 award were distributed. There are 1 thousand RSUs from the May 1, 2014 award and 22 thousand RSUs from the January 4, 2016 award which remain deferred until a future distribution date. Of the 67 thousand RSUs distributed, 49 thousand RSUs were distributed in common stock and 18 thousand RSUs were settled in cash.

NOTE 12 – INCOME TAXES

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both March 31, 2017 and December 31, 2016, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss (“NOL”) carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. We have approximately $47.2 million federal income tax benefits at December 31, 2016 derived from $138.8 million Federal NOLs at the U.S. statutory tax rate of 34% and $2.1 million state NOLs, available to offset future taxable income, some of which already have limitations for future use as prescribed under IRC Section 382. Our Federal and State NOLs will expire in varying amounts between 2017 and 2036 if not used, and those expirations will cause fluctuations in our valuation allowances. As of December 31, 2016 we had federal research and development tax credits of approximately $1.2 million, which expire in the years 2024 through 2034. We also had approximately $0.2 million of Indiana state research and development tax credits, which will expire in 2017.

NOTE 13 – EARNINGS PER SHARE (“EPS”)

Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 11). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2016 as the Company reported a net loss for the three month period, and including the effects of the common stock equivalents in the diluted EPS calculations would have been antidilutive. The weighted-average common shares outstanding (diluted) computation is not impacted during any period where the exercise price of a stock option is greater than the average market price.

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Three months Ended March 31,
	2017		2016
	(in thousands except per share data)
EPS - basic
Numerator: net income (loss)	$	405	$	(3,384	)
Denominator:
Common shares		11,881		11,832
Vested RSUs		26		5
Basic weighted average shares outstanding		11,907		11,837
EPS - basic	$	0.03	$	(0.28	)

EPS – assuming dilution
Numerator: net income (loss)	$	405	$	(3,384	)
Denominator:
Common shares		11,881		11,832
RSUs		202		5
Stock options		-		-
Common stock warrants		-		-
Diluted weighted average shares outstanding		12,083		11,837
EPS - diluted	$	0.03	$	(0.28	)

Excluded securities:
Common stock issuable:
Stock options		1,396		1,198
Common stock warrants		60		60
RSUs		-		66
Total excluded potentially dilutive shares		1,456		1,324

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

In the Pennsylvania action, over 200 lawsuits were filed against Acura and Halsey Drug Company alleging that plaintiffs developed neurological disorders as a result of their use of the Reglan brand and/or generic metoclopramide. In the New Jersey action, plaintiffs filed approximately 150 lawsuits against us, but served less than 50 individual lawsuits upon us. In the California action, there are 89 pending cases against us, with more than 445 individual plaintiffs.

In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 19 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing decision”) holding that state tort law failure to warn claims against generic drug companies are pre-empted by the 1984 Hatch-Waxman Act Amendments and federal drug regulations will assist us in favorably resolving these cases.

In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing decision, which the Court granted with a limited exception. In June 2012, the New Jersey trial court dismissed all of the New Jersey cases pending against us with prejudice.

In Pennsylvania, and California, Generic Defendants, including us, also filed dispositive motions based on the Mensing decision.

In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions, without prejudice. In July 2013, the Pennsylvania Superior Court issued an adverse decision, and a subsequent appeal to the Pennsylvania Supreme Court was denied. On December 16, 2014, the Generic Defendants filed a Joint Petition for Certiorari with the United States Supreme Court captioned Teva Pharmaceuticals USA, Inc. et al. v. Dorothy Bentley, et al., No. 14-711 (U.S.) seeking reversal of the Pennsylvania state court decision. On April 27, 2015, the U.S. Supreme Court denied this Petition and this matter has been returned to the trial court for further proceedings.

From July, 2015 to date, the court has taken procedural steps to narrow this litigation, including requests for plaintiffs to voluntarily discontinue cases, such as those filed against us, where there is no case-specific product identification. The trial court proceedings were stayed on January 12, 2017. We are in the process of obtaining voluntary dismissal without prejudice of all of the Pennsylvania cases pending against us. We expect that the Court will approve these dismissals during the second quarter of 2017 and should finally dismiss the Pennsylvania-based litigation against us with prejudice later this year. Legal fees related to this matter are currently covered by our insurance carrier.

In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generic Defendants’ appeals from this order were denied by the California appellate courts. In May 2014, the California Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett decision. Thus far, we and most Generic Defendants have not been required to file answers or other responsive pleadings in each individual case in which they are named defendants. On May 24, 2016, the Court entered an Order approving a stipulation which stays the individual cases against us and provides for an agreed upon dismissal protocol for all cases where there is a lack of product identification. On January 13, 2017, the Court also entered a general stay of this entire litigation. To date, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by us. Therefore, we expect that the lawsuits filed against us will be dismissed voluntarily within the next three to six months. Legal fees related to this matter are currently covered by our insurance carrier.

As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of March 31, 2017 and we are presently unable to determine if any potential loss would be covered by our insurance carrier.

Purdue Pharma Settlement

In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “ 007 patent”). In April 2016, Purdue commenced a second patent infringement lawsuit against us and Egalet in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s newly issued U.S. Patent No. 9,308,171 (the “171 Patent”). The actions regarding the 007 Patent and the 171 Patent are collectively referred to as the “Actions”. On April 6, 2016, we filed a petition for Inter Partes Review (the “IPR Review”) with the U.S. Patent and Trademark Office (“USPTO”) seeking to invalidate Purdue’s 007 Patent.

On May 20, 2016, Purdue on behalf of themselves and certain affiliates, Egalet Corporation, on behalf of itself and its affiliates and we, on behalf of ourselves and our affiliates entered into a settlement agreement (the “Settlement Agreement”) to settle the Actions and the IPR Review. Under the Settlement Agreement the parties dismissed or withdrew the Actions, requested that the USPTO terminate the IPR Review and exchanged mutual releases. No payments were made under the Settlement Agreement.

The Settlement Agreement also provides that Purdue will not, in the future, assert certain Purdue U.S. patents, including the 007 Patent, the 171 Patent and related technologies (the “Purdue Patents”) against any Acura Settlement Product or Egalet Settlement Product (except generally in an action or interference by Acura or Egalet challenging a Purdue Patent). Acura Settlement Products and Egalet Settlement Products are certain immediate-release and extended-release products, including Oxaydo. In addition, the Settlement Agreement provides that Purdue will not challenge, with certain exceptions, the Acura/Egalet Patents with respect to the Purdue Settlement Products (as defined below) and that Purdue provides Acura and/or Egalet certain waivers of non-patent marketing exclusivity with respect to Purdue Settlement Products.

The Settlement Agreement also provides that Acura and Egalet will not, in the future, assert certain Acura and/or Egalet U.S. patents (the “Acura/Egalet Patents”), including Acura’s Aversion® Technology patents, against any Purdue Settlement Products (except generally in an action or interference by Purdue challenging an Acura/Egalet Patent). Purdue Settlement Products are certain immediate-release and extended-release products. In addition, the Settlement Agreement provides that Acura and Egalet will not challenge, with certain exceptions, the Purdue Patents with respect to the Acura Settlement Products and Egalet Settlement Products and that Acura and Egalet provide Purdue certain waivers of non-patent marketing exclusivity with respect to the Acura Settlement Products and Egalet Settlement Products. In addition, Purdue has certain rights to negotiate to exclusively distribute an authorized generic version of certain Egalet Settlement Products, including, in some circumstances, Oxaydo® and other products using Acura’s Aversion® Technology if licensed to Egalet.

The Settlement Agreement specifically excludes our patents related to our Impede® and Limitx™ technologies from the scope of the Acura/Egalet Patents under the Settlement Agreement.

In December 2014, the Company entered into an agreement with Purdue Pharma L.P. to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby the Company conceded Purdue Pharma’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $500 thousand. In June 2015, the Company received an additional $250 thousand payment from Purdue Pharma relating to the December 2014 agreement.

Egalet Agreement

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the expenses and we will pay for the remaining fees and expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. At March 31, 2017 and December 31, 2016, we have accrued approximately $269 thousand and $150 thousand, respectively, of these cost sharing expenses under the Egalet Agreement.

Facility Lease

The Company leases administrative office space in Palatine, Illinois under a lease for $25 thousand annually. Such lease expired March 31, 2017, and effective April 1, 2017, the office space is leased on a month to month basis.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion and analysis should be read in conjunction with the Company's financial statements and accompanying notes included elsewhere in this Report. Historical operating results are not necessarily indicative of results in future periods.

Forward-Looking Statements

Certain statements in this Report constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:

our ability to fund or obtain funding for our continuing operations, including the development of our products utilizing our Limitx and Impede technologies;

our ability to remain in compliance with our obligations under our term loan with Oxford Finance LLC, or to obtain a waiver from Oxford Finance LLC for our failure to comply with our covenants contained in such term loan agreement;

the expected results of clinical studies relating to LTX-04, the date by which such study results will be available and whether LTX-04 will ultimately receive FDA approval;

whether Limitx will retard the release of opioid active ingredients as dose levels increase;

whether we will be able to reformulate LTX-04 to provide an efficacious level of drug when one or two tablets are taken;

whether we will be able to reformulate LTX-04 to improve its abuse deterrent performance;

whether the extent to which products formulated with the Limitx technology deter abuse will be determined sufficient by the FDA to support approval or labelling describing abuse deterrent features;

whether our Limitx technology can be expanded into extended-release formulations;

our and our licensee’s ability to successfully launch and commercialize our products and technologies, including Oxaydo® Tablets and our Nexafed® products;

the pricing and price discounting that may be offered by Egalet for Oxaydo;

whether we can successfully develop a product under our agreement with Bayer;

the results of our development of our Limitx Technology;

our licensees’ ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;

the market acceptance of, timing of commercial launch and competitive environment for any of our products;

expectations regarding potential market share for our products;

our ability to develop and enter into additional license agreements for our product candidates using our technologies;

our exposure to product liability and other lawsuits in connection with the commercialization of our products;

the increasing cost of insurance and the availability of product liability insurance coverage;

the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;

the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;

whether the FDA will agree with or accept the results of our studies for our product candidates;

the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter (“OTC”) Monograph standards, as applicable;

the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;

changes in regulatory requirements;

adverse safety findings relating to our commercialized products or product candidates in development;

whether the FDA will agree with our analysis of our clinical and laboratory studies;

whether further studies of our product candidates will be required to support FDA approval;

whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our abuse discouraging technologies; and

whether Oxaydo or our Aversion and Limitx product candidates will ultimately deter abuse in commercial settings and whether our Nexafed products and Impede technology product candidates will disrupt the processing of pseudoephedrine into methamphetamine.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “indicates,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our 2016 Annual Report on Form 10-K as filed with the U.S. Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Accordingly, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Company Overview

We are a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® and Limitx™ Technologies are intended to address methods of abuse associated with opioid analgesics while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first and only approved immediate-release oxycodone product in the United States with abuse deterrent labeling. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation, or collectively Egalet, pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the U. S. Food and Drug Administration, or FDA, for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015.

We launched our first Impede Technology product, Nexafed, into the United States market in December 2012 and launched our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC, or Bayer, entered into a License and Development Agreement, or the Bayer Agreement, pursuant to which we granted Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine – containing product and providing for the joint development of such product using our Impede Technology for the U.S. market. On March 16, 2017, we and MainPointe Pharmaceuticals, LLC (“MainPointe”), entered into a License, Commercialization and Option Agreement (“MainPointe Agreement”), pursuant to which we granted MainPointe an exclusive license to our Impede technology in the U.S. and Canada to commercialize our Nexafed products. The MainPointe Agreement also grants MainPointe the option to expand the licensed territory to the European Union, Japan and South Korea and to add additional pseudoephedrine-containing products utilizing our Impede technology.

Our third abuse deterrent technology, Limitx, is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. We have completed our first clinical study, Study AP-LTX-400, or Study 400, of our lead Limitx immediate release oral abuse deterrent drug candidate using the opioid hydromorphone HCI (LTX-04). Study 400 was a two cohort, open label, crossover design pharmacokinetic study in healthy adult subjects. The FDA has designated the LTX-04 development program as Fast Track, which is designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. On April 13, 2016 and June 8, 2016 we announced that topline interim results from cohorts 1 and 2, respectively, of Study 400 for one test formulation of LTX-04 successfully demonstrated the release of the active opioid ingredient was reduced when three or more tablets were ingested, but that additional formulation development will be required for LTX-04 to deliver a sufficient amount of the active ingredient when one or two tablets are administered. On December 14, 2016, we announced that we had received advice from the FDA on the continued development of LTX-04 following the FDA’s review of summary data from Study 400. The FDA confirmed our intention to reformulate LTX-04 to provide increased drug levels following an intended 1 or 2 tablet dose, noting that a scientific bridge of bioequivalence to the reference product will support a finding of safety and efficacy. The FDA also recommended that we identify studies to measure the clinical impact on abuser behavior and overdose outcome (such as drug liking and respiratory depression) associated with the reduction in maximum drug concentration, or Cmax, when three or more LTX-04 tablets were ingested. We identified a subpopulation of participants in Study 400 that demonstrated increased reductions in Cmax when taking LTX-04, or faster drug absorbers. The FDA noted that to label a product for a particular subpopulation, including faster drug absorbers, prescribers should be able to understand that only a subset of their patients may benefit from use of the product. After addressing certain excipient issues in our LTX-04 tablet formulation and developing a new, faster releasing micro-particle formulation for LTX-04, we expect to initiate enrollment in a second pharmacokinetic study, AP-LTX-401 in May 2017. We intend to develop LTX-04 through proof of concept and then rapidly advance a formulation of a product with greater prevalence of oral excessive tablet abuse, or ETA, such as immediate-release hydrocodone with acetaminophen.

Opioid analgesics are one of the largest prescription drug markets in the United States with 222 million prescriptions dispensed in 2016. Prescription opioids are also the most widely abused drugs with 11 million people abusing or misusing these products annually. Oxaydo will compete in the immediate-release opioid product segment. Because immediate-release opioid products are used for both acute and chronic pain, a prescription, on average, contains 66 tablets or capsules. According to IMS Health, in 2016, sales in the immediate-release opioid product segment were approximately 208 million prescriptions and $2.7 billion, of which approximately 98% was attributable to generic products. Immediate-release oxycodone tablets represent 20.1 million of these prescriptions or almost 1.7 billion tablets. The FDA approved label for our Oxaydo product describes the unique, and we believe promotable, abuse deterrent features of our product which we believe makes prescribing our product attractive to some healthcare providers. We are advised that Egalet has approximately 50 sales representatives promoting Oxaydo to a target group of approximately 6,000 opioid prescribing physicians.

In 2014, the United States retail market for over-the-counter market, or OTC, cold and allergy products containing the pseudoephedrine oral nasal decongestant was approximately $0.7 billion. In 2014, the DEA reported 9,339 laboratory incidents involving the illegal use of OTC pseudoephedrine products to manufacture the highly addictive drug methamphetamine, or meth. According to the Substance Abuse and Mental Health Services Administration, users of methamphetamine surged in 2013 to 595,000 people up from 440,000 in 2012. At March 15, 2017, Nexafed, our 30mg pseudoephedrine hydrochloride immediate-release tablet, were stocked in approximately 21% of the estimated 65,000 U.S. pharmacies. Many of these pharmacies are either actively recommending Nexafed to their patients or carry Nexafed as their only 30mg pseudoephedrine product.

We have a development program to develop an extended-release version of our Impede Technology to capitalize on higher sales products in the category. We also have investigated new technologies that would improve on our meth-resistant capabilities. On March 23, 2015, we announced preliminary top line results from our pilot clinical study demonstrating bioequivalence of our Nexafed extended release tablets to Johnson & Johnson’s Sudafed® 12-hour Tablets. In October 2016, we received FDA recommendations on our meth-resistant testing protocols for our Nexafed extended release tablets which utilizes our Impede 2.0 enhanced meth-resistant technology. Our Impede 2.0 Technology has demonstrated, in the direct conversion, or “one-pot”, methamphetamine conversion process performed by an independent pharmaceutical services company, the ability to reduce meth-yields, on average, by 75% compared to Sudafed® Tablets. We can now scale-up our manufacture batch size at a contract manufacturer which will allow us to submit an IND to the FDA for our Nexafed extended release tablets, however, we have not yet committed to that level of development.

Abuse of Prescription Opioid Products and Development of Abuse Deterrent Formulations

Prescription opioids drugs, such as morphine and oxycodone, have a long history of use for the management of pain. Because they are highly effective, they are one of the largest prescribed drug categories in the U.S. However, a side effect of high doses of opioids is euphoria, or “a high”. For these reasons, opioids are the most misused or abused prescription drugs in the U.S. Opioids are offered in a variety of dosages including immediate-release tablets (or capsules), extended-release tablets (or capsules), patches and other formats. Abusers will often manipulate or tamper with the formulations to achieve their high, including:

Oral Excessive Tablet Abuse (ETA). Generally recognized as the most prevalent route of administration by abusers, the abuser simply orally ingests more tablets (or capsules) than is recommended for pain relief.

Oral Manipulated Tablet Abuse (MTA). Extended-release tablets or patches are sometimes crushed, chewed or otherwise physically or chemically manipulated to defeat the extended-release mechanism and provide an immediate-release of the opioid for oral ingestion.

Nasal snorting. Crushed tablets are insufflated for absorption of the drug through the nasal tissues.

Injection. The opioid is physically or chemically removed from the dosage and injected into the vein using a syringe.

Poly-pharmacy. Opioids are sometimes used in conjunction with alcohol or other drugs to accentuate the high.

Abuse deterrent formulations of opioid dosages incorporate physical and/or chemical barriers or functionality in the formulations to prevent or discourage an abuser from inappropriately administering the product. The extent and manner in which any of the features of abuse deterrent opioids may be described in the FDA approved label for our pipeline products will be dependent on the results of and the acceptance by the FDA of our and our licensees’ studies for each product.

Development of our Limitx and Aversion (if recommenced) product candidates will require one or more abuse deterrent studies consistent with FDA’s 2015 Guidance. These studies may include in vitro laboratory studies to determine, among other things, syringeability of the formulation, extractability of the opioid, and particle size of the crushed product. It is also expected that development will include human abuse liability studies comparing the abuse liability of our product candidates to currently marketed products. Because our products use known active ingredients in approved dosage strengths, the safety and efficacy of the opioid will need to be established by a series of pharmacokinetic studies demonstrating: (a) bioequivalence to an approved reference drug, (b) food effect of our formulations, and (c) dose proportionality of our formulation. A product candidate that does not achieve satisfactory pharmacokinetic results may require a phase III clinical pain study although an FDA Advisory Committee recently recommended an opioid analgesic product for approval that did not meet the FDA’s bioequivalence standard.

Further development will likely also entail additional safety and/or efficacy assessment as may be identified by the FDA for each specific formulation during the Investigational New Drug application, or IND, or NDA phase of development. In accordance with the FDA’s 2015 Guidance, we will likely have a post-approval requirement for each of our products, if approved, to perform an epidemiology study to assess the in-market impact on abuse of our formulation.

Limitx™ Technology

Limitx Technology is intended to address oral ETA or accidental consumption of multiple tablets and provide a margin of safety during accidental over-ingestion of tablets. Limitx is also expected to exhibit barriers to abuse by snorting and injection.

The FDA’s 2015 Guidance singles out immediate-release combination products with acetaminophen as being predominately abused by the oral route and that reducing nasal snorting of these products may not be meaningful. The initial Limitx formulation (LTX-04) utilizes hydromorphone as its sole active ingredient. We have initiated formulation development of a hydrocodone/APAP product candidate utilizing our Limitx Technology (LTX-03). In August 2015, the United States Patent and Trademark Office, or USPTO, issued to us patent 9,101,636 covering, among other things, our Limitx Technology.

Development of our Limitx Technology was supported by a $300 thousand grant by the National Institute on Drug Abuse of the National Institutes of Health for Phase I development, which entailed the development of an optimized formulation of LTX-04 suitable for commercial manufacture and human testing.

NIDA Disclaimer: Research on LTX-04 was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number R44DA037921. The results and content of any such research is solely the responsibility of Acura and does not necessarily represent the official views of the National Institutes of Health.

The LTX-04 development program is also designated as Fast Track by the FDA for its potential to address an unmet medical need.

Limitx Technology Products in Development

We have the following products in development utilizing our Limitx Technology:

Limitx Technology Product		Status
Immediate-release hydromorphone HCI (LTX-04)		Phase I exploratory pharmacokinetic study completed; Follow-on pharmacokinetic study expected to commence in May 2017
Immediate-release hydrocodone bitartrate with acetaminophen (LTX-03)		Formulation development in process
Immediate-release oxycodone HCl (LTX-01) & (LTX-02)		Formulation development in process

The initial LTX-04 clinical study, or Study 400, was a two cohort, open label, crossover design pharmacokinetic study in healthy adult subjects. Study 400 measured the rate and extent of absorption of the active drug ingredient into the bloodstream with the maximum concentration, or Cmax, typically associated with an increase in drug abuse. Cohort 1 enrolled 30 subjects who were randomized into three subgroups of 10 taking either 1, 2 or 3 tablets. Each subgroup subject orally swallowed the planned number of tablets in a randomized manner taking single doses of two different test formulations of LTX-04 (designated as LTX-04P and LTX-04S and distinguished by their respective acid neutralizing capacity) and Purdue Pharma’s marketed drug Dilaudid® as a comparator. The 1, 2 and 3 tablets subgroups in Cohort 1 completed 8, 10 and 8 subjects, respectively.

Cohort 2 enrolled 30 subjects who were randomized into three subgroups of 10 taking either 4, 6 or 8 tablets. Each subgroup subject orally swallowed the planned number of tablets in a randomized manner taking single doses of LTX-04P and the marketed drug Dilaudid as a comparator. The 4, 6 and 8 tablets subgroups in Cohort 2 completed 8, 9 and 8 subjects, respectively.

All tablets contained 2mg of hydromorphone hydrochloride. All subjects received doses of naltrexone and there was a one week washout between doses. Blood samples were taken at pre-designated time-points after dosing and were subsequently analyzed for the concentration of hydromorphone contained in the sample. All subjects in Cohort 1 had continuous pH (a measure of acid concentration) monitoring of their gastric fluid. The objective of Cohort 1 was to determine if adequate active drug entered the blood stream when one or two Limitx tablets were swallowed and to begin assessing the ability of the Limitx Technology to start retarding the release of active ingredients when three tablets are ingested. The objective of Cohort 2 was to further explore the extent the release of the hydromorphone active ingredient from LTX-04P tablets is retarded as the dose level increases to abusive levels. A safety assessment of Limitx Hydromorphone will be made from both study cohorts.

The topline interim results from Study 400 test formulation LTX-04P, successfully demonstrated the release of the active opioid ingredient was reduced when three or more intact tablets were ingested, but that additional formulation development will be required for LTX-04P to deliver a sufficient amount of the active ingredient to patients when one or two tablets are administered. Specifically, the topline interim results of Study 400 demonstrated:

Subjects in Study 400 had an average 22% reduction in relative Cmax when 3 or more tablets were ingested as shown in the table below.

Study 400 – Mean Ratio of Cmax (ng/mL) by Dosing Group Compared to the 1 Tablet Group for the Same Formulation
	Dosing in mg			DILAUDID			LTX-04P			Change
2 Tablet Group		2	x		1.9	x		2.2	x		15	%
3 Tablet Group		3	x		4.8	x		3.8	x		-22	%
4 Tablet Group		4	x		6.4	x		4.8	x		-25	%
6 Tablet Group		6	x		6.2	x		5.2	x		-15	%
8 Tablet Group		8	x		8.4	x		6.8	x		-18	%
Average 3-8											-22	%

All Subjects in cohort 2 had extent of drug absorption (measured by AUC) for LTX-04P comparable to Dilaudid when the same number of tablets were ingested. Likewise, the time to maximum plasma concentration, or Tmax, was comparable at all doses to Dilaudid.

Subjects taking one or two tablets of both LTX-04 test formulations had comparable extent of drug absorption (measured by AUC) as the same number of tablets of Dilaudid. However, these tablets delivered approximately 50% less peak plasma concentration (Cmax) than Dilaudid. As such, the LTX-04 test formulations were considered to not have achieved equivalent blood levels of drug and will require further development. All study drugs were generally well tolerated and no serious adverse events were observed.

Further analysis of the 3, 4, 6 and 8 tablet subgroups in Study 400 identified a subpopulation of patients in which LTX-04P appeared to demonstrate enhanced reduction in drug absorption as compared to Dilaudid. This subpopulation is characterized by their propensity to absorb the opioid in Dilaudid quickly, reaching maximum drug concentration in the blood in 30 minutes or less, while, on average, having maximum blood levels of drug 1.8 times that of the slower drug absorbing subjects. This subpopulation may represent a more vulnerable abuse population as speed of drug absorption and higher peak drug levels in the blood are typically associated with more drug abuse and possibly addiction.

In the faster absorbing subpopulation of subjects, assuming each subject should have an expected Cmax for LTX-04P consistent with the average seen in the 1 and 2 tablets subgroups of 53% of Dilaudid, the subpopulations demonstrated:

82% of subjects had an estimated reduction in Cmax associated with Limitx

38% average estimated reduction in Cmax associated with Limitx

66% maximum reduction in estimated Cmax observed in two of 17 subjects

1.6x average increase in Tmax associated with Limitx

On December 14, 2016, we announced that we had received advice from the FDA on the continued development of LTX-04 following the FDA’s review of summary data from Study 400. The FDA confirmed our intention to reformulate LTX-04 to provide increased drug levels following an intended 1 or 2 tablet dose, noting that a scientific bridge of bioequivalence to the reference product will support a finding of safety and efficacy. The FDA also recommended that we identify studies to measure the clinical impact on abuser behavior and overdose outcome (such as drug liking and respiratory depression) associated with the reduction in Cmax when three or more LTX-04 tablets were ingested. We identified a subpopulation of participants in Study 400 that demonstrated increased reductions in Cmax when taking LTX-04, or faster drug absorbers. The FDA noted that to label a product for a particular subpopulation, including faster drug absorbers, prescribers should be able to understand that only a subset of their patients may benefit from use of the product. The FDA’s advice also identified longer term studies necessary for submitting a NDA for LTX-04, including in vitro extraction studies, drug interaction studies, additional pharmacokinetic studies assessing the impact of food and beverages, and a category 3 abuse liability study.

We have completed reformulation work on the Limitx Technology micro-particles and have two candidates which we believe will improve the drug delivery with one and two tablet dosing. We have also addressed stability issues experienced in an earlier formulation. After addressing certain excipient issues in our LTX-04 tablet formulation and developing a new, faster releasing micro-particle formulation for LTX-04, we expect to initiate enrollment in a second pharmacokinetic study, AP-LTX-401 in May 2017. We intend to develop LTX-04 through proof of concept and then rapidly advance a formulation of a product with greater prevalence of oral ETA, such as immediate-release hydrocodone with acetaminophen.

Aversion Technology

Aversion Technology incorporates gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Aversion Technology and related opioid products, like Oxaydo, are covered by claims in five issued U.S. patents, which expire between 2023 and 2025. Our Aversion Technology products are intended to provide the same therapeutic benefits of the active drug ingredient as currently marketed products containing the same active pharmaceutical ingredient.

Oxaydo Tablets

Oxaydo (oxycodone HCI tablets) is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is approved in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. On September 15, 2016, Egalet announced that a new 15 mg strength of Oxaydo that they are developing achieved bioequivalence to a reference dose in support of a potential NDA supplement filing.

The 2015 market for immediate-release oxycodone products was 20.1 million dispensed prescription or 1.7 billion tablets. The current market is predominately serviced by generic formulations that contain no abuse deterrent features and sell for approximately $0.10 to $0.40 per tablet, depending on strength. Immediate-release opioids are prescribed by a broad cross-section of healthcare providers including primary care physicians, surgeons and pain specialists. We believe Oxaydo, given its differentiated label compared to generic products, can offer an alternative for opioid prescribing physicians concerned with the abuse or diversion for abuse of their prescriptions even at premium pricing to generics.

The safety and efficacy of Oxaydo 5mg and 7.5mg tablets was established by demonstrating bioequivalence to commercially available oxycodone immediate-release tablets in the fasted state. Oxaydo differs from oxycodone tablets when taken with a high fat meal though these differences are not considered clinically relevant, and Oxaydo can be taken without regard to food. The FDA-approved label for Oxaydo describes elements unique to our Aversion Technology, which differs from current commercially available oxycodone immediate-release tablets. The label for Oxaydo includes the results from a clinical study that evaluated the effects of nasally snorting crushed Oxaydo and commercially available oxycodone tablets, and limitations on exposing Oxaydo tablets to water and other solvents and administration through feeding tubes. The clinical study evaluated 40 non-dependent recreational opioid users, who self-administered the equivalent of 15mg of oxycodone. After accounting for a first sequence effect, the study demonstrated:

30% of subjects exposed to Oxaydo responded that they would not take the drug again compared to 5% of subjects exposed to immediate-release oxycodone;

subjects taking Oxaydo reported a higher incidence of nasopharyngeal and facial adverse events compared to immediate-release oxycodone;

a decreased ability to completely insufflate two crushed Oxaydo tablets within a fixed time period (21 of 40 subjects), while all subjects were able to completely insufflate the entire dose of immediate-release oxycodone; and

small numeric differences in the median and mean drug liking scores, which were lower in response to Oxaydo than immediate-release oxycodone.

Although we believe these abuse deterrent characteristics differentiate Oxaydo from immediate-release oxycodone products currently on the market, consistent with FDA guidance which requires epidemiology studies to support a claim of abuse deterrence, the clinical significance of the difference in drug liking and difference in response to taking the drug again in this study has not been established. There is no evidence that Oxaydo has a reduced abuse liability compared to immediate release oxycodone. We and Egalet have a post-approval commitment with the FDA to perform an epidemiology study to assess the actual impact on abuse of Oxaydo tablets.

Further, the Oxaydo product label guides patients not to crush and dissolve the tablets or pre-soak, lick or otherwise wet the tablets prior to administration. Similarly, caregivers are advised not to crush and dissolve the tablets or otherwise use Oxaydo for administration via nasogastric, gastric or other feeding tubes as it may cause an obstruction. Our laboratory studies demonstrated that the Oxaydo tablet may gel when Oxaydo is exposed to certain solvents, including water.

Egalet has advised us that it has commenced formulation work on a 15mg dosage strength for Oxaydo, has achieved bioequivalence of this new strength to a reference formulation, and has set a target date for submission of this new dosage strength to the FDA in the second half of 2017. Egalet has also advised that late in the fourth quarter of 2016 it filed a supplemental NDA for Oxaydo with the FDA to support an abuse-deterrent label claim for the intravenous route of abuse.

We are advised that Egalet commenced promoting Oxaydo in September 2015 and is targeting approximately 6,000 immediate-release opioid prescribing physicians using approximately 50 sales representatives. Commercial shipments of Oxaydo commenced in early October 2015. Egalet has further advised us that they have implemented a co-pay support program in which any non-government insurance covered patient receiving an Oxaydo prescription will be eligible to receive a credit such that their out-of-pocket cost, or co-pay, is limited to $15 per prescription. Egalet is in the early stages of promoting Oxaydo to physicians and addressing the challenges of establishing retail pharmacy stocking of a Schedule II narcotic.

Egalet Agreement Covering Oxaydo

On January 7, 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation, or Egalet, entered into a Collaboration and License Agreement, or the Egalet Agreement, to commercialize Oxaydo tablets containing our Aversion® Technology. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved NDA for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide, or the Territory, in all strengths, subject to our right to co-promote Oxaydo in the United States.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to oversee commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.

Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and a $2.5 million milestone in October 2015 in connection with the launch of Oxaydo. In addition, we will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. In addition, we will receive from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts). In any calendar year in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commenced on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to the Product). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

KemPharm Agreement Covering Opioid Prodrugs

On October 13, 2016, we and KemPharm Inc., or KemPharm, entered into a worldwide License Agreement, or the KemPharm Agreement, pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities, although we may provide initial technical assistance.

Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the 2 prodrugs licensed, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free.

Aversion Technology Development Opioid Products

On April 9, 2015, we announced the indefinite suspension of further development of our Aversion hydrocodone/APAP product candidate, in order to focus our time and available resources on the development of our Limitx technology product candidates. We currently have 6 additional opioids at various stages of formulation development using the Aversion Technology which are not being actively developed.

Abuse of Pseudoephedrine Products

The chemical structure of pseudoephedrine, or PSE, is very similar to methamphetamine, facilitating a straight-forward chemical conversion to methamphetamine. OTC PSE products are sometimes purchased and used for this conversion. There are multiple known processes to convert PSE to methamphetamine, all of which are not complex and do not require specialized equipment; however, many do require readily available but uncommon ingredients. Two of the three most popular processes follow two general processing steps: (1) dissolving the PSE tablets in a solvent to isolate, by filtration, purified PSE and (2) a chemical reduction of the PSE into methamphetamine for drying into crystals. The third method, or the “one-pot” method, involves the direct chemical reduction of the PSE to methamphetamine in the presence of the tablet’s inactive ingredients. All the solvents used are ultimately dried off or otherwise removed, so a wide range of solvents are amenable to the process.

Impede 1.0 Technology

Our Impede 1.0 Technology, a proprietary mixture of inactive ingredients, prevents the extraction of PSE from tablets using known extraction methods and disrupts the direct conversion of PSE from tablets into methamphetamine.

Studies sponsored by us at an international, independent laboratory demonstrated our Impede 1.0 Technology prevents the extraction of PSE from tablets for conversion into methamphetamine using what we believe are the two most common extraction methods, each requiring extraction of PSE as an initial step. Laboratory tests conducted on our behalf by an independent Clinical Research Organization, or CRO, using the “one-pot” method demonstrated that our Impede Technology disrupted the direct conversion of PSE from the tablets into methamphetamine. The study compared the amount of pure methamphetamine hydrochloride produced from Nexafed and Johnson & Johnson’s Sudafed® tablets. Using one hundred 30 mg tablets of both products, multiple one-pot tests and a variety of commonly used solvents, the study demonstrated an average of 38% of the maximum 2.7 grams of pure methamphetamine hydrochloride was recovered from Nexafed. Comparatively, approximately twice as much pure methamphetamine hydrochloride was recovered from Sudafed tablets. Both products yielded a substantial amount of additional solids such that the purity of the total powder provided contained approximately 65% methamphetamine hydrochloride.

Impede 2.0 Technology

We have developed a next generation, or Impede 2.0 Technology to improve the meth-resistance of our technology. We have completed one-pot, direct conversion meth testing performed by our CRO on the following commercially available products and on our Nexafed Impede 2.0 extended-release product, with the following results:

Product/Formulation	Meth Resistant Technology	Meth Recovery¹			Purity²
Sudafed® 30mg Tablets	none		67	%		62	%
Nexafed 30mg Technology	Impede® 1.0		38	%		65	%
Zephrex-D® 30mg Pills	Tarex®		28	%		51	%
Nexafed 120mg Extended-release tablets	Impede® 2.0		17	%		34	%

¹Total methamphetamine HCl recovered from the equivalent of 100 PSE 30mg tablets divided by the maximum theoretical yield of 2.7 grams.

²Total methamphetamine HCl recovered from the equivalent of 100 PSE 30mg tablets divided by the total weight of powder recovered.

We have demonstrated in a pilot clinical study the bioequivalence of a formulation of our Nexafed extended release tablets utilizing our Impede 2.0 Technology to Sudafed® 12-hour Tablets. We have completed a project to integrate Impede 2.0 Technology into our commercially available Nexafed 30mg tablet while moving supply to an alternate contract manufacturer. We expect that MainPointe will complete process validation on this new formulation in the first half of 2017 and that it will introduce the new formulation into the market pursuant to the MainPointe Agreement.

Nexafed Products

The Nexafed products currently marketed consist of immediate release tablets which currently utilize our patented Impede 1.0 Technology. Nexafed is a 30mg pseudoephedrine tablet and Nexafed Sinus Pressure + Pain is a 30/325mg pseudoephedrine and acetaminophen tablet. PSE is a widely-used nasal decongestant available in many non-prescription and prescription cold, sinus and allergy products. While the 30mg PSE tablet is not the largest selling PSE product on the market, we believe it is the most often used product to make meth due to: (a) its relatively low selling price and (b) its simpler formulation provides better meth yields. However, as meth-resistant products become pervasive, we believe meth cooks will migrate to other, larger selling, PSE containing products.

We have demonstrated that our Nexafed 30mg tablets are bioequivalent to Johnson & Johnson’s Sudafed 30mg Tablets when a single 2 tablet dose is administered. Commencing in 2006, the CMEA, required all non-prescription PSE products to be held securely behind the pharmacy counter, has set monthly consumer purchase volume limits, and has necessitated consumer interaction with pharmacy personnel to purchase PSE-containing products. Prior the MainPointe Agreement, we capitalized on this consumer-pharmacist interaction at the point of sale by soliciting distribution to pharmacies and educating and encouraging pharmacists to recommend Nexafed to their customers. We also used telemarketing, direct mail, and online and journal advertising to educate pharmacists about Nexafed and encourage pharmacists to recommend Nexafed to their customers. Under the terms of the MainPointe Agreement, MainPointe will control the marketing and sale of our Nexafed products.

We launched Nexafed commercially in mid-December 2012 into the United States OTC market for cold and allergy products. Prior to the MainPointe Agreement, we distributed our Nexafed products through several regional and national drug wholesalers for redistribution to pharmacies, which included the three largest U.S. drug wholesalers: McKesson, Cardinal Health and AmerisourceBergen. We also shipped directly to the warehouses of certain pharmacy chains. At March 15, 2017, Nexafed was stocked in approximately 13,900 pharmacies or about approximately 21% of the estimated 65,000 U.S. pharmacy outlets. Initial adoption was primarily in independent pharmacies in predominately rural communities with high meth awareness. Chain pharmacies, with more centralized control of the pharmacy operations, began adopting in mid-2013, including Kroger, Publix, Fruth and Bartells. Some pharmacists actively recommend Nexafed to their customers while some have replaced all 30mg PSE products, brand and generic, with Nexafed. Rite Aid, the nation’s fourth largest pharmacy operator, began purchasing Nexafed in late 2013. In late 2014, Kmart and Kroger initiated chain-wide stocking of Nexafed.

We estimate that at March 15, 2017, approximately 56% of Nexafed stocking pharmacies are repeat customers, excluding Rite Aid and Kroger which purchase directly from us and we therefore do not have individual store data.

In February 2015, we began initial shipments of Nexafed Sinus Pressure + Pain. Prior to the MainPointe Agreement, we were marketing this product consistent with our Nexafed marketing efforts to pharmacists concerned with meth abuse of their products. We are not aware of any branded non-prescription product that contains PSE and acetaminophen believing that brands containing these ingredients have either been discontinued or reformulated with phenylephrine. We expect Nexafed Sinus Pressure + Pain to compete primarily against Advil® Cold and Sinus (PSE/ibuprofen) and to a lesser extent Aleve®-D and Sudafed® Pressure + Pain which are extended-release products.

Nexafed and Nexafed Sinus Pressure + Pain products are marketed under FDA’s regulations applicable to OTC Monograph products. Nexafed and Nexafed Sinus Pressure + Pain tablets are offered in 24-count blister packaged cartons.

We understand that in 2014, a majority of pharmacies in West Virginia voluntarily began selling only meth-resistant products for the single-ingredient immediate-release PSE offerings. In 2015, newspapers reported about 60% of single-ingredient immediate-release PSE sales in West Virginia were for meth-resistant formulations. In March 2016, Indiana enacted legislation, subject to adoption of rule and policy making by the Indiana Board of Pharmacy, to require state pharmacists to use professional discretion when selling PSE-containing cold and allergy products, including encouraging the use of new meth-resistant formulations, in an effort to help reduce local methamphetamine production. According to media reports, Rite Aid pharmacies and many independent pharmacies in small a geographic region in Maine have, at the request of local authorities and community leaders, removed all traditional pseudoephedrine-containing products from their shelves and stock only meth-resistant formulations such as Nexafed.

MainPointe Agreement covering Nexafed Products

On March 16, 2017, we and MainPointe entered into a License, Commercialization and Option Agreement, or the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement.

On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million plus approximately $425,000 for the net book value of inventory and equipment being transferred. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country.

MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1 million, $500,000 and $250,000, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500,000 per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750,000 per product. If the territory is expanded after the payment of the $500,000 product option fee, a one-time $250,000 fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.

Impede Technology Products in Development

Given the fragmented nature of the PSE market with products containing multiple active ingredients, we are developing additional products for our Nexafed franchise:

Impede Technology Product		Status
Nexafed 30mg with Impede 2.0 Technology		Transferring to alternate supplier and scaling-up to commercial supply for MainPointe
Immediate-release pseudoephedrine HCl in combination with other cold and allergy active ingredients		Nexafed Sinus Pressure + Pain launched and licensed to MainPointe Other formulations being considered
Extended-release formulation utilizing Impede 2.0 Technology		Pilot pharmacokinetic testing demonstrated bioequivalence to Sudafed® 12-hour Tablets. Pre-IND meeting held with the FDA
Extended-release combination products		Formulations being considered
Methamphetamine resistant pseudoephedrine – containing product		In development pursuant to Bayer Agreement

In July 2015, we had a pre-IND meeting with the FDA to discuss the results from our pharmacokinetic and meth-resistance testing studies to determine the development path for our extended-release development product. The FDA acknowledged the potential value of the development of risk-mitigating strategies for new formulations of pseudoephedrine products while also recognizing an approved “meth-deterrent” extended release pseudoephedrine product would be novel in the over-the-counter (OTC) setting. The FDA did not make a formal determination whether “meth-resistant” claims would be appropriate but is open to consider such an appropriately worded, evidence-based claim directed to the consumer and/or retailer. As recommended by the FDA, we have submitted additional “meth-resistant” testing information to the FDA for review prior to submitting an IND. In October 2016, we received FDA recommendations on our meth-resistant testing protocols for our Nexafed extended release tablets. We can now scale-up our manufacture batch size at a contract manufacturer which allows us to submit an IND to the FDA for our Nexafed extended release tablets, however, we have not yet committed to that level of development.

Our objective is to establish, either directly or through third-party licensees, the Nexafed franchise in the United States with multiple product offerings, including both immediate and extended release products utilizing both single and combinations of active ingredients. We aim to make meth-resistant PSE product the standard of care in all U.S. pharmacies. In addition to the MainPointe Agreement, we may license our Impede technology to commercial partners to extend our internal development resources to develop difficult to formulate products, such as extended-release.

Bayer Agreement

On June 15, 2015, we and Bayer entered into a License and Development Agreement, or the Bayer Agreement, pursuant to which we granted Bayer an exclusive worldwide license to our Impede® Technology for use in an undisclosed methamphetamine resistant pseudoephedrine-containing product and providing for the joint development of such product using our Impede Technology for the U.S. market. The Bayer Agreement also grants Bayer first right to negotiate a license to the Impede® Technology for certain other products. We are eligible to receive reimbursement of certain our development expenses, success-based development and regulatory milestone payments, and low mid-single digit royalties on the net sales of the developed product in countries with patent coverage and a reduced royalty elsewhere.

U.S. Market Opportunity for Impede PSE Products

PSE is a widely-used nasal decongestant available in many non-prescription and prescription cold, sinus and allergy products. PSE is sold in products as the only active ingredient in both immediate and extended-release products. In addition, PSE is combined with other cold, sinus and allergy ingredients such as pain relievers, cough suppressants and antihistamines. PSE also competes against phenylephrine, an alternate nasal decongestant available in non-prescription products. In 2014, a data service reported approximately $0.7 billion in retail sales of non-prescription products containing PSE. The top retail selling PSE OTC cold/allergy products in 2014 were:

Reference Brand¹	Brand Company	Active Ingredient(s)	2014 Retail Sales ($ Millions)
Claritin-D	Bayer	PSE & Loraditine²	$	208.0
Allegra-D	Chattem	PSE & Fexofenadine²	$	101.3
Zyrtec-D	Pfizer	PSE & Ceterizine²	$	101.7
Advil Sinus	Pfizer	PSE & Ibuprofen	$	58.4
Sudafed 12 Hour	J&J	PSE²	$	82.3
Sudafed 30mg	J&J	PSE	$	70.4

¹ Branded product only. Does not include store brand sales.

² Extended release PSE formulations

The 2014 market for 30mg PSE tablets, including store brands was approximately 470 million tablets or 19 million boxes of 24 tablets. Prior to the MainPointe Agreement, Nexafed was priced at $4.39 for a box of 24 tablets and Nexafed Sinus Pressure + Pain at $7.95 for a box of 24 tablets. MainPointe will control the price of Nexafed and Nexafed Sinus under the terms of the MainPointe Agreement.

The market for cold, sinus and allergy products is highly competitive and many products have strong consumer brand recognition and, in some cases, prescription drug heritage. Category leading brands are often supported by national mass marketing and promotional efforts. Consumers often have a choice to purchase a less expensive store brand. Store brands contain the same active ingredients as the more popular national brands but are not supported by large marketing campaigns and are offered at a lower price. Non-prescription products are typically distributed through retail outlets including drug store chains, food store chains, independent pharmacies and mass merchandisers. The distribution outlets for PSE products are highly consolidated. According to Chain Drug Review, the top 50 drug, food and mass merchandising chains operate approximately 40,000 pharmacies in the U.S., of which 58% are operated by the four largest chains. Stocking decisions and pharmacists recommendations for these chain pharmacies are often centralized at the corporate headquarters.

Product Labeling for Impede Technology Products

Nexafed and Nexafed Sinus Pressure + Pain products are marketed pursuant to the FDA’s OTC Monograph regulations, which require that our product have labeling as specified in the regulations. Marketing for the Nexafed products includes advertising the extraction characteristics and methamphetamine-resistant benefits of these products which is supported by our published research studies.

We expect that any of our other Impede Technology products that are marketed pursuant to an NDA or ANDA will be subject to a label approved by the FDA. We expect that such a label will require submission of our scientifically derived abuse liability data and we intend to seek descriptions of our abuse liability studies in the FDA approved product label, although there can be no assurance that this will be the case.

U.S. Market Opportunity for Opioid Analgesic Products

The misuse and abuse of controlled prescription drugs, or CPDs, in general, and opioid analgesics in particular, continues to constitute a dynamic and challenging threat to the United States and is the nation’s fastest growing drug problem. Results from the 2013 National Drug Threat Assessment conducted by the U.S. Drug Enforcement Administration, or DEA, report that CPD rates of abuse remain high, with individuals abusing CPDs at a higher prevalence rate than any illicit drug except marijuana. Opioid analgesics are the most common type of CPDs taken illicitly and are the CPDs most commonly involved in overdose incidents. According to the Drug Abuse Warning Network (DAWN), the estimated number of emergency department visits involving nonmedical use of prescription opiates/ opioids increased 112 percent—84,671 to 179,787— between 2006 and 2010. Immediate release, or IR, opioid products comprise the vast majority of this abuse compared with extended release, or ER, opioid products.

It is estimated that more than 75 million people in the United States suffer from pain and the FDA estimates more than 45 million people receive a prescription for the opioid hydrocodone annually. For many pain sufferers, opioid analgesics provide their only pain relief. As a result, opioid analgesics are among the largest prescription drug classes in the United States with over 222 million tablet and capsule prescriptions dispensed in 2016 of which approximately 208 million were for IR opioid products and 14 million were for ER opioid products. However, physicians and other health care providers at times are reluctant to prescribe opioid analgesics for fear of misuse, abuse, and diversion of legitimate prescriptions for illicit use.

We expect our Aversion and Limitx Technology opioid products, to compete primarily in the IR opioid product segment of the United States opioid analgesic market. Because IR opioid products are used for both acute and chronic pain, a prescription, on average, contains 66 tablets or capsules. According to IMS Health, in 2016, sales in the IR opioid product segment were approximately $2.7 billion, of which ~98% was attributable to generic products. Due to fewer identified competitors and the significantly larger market for dispensed prescriptions for IR opioid products compared to ER opioid products, we have initially focused on developing IR opioid products utilizing our Aversion and Limitx Technologies. A summary of the IR opioid product prescription data for 2016 is provided below:

IR Opioid Products⁽¹⁾	2016 US Prescriptions (Millions)⁽²⁾		% of Total
Hydrocodone		90		43	%
Oxycodone		55		26	%
Tramadol		43		21	%
Codeine		15		7	%
4 Others		5		3	%
Total		208		100	%

¹Includes all salts and esters of the opioid and opioids in combination
with other active ingredients such as acetaminophen.

²IMS Health, 2016

Despite considerable publicity regarding the abuse of OxyContin® extended-release tablets and other ER opioid products, U.S. government statistics suggest that far more people have used IR opioid products non-medically than ER opioid products. These statistics estimate that nearly four times as many people have misused the IR opioid products Vicodin®, Lortab® and Lorcet® (hydrocodone bitartrate/acetaminophen brands and generics) than OxyContin®.

Product Labeling for Abuse-Deterrent Opioid Products

In April 2015, the FDA published guidance for industry on the evaluation and labeling of abuse-deterrent opioids. While the 2015 FDA Guidance is non-binding on the FDA, it outlines FDA’s current thinking on the development and labeling of abuse-deterrent products. The 2015 FDA Guidance provides for three distinct levels of pre-marketing studies that are potentially eligible for inclusion in the labeling: (1) laboratory-based in vitro manipulation and extraction studies, (2) pharmacokinetic studies, and (3) clinical abuse potential studies. The Guidance further prescribes additional post-approval or epidemiology studies to determine whether the marketing of a product with abuse-deterrent properties results in meaningful reductions in abuse, misuse, and related adverse clinical outcomes, including addiction, overdose, and death in the post-approval setting, which can also be included in the labeling. FDA notes “the science of abuse deterrence is relatively new. Both the technologies involved and the analytical, clinical, and statistical methods for evaluating those technologies are rapidly evolving. For these reasons, FDA will take a flexible, adaptive approach to the evaluation and labeling of potentially abuse-deterrent opioid products”.

We or our licensee may seek to include descriptions of studies that characterize the abuse-deterrent properties in the label for our Aversion and Limitx Technology products in development. Although the FDA approved label for Oxaydo contains limitations on exposing Oxaydo tablets to water and other solvents and administration through feeding tubes, the FDA approved Oxaydo label does not contain a description of the I.V. injection studies we performed to characterize the abuse deterrent properties of Oxaydo. Egalet has committed to the FDA to undertake epidemiological studies to assess the actual consequences of abuse of Oxaydo in the market. Under the terms of the Egalet Agreement, we share a minority portion of the fees and expenses relating to such FDA required epidemiological studies. The extent to which a description of the abuse-deterrent properties or results of epidemiological or other studies will be added to or included in the FDA approved product label for our products in development will be the subject of our discussions with the FDA as part of the NDA review process, even after having obtained approval of Oxaydo. Further, because the FDA closely regulates promotional materials, even if FDA initially approves labeling that includes a description of the abuse deterrent properties of the product, the FDA’s Office of Prescription Drug Promotion, or OPDP, will continue to review the acceptability of promotional labeling claims and product advertising campaigns for our marketed products.

Patents and Patent Applications

We have the following issued patent covering, among other things, our Limitx Technology:

Patent No. (Jurisdiction)	Subject matter	Issued	Expires
9,101,636 (US)	Abuse deterrent products wherein the release of active ingredient is retarded when 3 or more doses are consumed	Aug. 2015	Nov. 2033
9,320,796 (US)	Abuse deterrent products wherein the release of active ingredient is retarded when 3 or more doses are consumed	Apr. 2016	Nov. 2033
2,892,908 (CAN)	Abuse deterrent products wherein the release of active ingredient is retarded when excessive doses are consumed	Apr. 2016	Nov. 2033
5,922,851 (JAPAN)	Abuse deterrent products wherein the release of active ingredient is retarded when excessive doses are consumed	Apr. 2016	Nov. 2033

We have the following issued patents covering, among other things, Oxaydo and our Aversion Technology:

Patent No. (Jurisdiction)	Subject Matter	Issued	Expires
7,201,920 (US)	Pharmaceutical compositions including a mixture of functional inactive ingredients and specific opioid analgesics	Apr. 2007	Mar. 2025
7,510,726 (US)	A wider range of compositions than those described in the 7,201,920 Patent	Mar. 2009	Nov. 2023
7,981,439 (US)	Pharmaceutical compositions including any water soluble drug susceptible to abuse	Jul. 2011	Aug. 2024
8,409,616 (US)	Pharmaceutical compositions of immediate-release abuse deterrent dosage forms	Apr. 2013	Nov. 2023
8,637,540 (US)	Pharmaceutical compositions of immediate-release abuse deterrent opioid products	Jan. 2014	Nov. 2023
9,492,443 (US)	Pharmaceutical compositions of immediate-release abuse deterrent opioid products	Nov. 2016	Nov. 2023

We have the following additional issued patents relating to our Aversion Technology:

Patent No. (Jurisdiction)	Subject Matter	Issued	Expires
7,476,402 (US)	Pharmaceutical compositions of certain combinations of kappa and mu opioid receptor agonists and other ingredients intended to deter opioid analgesic product misuse and abuse	Jan. 2009	Nov. 2023
8,822,489 (US)	Pharmaceutical compositions of certain abuse deterrent products that contain polymers, surfactant and polysorb 80	Jul. 2014	Nov. 2023
2,004,294,953 (AUS)	Abuse deterrent pharmaceuticals	Apr. 2010	Nov. 2024
2,010,200,979 (AUS)	Abuse deterrent pharmaceuticals	Aug. 2010	Nov. 2024
2,547,334 (CAN)	Abuse deterrent pharmaceuticals	Aug. 2010	Nov. 2024
2,647,360 (CAN)	Abuse deterrent pharmaceuticals	May 2012	Apr. 2027
175,863 (ISR)	Abuse deterrent pharmaceuticals	Nov. 2004	Nov. 2024
221,018 (ISR)	Abuse deterrent pharmaceuticals	Nov. 2004	Nov. 2024

We have the following issued patent covering, among other things, our Nexafed product line and Impede 1.0 and 2.0 technologies:

Patent No. (Jurisdiction)	Subject Matter	Issued	Expires
8,901,113 (US)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Dec. 2014	Feb. 2032
2010300641 (AUS)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Jun. 2016	Sep. 2030
2,775,890 (CAN)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Jun. 2016	Sep. 2030
2,488,029 (EUR)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Mar. 2016	Sep. 2030
218533 (ISR)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Jan. 2016	Sep. 2030

In addition to our issued patents listed above and additional unlisted issued patents, we have filed multiple U.S. patent applications and international patent applications relating to compositions containing abusable active pharmaceutical ingredients as well as applications covering our Impede 1.0 and 2.0 Technologies and filed U.S. patent applications for our Limitx Technology. Except for the rights granted in the Egalet Agreement, the KemPharm Agreement, the Bayer Agreement, and the MainPointe Agreement and in the patent infringement settlement agreements described below, we have retained all intellectual property rights to our Aversion Technology, Impede Technology, Limitx Technology and related product candidates.

In 2012 and 2013, we received Paragraph IV Certification Notices from five generic sponsors of ANDAs for a generic drug listing our Oxaydo product as the reference listed drug. The Paragraph IV Notices referred to our 920, 726 and 439 Patents, which cover our Aversion® Technology and our Oxaydo product. We filed suit against each of such generic sponsors, Watson Laboratories, Inc., Par Pharmaceutical, Inc., Impax Laboratories, Inc., Sandoz Inc. and Ranbaxy Inc., in the United States District Court for the District of Delaware alleging infringement of our 726 Patent listed in the FDA’s Orange Book. Our litigation against Watson Laboratories was dismissed by us following Watson Laboratories’ change of its Paragraph IV Certification to a Paragraph III Certification, indicating it would not launch its generic product until the expiry of our applicable Patents. Our litigation against each of the remaining generic sponsors was settled during the period October 2013 through May 2014 on an individual basis, upon mutual agreement between us and such generic sponsors. None of such settlements impacted the validity or enforceability of our Patents. See our Annual Report on Form 10K under the caption “Item 1A. Risk Factors – Generic manufacturers are using litigation and regulatory means to seek approval for generic versions of Oxaydo, which could cause Egalet’s sales to suffer and adversely impact our royalty revenue” for a discussion of the settlements and license grants relating to such patent litigation. Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition.

In April, 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc., or collectively Purdue, commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007, or the 007 Patent. In April 2016, Purdue commenced a second patent infringement lawsuit against us and Egalet in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s newly issued U.S. Patent No. 9,308,171, or the 171 Patent. The actions regarding the 007 Patent and the 171 Patent are collectively referred to as the “Actions”. On April 6, 2016, we filed a petition for Inter Parties Review, or IPR Review, with the USPTO seeking to invalidate Purdue’s 007 Patent.

On May 20, 2016, we, Purdue and Egalet entered into a settlement agreement to settle the Actions and the IPR Review. Under the Settlement Agreement the parties dismissed or withdrew the Actions, requested that the USPTO terminate the IPR Review and exchanged mutual releases. No payments were made by the parties under the Settlement Agreement. The Settlement Agreement specifically excludes our patents related to our Impede and Limitx technologies from the scope of our patents subject to the Settlement Agreement.

Reference is made to the Risk Factors contained in our Annual Report on Form 10-K for the year ended December 31, 2016 for a discussion, among other things, of patent applications and patents owned by third parties, including claims that may encompass our Aversion Technology and Oxaydo tablets, and the risk of infringement, interference or opposition proceedings that we may be subject to arising from such patents and patent applications.

Company’s Present Financial Condition

At March 31, 2017, we had unrestricted cash and cash equivalents of $3.8 million compared to $2.7 million of unrestricted cash and cash equivalents at December 31, 2016, (which is after the deduction of the $2.5 million compensating balance requirement under our term loan with Oxford). Under our term loan with Oxford Finance LLC, we are required to maintain a $2.5 million compensating balance until such time as we raise, as of March 31, 2017, an additional approximately $3.5 million through the issuance of equity securities and from upfront payments under license, joint venture, collaboration or other partnering transactions. We had an accumulated deficit of approximately $374.3 million at March 31, 2017. Though we had income from operations of $0.6 million and net income of $0.4 million for the three months ended March 31, 2017, we had a net loss from operations of $6.6 million and net loss of $7.4 million for the year ended December 31, 2016. Our current unrestricted cash and cash equivalents will be sufficient to fund the development of our products and our related operating expenses only through mid-2017 while maintaining compliance with the $2.5 million compensating balance requirement under our term loan with Oxford Finance LLC.

We expect to continue to incur substantial losses for the foreseeable future as we continue to develop our clinical and preclinical product candidates. To fund further operations and product development activities, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations.

Our losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and sales, marketing and general corporate expenses. Research and development activities include costs of pre-clinical studies, clinical trials, and clinical trial product supplies associated with our product candidates as well as cost sharing expenses of line extension studies and post-marketing studies under the Egalet Agreement. Sales and marketing expenses include costs associated with the Nexafed product line advertising, salaries and other personnel-related costs include the stock-based compensation associated with stock options and restricted stock units granted to employees and non-employee directors.

Three months Ended March 31, 2017 Compared to Three months Ended March 31, 2016

	March 31
	2017			2016			Increase (decrease)
	$000’s									Percent
Revenues:
License fee revenue	$	2,500		$	-		$	2,500			100	%
Collaboration revenue		36			100			(64	)		(64	)
Royalty revenue		74			17			57			335
Product sales, net		107			107			-			-
Total revenues, net		2,717			224			2,493			1,113

Cost and expenses:
Cost of sales		128			102			26			26
Research and development		711			1,014			(303	)		(30	)
Sales, marketing, general and administrative		1,296			2,246			(950	)		(42	)
Total operating expenses		2,135			3,362			(1,227	)		(37	)
Operating income (loss)		582			(3,138	)		3,720			119

Non-operating income (expense):
Investment income		1			27			(26	)		(96	)
Interest expense		(178	)		(249	)		(71	)		(29	)
Other expense		-			(24	)		(24	)		(100	)
Total other expense, net		(177	)		(246	)		(69	)		(28	)

Income (loss) before provision for income taxes		405			(3,384	)		3,789			112
Provision for income taxes		-			-			-			-
Net income (loss)	$	405		$	(3,384	)		3,789			112	%

Revenue and Cost of Sales

License Fees

In March 2017, the Company entered into a License Agreement (the “MainPointe Agreement”) pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million.

Collaboration Revenue

Collaboration revenue is derived from reimbursement of development expenses under various development agreements, such as the collaboration agreement with Bayer, and are recognized when costs are incurred pursuant to the collaboration agreement. We recognized $36 thousand and $100 thousand of collaboration revenue during the three months ended March 31, 2017 and 2016, respectively.

Royalty Revenue

In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts). Egalet’s first commercial sale of Oxaydo occurred in October 2015. We recognized $72 thousand and $17 thousand of royalty revenue during the three months ended March 31, 2017 and 2016, respectively.

In connection with our License, Commercialization and Option Agreement with MainPointe on March 16, 2017, we will receive a royalty of 7.5% on net sales of the licensed products over the term of the agreement. Such royalty shall be payable for sales made during each calendar quarter and payment will be remitted within forty-five (45) days after the end of the quarter to which it relates. We have recorded royalties of $2 on net sales for the three months ended March 31, 2017.

Net Product Sales

Nexafed® was launched in December 2012. Nexafed® Sinus Pressure + Pain was launched in February 2015. Prior to the MainPointe Agreement, the Company sold the Nexafed® product line in the United States to wholesale pharmaceutical distributors and as well as directly to chain drug stores. The product line is sold subject to the right of return usually for a period of up to twelve months after the product expiration. Both products currently have a shelf life of twenty-four months from the date of manufacture. Our net product sales for the three months ended March 31, 2017 and 2016 were $107 thousand and $107 thousand, respectively. As of March 16, 2017, our licensee, MainPointe Pharmaceuticals LLC, is manufacturing, distributing, and selling the Nexafed product line.

Cost and Expenses

Cost of Sales

Cost of sales includes third-party acquisition costs, third-party warehousing and product distribution charges and inventory reserve expense for the Nexafed product line. Our cost of sales for the three months ended March 31, 2017 and 2016 were $128 thousand and $102 thousand, respectively. As of March 16, 2017, our licensee, MainPointe Pharmaceuticals LLC, is manufacturing, distributing, and selling the Nexafed product line.

Research and Development

Research and development expense (R&D) for the three months ended March 31, 2017 includes costs of preclinical and non-clinical, clinical trials, clinical supplies and related formulation and design costs, salaries and other personnel related expenses, and facility costs as well as approximately $86 thousand of cost sharing expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States under the Egalet Agreement and approximately $23 thousand of cost sharing expenses of the FDA required post-marketing study for Oxaydo under the Egalet Agreement. R&D expense for the three months ended March 31, 2016 was primarily for our Aversion and our Impede Technologies development including costs of preclinical and non-clinical, clinical trials, clinical supplies and related formulation and design costs, salaries and other personnel related expenses, and facility costs. Included in each of 2017 and 2016 quarterly results are non-cash share-based compensation expenses of approximately $34 thousand and $43 thousand, respectively. Excluding the share-based compensation expense, our R&D expenses decreased approximately $300 thousand between reporting periods. The initial LTX-04 clinical study, Study AP-LTX-400 or Study 400, was completed during 2016. During the first quarter 2017, our activities were addressing certain excipient issues in our LTX-04 tablet formulation and developing a new, faster releasing micro-particle formulation for LTX-04. We expect to initiate enrollment in a second pharmacokinetic study, AP-LTX-401 in May 2017.

General, Administrative, Selling and Marketing

Selling and marketing expenses for the three months ended March 31, 2017 was primarily of advertising and marketing activities on the Nexafed product line. Our general and administrative expenses primarily consisted of legal, audit and other professional services, corporate insurance, and payroll. Included in each of the March 31, 2017 and 2016 quarterly results are non-cash share-based compensation expenses of approximately $83 thousand and $107 thousand, respectively. Excluding the share-based compensation expense our selling, marketing, general and administrative expenses decreased by approximately $900 thousand between reporting periods, resulting primarily from decreases in advertising and marketing activities as well as patent and general legal activities.

Non-Operating Income (Expense)

During the three months ended March 31, 2017 and 2016, non-operating expense consisted principally of interest expense on our term loan from Oxford Finance LLC.

Income Taxes

Our results for 2017 and 2016 show no federal or state income tax benefit provisions due to 100% allowances placed against them for the uncertainty of their future utilization.

Liquidity and Capital Resources

At March 31, 2017, we had unrestricted cash and cash equivalents of $3.8 million compared to unrestricted cash and cash equivalents of $2.7 million at December 31, 2016. Under our term loan with Oxford, we are required to maintain a $2.5 million compensating balance. As of April 30, 2017, our unrestricted cash and cash equivalents was $3.0 million (which is after the deduction of the $2.5 million compensating balance requirement under our term loan with Oxford). We estimate that our unrestricted working capital, together with milestone and royalty payments, if any, that may be made under the Egalet Agreement, the KemPharm Agreement, the Bayer Agreement and the MainPointe Agreement, will be sufficient to fund our continuing operations only through mid-2017 while maintaining compliance with the $2.5 million compensating balance requirement under our term loan with Oxford.

To fund further operations and product development activities beyond mid-2017, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. The Company intends to explore a variety of capital raising and other transactions to provide additional funding to continue operations. These include a registered public offering of the Company’s common stock, for which the Company filed a registration statement on Form S-1 with the SEC on February 3, 2017, and potential private offerings of common stock to institutional and/or accredited investors. The Company is also actively seeking a licensing partner for its Limitx Technology, with the objective of receiving an upfront license fee, development milestone payments and royalties on the net sales of products utilizing the Limitx Technology, similar to the Egalet and Bayer Agreements. The Company is also exploring licensing or selling select assets and intellectual property in an effort to raise capital and reduce operating expenses. Finally, the Company is evaluating the potential for a strategic transaction which may involve the Company being acquired in a merger or asset purchase transaction. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. Our auditors have included in their report relating to our 2016 financial statements a “going concern” explanatory paragraph as to substantial doubt of our ability to continue as a going concern. In the absence of such financing or third-party license or collaboration agreements, there will be substantial doubt about the Company’s ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations.

Our future sources of revenue, if any, will be derived from milestone payments and royalties under the Egalet Agreement, the Bayer Agreement, the KemPharm Agreement, the MainPointe Agreement and similar agreements for our Limitx products in development with other pharmaceutical company partners, for which there can be no assurance.

The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our product candidates and the resources we devote to the development and commercialization of our product candidates.

Critical Accounting Policies

Note A of the Notes to Consolidated Financial Statements, in the Company’s 2016 Annual Report on Form 10-K, includes a summary of the Company's significant accounting policies and methods used in the preparation of the financial statements. The application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates. The Company's critical accounting policies described in the 2016 Annual Report are also applicable to 2017.

Item 4. Controls and Procedures

(a) Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined on Rules 13a – 13(e) and 15(d) – 15(e) under the Exchange Act) as of the end of the period covered by this Report. The Company’s disclosure controls and procedures are designed to provide reasonable assurance that information is recorded, processed, summarized and reported accurately and on a timely basis in the Company’s periodic reports filed with the SEC. Based upon such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company's disclosure controls and procedures are effective to provide reasonable assurance. Notwithstanding the foregoing, a control system, no matter how well designed and operated, can provide only reasonable, not absolute assurance that it will detect or uncover failures within the Company to disclose material information otherwise require to be set forth in the Company’s periodic reports.

(b) Changes in Internal Controls over Financial Reporting. There were no changes in our internal controls over financial reporting during the first fiscal quarter of 2017 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

The information required by this Item is incorporated by reference to Note 17, “Commitments and Contingencies,” in Part I, Item 1, “Financial Statements.”

Item 1A. Risk Factors

Investors in our common stock should consider the following risk factors, in addition to those risk factors set forth in our 2016 Annual Report on Form 10-K:

We require additional funding; if we fail to raise additional funding we will cease operations and/or seek protection under applicable bankruptcy laws.

We require additional financing or entry into license or collaborative agreements with third parties providing for net proceeds to us in order to continue to fund operations. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaborative agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaborative agreements will provide for funding or payments to us sufficient to continue to fund operations. Under our term loan with Oxford Finance LLC, we are required to maintain a $2.5 million compensating balance. Our auditors have included in their report relating to our 2016 financial statements a “going concern” explanatory paragraph as to substantial doubt of our ability to continue as a going concern. Giving effect to our term loan compensating balance requirement, we believe we have unrestricted cash sufficient to fund operations only through mid-2017. In the absence of the receipt of additional financing or payments under third-party license or collaborative agreements prior to such time, we will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. This could result in a complete loss of shareholder value in the Company. Even assuming we are successful in securing additional sources of financing to fund continued operations, there can be no assurance that the proceeds of such financing will be sufficient to fund operations until such time, if at all, that we generate sufficient revenue from our products and product candidates to sustain and grow our operations.

Item 6. Exhibits

The exhibits required by this Item are listed below.

10.1	Intellectual Property Security Agreement entered into as of March 15, 2017 between the Company, Acura Pharmaceutical Technologies, Inc. and Oxford Finance LLC (certain information has been omitted and filed separately with the Securities and Exchange Commission and confidential treatment has been requested with respect to the omitted portion).

10.2	Consent and Third Amendment entered into as of March 15, 2017 between the Company, Acura Pharmaceutical Technologies, Inc. and Oxford Finance LLC (certain information has been omitted and filed separately with the Securities and Exchange Commission and confidential treatment has been requested with respect to the omitted portion).

31.1	Certification of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

31.2	Certification of Periodic Report by Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

32.1	Certification of Periodic Report by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	XBRL Instance Document

101.SCH	XBRL Taxonomy Extension Schema Document

101.CAL	XBRL Taxonomy Extension Calculation Linkbase

101.LAB	XBRL Taxonomy Extension Label Linkbase

101.PRE	XBRL Taxonomy Extension Presentation Linkbase

101.DEF	XBRL Taxonomy Extension Definition Linkbase

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 12, 2017	ACURA PHARMACEUTICALS, INC.

	/s/ Robert B. Jones
	Robert B. Jones
	Chief Executive Officer

	/s/ Peter A. Clemens
	Peter A. Clemens
	Senior VP & Chief Financial Officer

EX-10.1 2 v464992_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of March 15, 2017, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois and ACURA PHARMACEUTICAL TECHNOLOGIES, INC., an Indiana corporation with offices locates at 16235 State Road 17, Culver, IN 46511 (individually and collectively, jointly and severally, “Grantor”).

RECITALS

A. Lenders agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “Loans”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among the Collateral Agent, Lenders and Grantor dated as of December 27, 2013 (as the same may be, and may have been, amended, modified or supplemented from time to time, the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). In accordance with the terms of the Loan Agreement, Grantor is granting to Collateral Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Grantor has already granted to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (other than the Intellectual Property Collateral (as defined herein below)).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, effective as of the date hereof, Grantor hereby grants and pledges to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

*****Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with the Commission.

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Grantor hereby represents and warrants that the Copyrights set forth on Exhibit A, the Patents set forth on Exhibit B and the Trademarks set forth on Exhibit C include all Copyrights, Patents and Trademarks of Grantor and its Subsidiaries that are either registered, or for which applications for registration or grant, as applicable, are pending, on the date hereof. Grantor hereby covenants to provide prompt notice of (A) any material change in the composition of the Intellectual Property, and (B) any new the Copyrights, Trademarks, Patents, or Mask Works of Grantor or any of its Subsidiaries that are either registered or for which an application for registration or grant is filed.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the ratable benefit of the Lenders under the Loan Agreement, and shall become effective upon the date hereof. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Collateral Agent, of any or all other rights, powers or remedies.

Notwithstanding the foregoing, the Liens granted by this Intellectual Property Security Agreement are subject to any and all existing licenses, rights and remedies granted by Grantor on or prior to the date hereof in accordance with the provisions of the Loan Agreement, including those set forth in Exhibit E, with respect to the Intellectual Property Collateral. Any Intellectual Property Collateral Transferred in accordance with the provisions of the Loan Agreement shall be deemed to have been Transferred free of Collateral Agent’s Lien (upon consummation of the applicable Transfer in accordance with the terms of the applicable agreement(s) between the Grantor and the party(ies) to which such Transfer is made); provided, however, the proceeds of such Intellectual Property Collateral shall be, and for all purposes shall be deemed to be, automatically included in the Collateral and subject to the Lien and first priority perfected security interest of Collateral Agent.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

	GRANTOR:

Address of Grantor:	ACURA PHARMACEUTICALS, INC.

616 N. North Court, Suite 120, Palatine, Illinois

Attn: Chief Financial Officer	By:	/s/ Robert B. Jones

	Title:	President & CEO

	GRANTOR:

Address of Grantor:	ACURA PHARMACEUTICAL TECHNOLOGIES, INC.

16235 State Road 17, Culver, IN 46511

Attn: Chief Financial Officer	By:	/s/ Robert B. Jones

	Title:	President

	LENDER AND COLLATERAL AGENT:

Address of Lender:	OXFORD FINANCE LLC, AS COLLATERAL AGENT AND AS LENDER

133 North Fairfax Street	By:	/s/ Mark Davis
Alexandria, Virginia 22314
Attn: Legal Department	Title:	Vice President – Finance, Secretary & Treasurer

EXHIBIT A

Copyrights

Description

Registration/

Application

Number

Registration/

Application

Date

None

EXHIBIT B

Patents

Description	Registration/ Application Number	Registration/ Application Date
Methods and compositions for deterring abuse of opioid containing dosage forms	US 7,201,920 US 7,476,402 US 7,510,726 US 7,981,439 US 8,409,616 US 8,822,489 US 8,637,540 US 9,492,443 AU 2004294953 AU 2010200979 CA 2,547,334 IL 175863 IL 221018 [*] AU 2010200979 AU 2013206525 EP 04812083.6 EP 11158284.7 HK 12106471.1	4/10/2007 1/13/2009 3/31/2009 7/19/2011 4/2/2013 7/24/2014 1/28/2014 11/15/2016 4/1/2010 11/23/2004 8/10/2010 11/23/2004 11/23/2004 [******] 3/15/2010 11/23/2004 11/23/2004 11/23/2011 11/23/2004
Process to manufacture oxycodone	US 6,864,370	3/8/2005
Process for manufacturing thebaine	US 6,790,959	9/14/2004
Process for manufacturing codeine	US 6,972,332	12/6/2005
Process for manufacturing codeine	US 6,949,645	9/27/2005
Process for preparing dihydrocodeine from codeine	US 6,887,999	5/3/2005
Preparation of opioid analgesics by a one-pot process	US 6,946,556	9/20/2005
Preparation of oxycodone	US 7,071,336	7/4/2006
Preparation of a 4,5-epoxymorphinan	US 7,348,430	3/25/2008
Methods and compositions for deterring abuse	US 8,901,113 AU 2010300641 CA 2,775,890 EP 2,488,029 HK 13102020.5 IL 218533 US 14/552,067 [*] CA 2,775,890 AU 2016204065 EP 16161681.8 HK 13102020.5 IL 245734	12/2/[2014] 6/3/2016 6/21/2016 3/23/2016 10/14/2016 9/29/2016 11/24/2014 [******] 9/29/2010 9/29/2010 9/29/2010 9/29/2010 9/29/2010
Methods and compositions for self-regulated release of active pharmaceutical ingredient	US 9,101,636 US 9,320,796 CA 2,892,908 JP 5,922,851 [*] WO PCT/US13/72249 RU 2015124694	8/11/2015 4/26/2016 4/12/2016 4/22/2016 [*****] 11/27/2013 6/23/2015
Methods and Compositions for Deterring Abuse	US 14/322,596 CA 2,916,973 AU 2014284333 EP 14820721.0 IL 242880 CH 201480037082.5 NZ 716482	7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse	US 14/734,364 CA 2,951,563 AU 2015274936 EP 15807096.1 CH 201580030318.7	6/9/2015 6/9/2015 6/9/2015 6/9/2015 6/9/2015
*****	[*****]	[*****]
*****	[*****]	[*]
Pharmaceutical Compositions for Deterring Misuse, Abuse, and Diversion	WO PCT/US2010/061331	12/20/2010

EXHIBIT C

Trademarks

Description	Registration/ Application Number	Registration/ Application Date

US- ACURA PHARMACEUTICALS	3114970	7/11/2006

US- OXAYDO	4847742	11/3/2015

US- NEXAFED	4151083	4/24/2012

US- IMPEDE	4289295	2/12/2013

US- AVERSION	3059542	2/14/2006

MEX- ACURACET	1087322	2/26/2009

MEX- IMPEDE	1130279	11/13/2009

MEX- ACUROX	1070309	11/4/2008

MEX- AVERSION	1182320 1087323	9/30/2010 2/26/2009

MEX- VYCAVERT	1109785	7/9/2009

CAN- OXAYDO	1724857	5/23/2016

CAN- AVERSION	832700	9/25/2012

CAN- ACUROX	757997	2/17/2010

CAN- VYCAVERT	825294	6/1/2012

EU- OXAYDO	13955935	8/19/2015

EXHIBIT D

Mask Works

Description

Registration/

Application

Number

Registration/

Application

Date

None

EXHIBIT E

Agreements potentially transferring Intellectual Property Collateral

1.	License, Commercialization and Option Agreement dated on or about March 15, 2017 between Mainpointe Pharmaceuticals, LLC and Acura Pharmaceuticals, Inc. (“Acura”).

2.	Collaboration and License Agreement entered into as of January 7, 2015 between Acura, Egalet US, Inc., Egalet Limited and with respect to Section 17.21, Egalet Corporation.

3.	License and Development Agreement dated as of June 5, 2015 between the Registrant and Bayer HealthCare LLC.

4.	License Agreement dated as of October 13, 2016 between Acura and Kempharm Inc.

5.	License and Settlement Agreement dated September 27, 2013 between Acura and Impax Laboratories, Inc.

6.	License Agreement dated September 27, 2013 between Acura and Par Pharmaceutical, Inc.

7.	License and Settlement Agreement dated May 20, 2014 between Acura and Sandoz, Inc.

8.	Settlement and Patent license Agreement between Highland Pharmaceutical LLC and Acura dated as August 1, 2014

EX-10.2 3 v464992_ex10-2.htm EXHIBIT 10.2

Exhibit 10.2

CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS CONSENT AND THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of 15th March, 2017 (the “Third Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”) and ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Parent”) and ACURA PHARMACEUTICAL TECHNOLOGIES, INC., an Indiana corporation with offices locates at 16235 State Road 17, Culver, IN 46511 (“APT”, and along with Parent, individually and collectively, jointly and severally, “Borrower”).

WHEREAS, Collateral Agent, Borrower and Lenders party thereto from time to time have entered into that certain Loan and Security Agreement, dated as of December 27, 2013 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof;

WHEREAS, Borrower anticipates entering into a License, Commercialization and Option Agreement on or about March 15th, 2017 with MainPointe Pharmaceuticals, LLC, (“MainPointe”), in the form provided to Collateral Agent prior to the execution hereof (the “License Agreement”);

WHEREAS, Loan Agreement requires Borrower to obtain the consent of Required Lenders prior to granting certain licenses and consummating the Transfers contemplated in the License Agreement;

WHEREAS, Borrower has requested that Collateral Agent and Lenders consent to grant of certain licenses and Transfers by Borrower to MainPointe, pursuant to the License Agreement, as described herein below; and

WHEREAS, in connection with and in consideration for providing the aforementioned consent, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:

Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.

Subject to the terms and conditions hereof, the Collateral Agent and the Required Lenders hereby consent to the Borrower’s entry into the License Agreement in the form, and only in the form, provided to Collateral Agent prior to the execution hereof, and consummation of the transactions contemplated therein; provided, however, Borrower may enter into and deliver any amendment to the License Agreement and consummate the transactions as contemplated by the License Agreement after giving effect to such amendment if, and only if, such amendments to the terms of the License Agreement: (i) would not require the consent of the Required Lenders under Section 7 of the Loan Agreement, (ii) are not be adverse to the interests of Borrower, (iii) do not reduce the amount or change the form of consideration due to Borrower under the License Agreement and (iv) do not postpone any payment due to Borrower under the License Agreement. Concurrently with the execution of the Mainpointe Agreement, Collateral Agent shall have been deemed to release its Lien (granted to it under the Loan Agreement) only on the Collateral described on Exhibit C (“Described Collateral”); provided, however, all proceeds of the Described Collateral are and shall be included in the Collateral in which Collateral Agent has a continuing Lien and perfected security interest under the Loan Agreement and nothing herein shall be deemed to be a release of Collateral Agent’s Lien in the proceeds of the Described Collateral or any other Collateral.

Borrower hereby reaffirms the security interest granted by Borrower previously in Section 4.1 of the Agreement with respect to the Collateral (as defined herein) and hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, such part of the Collateral that was not pledged previously or in which security interest was not granted prior to the Third Amendment Date, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. Furthermore, Borrower hereby authorizes Collateral Agent to file financing statements or take any other action required to perfect Collateral Agent’s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent’s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.

Section 5.2(d) of the Loan Agreement is hereby amended and restated as follows:

(d) Borrower and each of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens. (i) No part of Borrower’s or its Subsidiaries’ Intellectual Property has been judged invalid or unenforceable, in whole or in part, and to the best of Borrower’s knowledge, each of Borrower’s and its Subsidiaries’ Copyrights, Trademarks and issued Patents are valid and enforceable and, and (ii) to the best of Borrower’s knowledge, no claim has been made that any part of the Intellectual Property or any practice by Borrower or its Subsidiaries violates the rights of any third party except to the extent such claim could not reasonably be expected to have a Material Adverse Change. Except as noted on the Perfection Certificates, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material agreement with respect to which Borrower or such Subsidiary is the licensee that (i) prohibits or otherwise restricts Borrower or its Subsidiaries from granting a security interest in Borrower’s or such Subsidiaries’ interest in such material license or material agreement or any other property, or (ii) for which a default under or termination of could interfere with Collateral Agent’s or any Lender’s right to sell any Collateral. Borrower shall provide written notice to Collateral Agent and each Lender within ten (10) days of Borrower or any of its Subsidiaries entering into or becoming bound by any license or agreement with respect to which Borrower or any Subsidiary is the licensee (other than over the counter software that is commercially available to the public).

Section 6.2(a)(ii) of the Loan Agreement is hereby amended and restated in its entirety as follows:

(ii) as soon as available, but no later than one hundred twenty (120) days after the last day of Borrower’s fiscal year or within five (5) days of filing with the SEC, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion (provided, however, that for the fiscal year 2016, such opinion may be qualified strictly with respect to Borrower and its Subsidiary as a going concern and unqualified otherwise) on the financial statements from an independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion;

Section 6.2(a)(vii) of the Loan Agreement is hereby amended and restated in its entirety as follows:

(vii) prompt notice of (A) any material change in the composition of the Intellectual Property, (B) the registration of any copyright, including any subsequent ownership right of Borrower or any of its Subsidiaries in or to any copyright, patent or trademark, including a copy of any such registration, and (C) any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property;

Section 6.7 of the Loan Agreement is hereby amended and restated in its entirety as follows:

Protection of Intellectual Property Rights. Borrower and each of its Subsidiaries shall: (a) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to Borrower’s business; (b) promptly advise Collateral Agent in writing of material infringement by a third party of its Intellectual Property; and (c) not allow any Intellectual Property material to Borrower’s business to be abandoned, forfeited or dedicated to the public without Collateral Agent’s prior written consent. If Borrower or any of its Subsidiaries (i) obtains any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applies for any patent or the registration of any trademark or servicemark, then Borrower or such Subsidiary shall substantially contemporaneously provide written notice thereof to Collateral Agent and each Lender and shall execute such intellectual property security agreements and other documents and take such other actions as Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in such property. If Borrower or any of its Subsidiaries decides to register any copyrights or mask works in the United States Copyright Office, Borrower or such Subsidiary shall: (x) provide Collateral Agent and each Lender with at least fifteen (15) days prior written notice of Borrower’s or such Subsidiary’s intent to register such copyrights or mask works together with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral Agent may reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in the copyrights or mask works intended to be registered with the United States Copyright Office; and (z) record such intellectual property security agreement with the United States Copyright Office contemporaneously with filing the copyright or mask work application(s) with the United States Copyright Office. Borrower or such Subsidiary shall promptly provide to Collateral Agent and each Lender with evidence of the recording of the intellectual property security agreement necessary for Collateral Agent to perfect and maintain a first priority perfected security interest in such property.

Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definition therein as follows:

“Loan Documents” are, collectively, this Agreement, the Warrants, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter, Mortgage, the Post Closing Letter and any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement; all as amended, restated, or otherwise modified.

10.

Section 13.1 of the Loan Agreement is hereby further amended by adding the following definitions thereto in alphabetical order:

“Third Amendment Date” is March 15th, 2017.

“IP Agreement” is that certain Intellectual Property Security Agreement entered into by and between Borrower and Collateral Agent dated as of the Third Amendment Date, as such may be amended from time to time.

11.

Exhibit A to the Loan Agreement is hereby amended and restated in its entirety as set forth on Exhibit A hereto.

12.

Borrower hereby represents and warrants that a complete and accurate list of its Copyright registrations, Patents, applications to register and registrations of Trademarks, as of the Third Amendment Date is attached hereto as Exhibit B.

13.

Borrower hereby authorizes Collateral Agent to file financing statements, amendments to financing statements or take any other action required to perfect Collateral Agent’s security interests in the Collateral (as such term has been amended pursuant to this Amendment) , without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent’s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.

14.

Limitation of Amendment.

The amendments and the consent set forth in Sections 2 through 13 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.

This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

15.

To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;

Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;

The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Borrower, (ii) any contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;

The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and

This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

16.

Collateral Agent represents and warrants to Borrower that all Required Lenders have executed this Amendment.

17.

Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.

18.

This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto, (b) the due execution and delivery to Collateral Agent of the IP Agreement by each party thereto, (c) Collateral Agent’s receipt of the fully executed License Agreement and (d) Borrower’s payment of all Lenders’ Expenses incurred through the date hereof (not to exceed $7,500.00), which may be debited from any of Borrower’s accounts with Lenders.

19.

This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.

20.

This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties hereto have caused this Consent and Third Amendment to Loan and Security Agreement to be executed as of the Third Amendment Date.

BORROWER:

ACURA PHARMACEUTICALS, INC.

By	/s/ Robert B. Jones
Name: Robert B. Jones
Title: President and CEO

BORROWER:

ACURA PHARMACEUTICAL TECHNOLOGIES, INC.

By	/s/ Robert B. Jones
Name: Robert B. Jones
Title: President

COLLATERAL AGENT AND LENDER:

OXFORD FINANCE LLC

By	/s/ Mark Davis
Name:	Mark Davis
Title:	/s/ Vice President – Finance, Secretary & Treasurer

EXHIBIT A

Description of Collateral

The Collateral consists of all of Borrower’s right, title and interest in and to the following personal property:

All goods, Accounts (including health-care receivables), Equipment, Inventory, contract rights, rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (including Intellectual Property), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and

All Borrower’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

Notwithstanding the foregoing, the Collateral does not include any license or contract, in each case if the granting of a Lien in such license or contract is prohibited by or would constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition is enforceable under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the termination, lapsing or expiration of any such prohibition, such license or contract, as applicable, shall automatically be subject to the security interest granted in favor of Collateral Agent hereunder and become part of the “Collateral.”

Pursuant to the terms of a certain negative pledge arrangement with Collateral Agent and the Lenders, Borrower has agreed not to encumber any of its Intellectual Property (excluding Permitted Licenses).

EXHIBIT B

Intellectual Property

Registered Copyrights

None

Patents

Description	Registration/ Application Number	Registration/ Application Date
Methods and compositions for deterring abuse of opioid containing dosage forms	US 7,201,920 US 7,476,402 US 7,510,726 US 7,981,439 US 8,409,616 US 8,822,489 US 8,637,540 US 9,492,443 AU 2004294953 AU 2010200979 CA 2,547,334 IL 175863 IL 221018 [*****] AU 2010200979 AU 2013206525 EP 04812083.6 EP 11158284.7 HK 12106471.1	4/10/2007 1/13/2009 3/31/2009 7/19/2011 4/2/2013 7/24/2014 1/28/2014 11/15/2016 4/1/2010 11/23/2004 8/10/2010 11/23/2004 11/23/2004 [*****] 3/15/2010 11/23/2004 11/23/2004 11/23/2011 11/23/2004
Process to manufacture oxycodone	US 6,864,370	3/8/2005
Process for manufacturing thebaine	US 6,790,959	9/14/2004
Process for manufacturing codeine	US 6,972,332	12/6/2005
Process for manufacturing codeine	US 6,949,645	9/27/2005
Process for preparing dihydrocodeine from codeine	US 6,887,999	5/3/2005
Preparation of opioid analgesics by a one-pot process	US 6,946,556	9/20/2005
Preparation of oxycodone	US 7,071,336	7/4/2006
Preparation of a 4,5-epoxymorphinan	US 7,348,430	3/25/2008
Methods and compositions for deterring abuse	US 8,901,113 AU 2010300641 CA 2,775,890 EP 2,488,029 HK 13102020.5 IL 218533 US 14/552,067 [*****] CA 2,775,890 AU 2016204065 EP 16161681.8 HK 13102020.5 IL 245734	12/2/[2014] 6/3/2016 6/21/2016 3/23/2016 10/14/2016 9/29/2016 11/24/2014 [*****] 9/29/2010 9/29/2010 9/29/2010 9/29/2010 9/29/2010
Methods and compositions for self-regulated release of active pharmaceutical ingredient	US 9,101,636 US 9,320,796 CA 2,892,908 JP 5,922,851 [*****] WO PCT/US13/72249 RU 2015124694	8/11/2015 4/26/2016 4/12/2016 4/22/2016 [*****] 11/27/2013 6/23/2015
Methods and Compositions for Deterring Abuse	US 14/322,596 CA 2,916,973 AU 2014284333 EP 14820721.0 IL 242880 CH 201480037082.5 NZ 716482	7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse	US 14/734,364 CA 2,951,563 AU 2015274936 EP 15807096.1 CH 201580030318.7	6/9/2015 6/9/2015 6/9/2015 6/9/2015 6/9/2015
Methods and compositions for self-regulated release of active pharmaceutical	[*****]	[*****]
Methods and compositions of self-regulating the conversion of pro-drugs to active pharmaceutical ingredients22	[*****]	[*****]
Pharmaceutical Compositions for Deterring Misuse, Abuse, and Diversion	WO PCT/US2010/061331	12/20/2010

Trademark Registrations and Applications

Description	Registration/ Application Number	Registration/ Application Date

US- ACURA PHARMACEUTICALS	3114970	7/11/2006

US- OXAYDO	4847742	11/3/2015

US- NEXAFED	4151083	4/24/2012

US- IMPEDE	4289295	2/12/2013

US- AVERSION	3059542	2/14/2006

MEX- ACURACET	1087322	2/26/2009

MEX- IMPEDE	1130279	11/13/2009

MEX- ACUROX	1070309	11/4/2008

MEX- AVERSION	1182320 1087323	9/30/2010 2/26/2009

MEX- VYCAVERT	1109785	7/9/2009

CAN- OXAYDO	1724857	5/23/2016

CAN- AVERSION	832700	9/25/2012

CAN- ACUROX	757997	2/17/2010

CAN- VYCAVERT	825294	6/1/2012

EU- OXAYDO	13955935	8/19/2015

Exhibit C

Schedule of Deleted Collateral

Inventory
Warehouse:	[*****]
Item	Lot	Description	Qty	Exp Date	Alt Product	UOI	UOM
[*****]

Equipment


Location:	[*]
Item	Asset Class	Description

[*****]

Contracts and POS

Contracts

[*****]

Purchase Orders

Purchase Order #1048 to Patheon Pharmaceuticals, Inc. for Nexafed Sinus 30/325 mg Tablets.

[*****]

Other

All domain names, brochures, promotional and printed materials, tradeshow materials (including displays), videos, advertising materials, marketing materials, package inserts and packaging materials (in all cases, in any form or medium) if any, owned by Acura Pharmaceuticals, Inc. or Acura Pharmaceutical Technologies, Inc. related exclusively to the commercialization of the Nexafed products.

EX-31.1 4 v464992_ex31-1.htm EXHIBIT 31.1

Exhibits 31.1

CERTIFICATION OF PERIODIC REPORT PURSUANT TO RULES 13a-14 AND 15d-14

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Robert B. Jones, the President & Chief Executive Officer of Acura Pharmaceuticals, Inc., certify that:

I have reviewed this quarterly report on Form 10-Q of Acura Pharmaceuticals, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d – 15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls.

May 12, 2017	/s/ Robert B. Jones
	Robert B. Jones
	President & Chief Executive Officer

EX-31.2 5 v464992_ex31-2.htm EXHIBIT 31.2

Exhibits 31.2

CERTIFICATION OF PERIODIC REPORT PURSUANT TO RULES 13a-14 AND 15d-14

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Peter A. Clemens, the Chief Financial Officer of Acura Pharmaceuticals, Inc., certify that:

I have reviewed this quarterly report on Form 10-Q of Acura Pharmaceuticals, Inc.;

a. all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls.

May 12, 2017	/s/ Peter A. Clemens
	Peter A. Clemens
	Chief Financial Officer

EX-32.1 6 v464992_ex32-1.htm EXHIBIT 32.1

Exhibits 32.1

CERTIFICATIONS OF THE CHIEF EXEUTIVE OFFICER AND THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Acura Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ending March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Robert B. Jones, the Chief Executive Officer of the Company, and Peter A. Clemens, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 12, 2017	/s/ Robert B. Jones
	Robert B. Jones
	Chief Executive Officer

	/s/ Peter A. Clemens
	Peter A. Clemens
	Chief Financial Officer

EX-101.INS 7 acur-20170331.xml XBRL INSTANCE DOCUMENT 0000786947 2015-01-01 2015-01-07 0000786947 2016-01-01 2016-03-31 0000786947 2016-01-01 2016-12-31 0000786947 2017-01-01 2017-03-31 0000786947 2017-03-01 2017-03-16 0000786947 2016-03-31 0000786947 2017-03-31 0000786947 2017-05-05 0000786947 2016-10-01 2016-10-31 0000786947 2013-12-27 0000786947 2013-12-31 0000786947 2016-12-31 0000786947 2015-12-31 0000786947 acur:OxfordTermLoanAgreementMember 2017-03-31 0000786947 acur:KempharmAgreementMember 2016-10-01 2016-10-31 0000786947 acur:KempharmAgreementMember us-gaap:MinimumMember 2016-10-31 0000786947 acur:EgaletAgreementMember 2015-10-01 2015-10-09 0000786947 acur:PfizerAgreementMember 2017-01-01 2017-03-31 0000786947 us-gaap:BuildingImprovementsMember 2017-03-31 0000786947 acur:ScientificEquipmentMember 2017-03-31 0000786947 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2017-03-31 0000786947 us-gaap:LandImprovementsMember 2017-03-31 0000786947 us-gaap:MachineryAndEquipmentMember 2017-03-31 0000786947 acur:ComputerHardwareAndSoftwareMember 2017-03-31 0000786947 us-gaap:OfficeEquipmentMember 2016-12-31 0000786947 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2016-12-31 0000786947 us-gaap:LandImprovementsMember 2016-12-31 0000786947 us-gaap:MachineryAndEquipmentMember 2016-12-31 0000786947 acur:ComputerHardwareAndSoftwareMember 2016-12-31 0000786947 acur:ScientificEquipmentMember 2016-12-31 0000786947 us-gaap:BuildingImprovementsMember 2016-12-31 0000786947 us-gaap:OfficeEquipmentMember 2017-03-31 0000786947 acur:LoanAgreementMember 2013-12-27 0000786947 us-gaap:WarrantMember 2017-03-31 0000786947 us-gaap:WarrantMember 2017-01-01 2017-03-31 0000786947 us-gaap:WarrantMember 2015-01-01 2015-01-07 0000786947 acur:LoanAgreementMember 2015-01-01 2015-01-07 0000786947 us-gaap:MaximumMember 2015-01-07 0000786947 us-gaap:MinimumMember 2015-01-07 0000786947 acur:LoanAgreementMember 2016-10-01 2016-10-31 0000786947 us-gaap:MinimumMember 2016-10-01 2016-10-31 0000786947 acur:PriorToDecemberTwentySevenTwoThousandFifteenMember 2017-01-01 2017-03-31 0000786947 acur:FirstRevenueEventDoesNotOccursMemberMember 2017-03-31 0000786947 acur:TermLoanMember 2017-01-01 2017-03-31 0000786947 acur:TermLoanMember 2017-03-31 0000786947 acur:TermLoanMember 2016-12-31 0000786947 us-gaap:ShortTermDebtMember 2017-01-01 2017-03-31 0000786947 us-gaap:LongTermDebtMember 2017-01-01 2017-03-31 0000786947 us-gaap:ShortTermDebtMember 2016-12-31 0000786947 us-gaap:LongTermDebtMember 2016-12-31 0000786947 us-gaap:ShortTermDebtMember 2017-03-31 0000786947 us-gaap:LongTermDebtMember 2017-03-31 0000786947 acur:StockOptionPlanMember 2016-12-31 0000786947 acur:StockOptionPlanMember 2015-12-31 0000786947 acur:StockOptionPlanMember 2017-01-01 2017-03-31 0000786947 acur:StockOptionPlanMember 2017-03-31 0000786947 acur:StockOptionPlanMember 2016-03-31 0000786947 acur:StockOptionPlanMember 2016-01-01 2016-03-31 0000786947 us-gaap:StockOptionMember 2016-01-01 2016-12-31 0000786947 acur:RsusMember 2016-12-31 0000786947 acur:VestedRestrictedStockUnitsMember 2016-12-31 0000786947 acur:RsusMember 2015-12-31 0000786947 acur:VestedRestrictedStockUnitsMember 2015-12-31 0000786947 acur:RsusMember 2017-01-01 2017-03-31 0000786947 acur:VestedRestrictedStockUnitsMember 2017-01-01 2017-03-31 0000786947 acur:RsusMember 2016-01-01 2016-03-31 0000786947 acur:VestedRestrictedStockUnitsMember 2016-01-01 2016-03-31 0000786947 acur:RsusMember 2017-03-31 0000786947 acur:RsusMember 2016-03-31 0000786947 acur:VestedRestrictedStockUnitsMember 2016-03-31 0000786947 acur:VestedRestrictedStockUnitsMember 2017-03-31 0000786947 acur:RestrictedStockAwardPlanMember 2014-05-01 0000786947 acur:RestrictedStockAwardPlanMember acur:FourNonEmployeeDirectorsMember 2014-05-02 2015-01-02 0000786947 acur:RestrictedStockAwardPlanMember acur:FourNonEmployeeDirectorsMember 2015-12-20 2016-01-04 0000786947 acur:RestrictedStockAwardPlanMember acur:FourNonEmployeeDirectorsMember 2016-12-31 0000786947 acur:RestrictedStockAwardPlanMember 2015-12-20 2016-01-04 0000786947 acur:RestrictedStockAwardPlanMember us-gaap:ConvertibleCommonStockMember 2015-12-20 2016-01-04 0000786947 acur:RestrictedStockAwardPlanMember acur:SettledInCashMember 2015-12-20 2016-01-04 0000786947 acur:RestrictedStockAwardPlanMember acur:DistributedInCommonStockMember 2015-12-20 2016-01-04 0000786947 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0000786947 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000786947 acur:PennsylvaniaStateMember 2017-03-31 0000786947 acur:NewJerseyStateMember 2017-03-31 0000786947 acur:CaliforniaStateMember 2017-01-01 2017-03-31 0000786947 acur:PurduePharmaMember 2014-01-01 2014-12-31 0000786947 acur:PalatineIllinoisMember 2017-01-01 2017-03-31 0000786947 us-gaap:CommonStockMember 2016-12-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000786947 us-gaap:RetainedEarningsMember 2016-12-31 0000786947 us-gaap:CommonStockMember 2017-01-01 2017-03-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-03-31 0000786947 us-gaap:RetainedEarningsMember 2017-01-01 2017-03-31 0000786947 us-gaap:CommonStockMember 2017-03-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0000786947 us-gaap:RetainedEarningsMember 2017-03-31 0000786947 acur:MainPointeAgreementMember 2017-03-01 2017-03-16 0000786947 acur:MainPointeAgreementMember 2017-03-16 0000786947 acur:MainPointeAgreementMember acur:NexafedInventoryMember 2017-03-01 2017-03-16 0000786947 acur:PurduePharmaMember 2015-06-01 2015-06-30 0000786947 acur:MainPointeAgreementMember country:GB 2017-03-01 2017-03-16 0000786947 acur:MainPointeAgreementMember country:JP 2017-03-01 2017-03-16 0000786947 acur:MainPointeAgreementMember acur:SouthKoreaMember 2017-03-01 2017-03-16 0000786947 acur:EgaletAgreementMember 2017-01-01 2017-03-31 0000786947 us-gaap:WarrantMember 2017-01-01 2017-03-31 0000786947 us-gaap:WarrantMember 2016-01-01 2016-03-31 0000786947 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0000786947 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0000786947 acur:PfizerAgreementMember 2017-03-31 0000786947 acur:MainPointeAgreementMember 2017-01-01 2017-03-31 0000786947 acur:FederalResearchAndDevelopmentMember 2016-12-31 0000786947 acur:IndianaStateResearchAndDevelopmentMember 2016-12-31 0000786947 us-gaap:MinimumMember 2016-01-01 2016-12-31 0000786947 us-gaap:MaximumMember 2016-01-01 2016-12-31 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0000786947 acur:RestrictedStockAwardPlanMember acur:FourNonEmployeeDirectorsMember 2017-01-01 2017-01-03 0000786947 acur:RestrictedStockAwardPlanMember acur:FourNonEmployeeDirectorsMember 2017-01-03 0000786947 acur:RestrictedStockAwardPlanMember 2017-01-01 2017-01-03 0000786947 acur:RestrictedStockAwardPlanMember 2014-04-02 2014-05-01 0000786947 acur:RestrictedStockAwardPlanMember acur:DistributedInCommonStockMember 2017-01-01 2017-01-03 0000786947 acur:RestrictedStockAwardPlanMember us-gaap:ConvertibleCommonStockMember 2017-01-01 2017-01-03 0000786947 acur:RestrictedStockAwardPlanMember acur:SettledInCashMember 2017-01-01 2017-01-03 0000786947 us-gaap:WarrantMember 2016-03-31 0000786947 us-gaap:WarrantMember 2013-12-31 0000786947 acur:RestrictedStockAwardPlanMember 2017-01-01 2017-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

6738000

5910000

268000

301000

309000

739000

867000

1379000

1431000

8856000

8208000

209000

77000

1040000

703000

19000

27000

302000 304000

2798000

2376000

7143000

7025000

119000

118000

375887000

375763000

-374293000

-374698000

1713000

1183000

8856000

8208000

4403000

3487000

2142000

2979000

598000 559000

2500000

2681000

3843000

6000

23000

36000 79000 52000 50000

74000

17000

107000

2500000

2717000

224000

128000 102000

711000

1014000

1296000

2246000

582000

-3138000

1000

27000

178000

249000

405000

-3384000

405000

-3384000

70000

405000

-3314000

0.03

-0.28

0.03

-0.28

-177000

-246000

11907000

11837000

12083000

11837000

36000

100000

2135000

3362000

-24000

25000

34000

30000

40000

0 19000

52000

-12000

-103000

-74000

33000

-121000

132000

265000

337000

591000

1298000

-1922000

74000

99000

-445000

-409000

1162000

797000

49000 39000

3177000

309000

3128000

445000

409000

-24000

-43000 0 2000 0 3800000

2500000

200000

2500000

3500000

1000000

5000000

2500000 2000000

243000

341000

98000

1273000

598000

70000

162000

415000

109000

27000

70000

162000

568000

109000

598000

1273000

27000

1833000

1858000

-82000

173000

116000

173000

232000

6000 1000

18000

16000

51000

47000

131000 5000 10000 136000

10000000

0.0835

0.1335

260000

2018-12-01

400000

7.98

60000

December 27, 2020 33000 2500000

5000000

7.98

2.52

6000000

5000000

2500000

3000000

0.01

795000

50000

100000

231000

0.1016

598000

559000

445000

0 722000 -722000

5500000

2521000

2979000

5055000

2798000

2257000

20000

98000

78000

0 0 0 -47000 0 -47000 10000 0 10000 -37000 0 -37000

4940000

2798000

2142000

0 0 0 20000 26000

10000

14000

148000

209000

2077000

2978000

10000000

1397000

1198000

1000

1396000

1198000

1125000

15.67

876000

13.57

13.58

15.67

16.52

20.64

335000

64000

271000

1.18

1.36

1.14

0.023

P10Y

0.77

0.85

91000

45000

238000

88000

67000 67000 42000 42000

59000

22000

262000

91000

25000

83000

400000

0.25

10000

22000

0.25

27000

1000

2000

33000

9000

42000

41000

11881000

11832000

26000

5000

11881000 11832000 202000 5000

1456000

1396000

1324000

1198000

200 150 50

445

500000

25000

269000

March 31, 2017

10-Q false 2017-03-31 2017 Q1 ACURA PHARMACEUTICALS, INC 0000786947 --12-31 Smaller Reporting Company ACUR 11883339

35000

7000

27000

32000

621000

569000

0.01

100000000

11883000

11834000

11883000

11834000

118000

375763000

-374698000

11834000

405000

117000

8000

1000

7000

49000

119000

375887000

-374293000

11883000

117000

150000

-17000

57000

51000 2000

103000

206000 0

49000

75000

110000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">NOTE 1  OPERATIONS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Principal Operations</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® and Limitx Technologies are intended to address methods of product tampering associated with opioid abuse while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">·</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Oxaydo® Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first and only approved immediate-release oxycodone product in the United States with abuse deterrent labeling. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo®. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. (see Note 4).</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">·</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Nexafed® Tablets (30mg pseudoephedrine) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine and acetaminophen), utilizing the Impede Technology, were launched by us into the United States market in December 2012 and February 2015, respectively. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC entered into a License and Development Agreement pursuant to which we granted Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine  containing product and providing for the joint development of such product using our Impede Technology for the U.S. market. On March 16, 2017, we and MainPointe Pharmaceuticals, LLC (“MainPointe”), entered into a License, Commercialization and Option Agreement (“MainPointe Agreement”), pursuant to which we granted MainPointe an exclusive license to our Impede technology in the United States and Canada to commercialize our Nexafed products. The MainPointe Agreement also grants MainPointe the option to expand the licensed territory to the European Union, Japan and South Korea and to add additional pseudoephedrine-containing products utilizing our Impede technology. (see Note 4).</font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">·</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our third abuse deterrent technology, Limitx, is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. We have completed our first clinical study, Study AP-LTX-400, of our lead Limitx immediate release oral abuse deterrent drug candidate using the opioid hydromorphone HCI (LTX-04). Study AP-LTX-400, or Study 400, was a two cohort, open label, crossover design pharmacokinetic study in healthy adult subjects. The FDA has designated the development program for LTX-04 as Fast Track, which is designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. We are also developing an immediate-release hydrocodone bitartrate with acetaminophen product utilizing our Limitx Technology.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Going Concern</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The going concern basis of presentation assumes that we will continue in operation for the next twelve months and will be able to realize our assets and discharge our liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. At March 31, 2017, we had unrestricted cash and cash equivalents of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.8</font> million, working capital deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million and an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">374.3</font> million. Though we had income from operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.6</font> million and net income of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.4</font> million for the three months ended March 31, 2017, we have suffered annual losses from operations in prior years and have not generated or have generated limited annual positive cash flows from operations. Our current unrestricted cash and cash equivalents will not be sufficient to fund the development of our products and our related operating expenses beyond mid-2017 while maintaining compliance with the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million compensating balance requirement under our term loan with Oxford Finance LLC or Oxford.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In addition to our $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million cash reserve requirement, our term loan agreement with Oxford contains customary affirmative and negative covenants. One such covenant is that the Company must submit on an annual basis to Oxford, within 120 days after the end of its fiscal year, audited consolidated financial statements, together with an unqualified audit opinion from an independent registered public accounting firm, or the Unqualified Audit Opinion Covenant. Per the term loan agreement an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business (the “going concern opinion”) is deemed to violate the Unqualified Audit Opinion Covenant. Failure to comply with the Unqualified Audit Opinion Covenant is a breach of the term loan agreement and unless such covenant or breach is waived, Oxford would have the option of accelerating the debt under the term loan agreement and initiating enforcement collection actions, foreclosing on collateral (which includes most assets of the Company) and, among other things, preventing the Company from using any funds in its bank or securities accounts. On March 16, 2017, we and Oxford entered into a third amendment to the Loan Agreement, or the Third Amendment. Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">However, these factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. To fund further operations and product development activities beyond mid-2017, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. The Company intends to explore a variety of capital raising and other transactions to provide additional funding to continue operations. These include a registered public offering of the Company’s common stock, for which the Company filed a registration statement on Form S-1 with the SEC on February 3, 2017, and potential private offerings of common stock to institutional investors. The Company is also actively seeking a licensing partner for its Limitx Technology, with the objective of receiving an upfront license fee, development milestone payments and royalties on the net sales of products utilizing the Limitx Technology, similar to the Egalet and Bayer Agreements. The Company is also exploring licensing or selling select assets and intellectual property in an effort to raise capital and reduce operating expenses. Finally, the Company is evaluating the potential for a strategic transaction which may involve the Company being acquired in a merger or asset purchase transaction. No assurance can be given that we will be successful in completing any one or more of such transactions on acceptable terms, if at all, or if completed, that such transactions will provide payments to the Company sufficient to fund continued operations. In the absence of the Company’s completion of one or more of such transactions, there will be substantial doubt about the Company’s ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2500000

309000

117000

0.075 150000

250000

1000000

500000

250000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">NOTE 13  EARNINGS PER SHARE (“EPS”)</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 11). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2016 as the Company reported a net loss for the three month period, and including the effects of the common stock equivalents in the diluted EPS calculations would have been antidilutive. The weighted-average common shares outstanding (diluted) computation is not impacted during any period where the exercise price of a stock option is greater than the average market price.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.2in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>Three months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div> (in thousands except per share data)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Numerator: net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(3,384)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,881</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Vested RSUs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 40px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Basic weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,837</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>(0.28)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS  assuming dilution</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Numerator: net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(3,384)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,881</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>RSUs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 40px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Diluted weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>12,083</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,837</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>(0.28)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Excluded securities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common stock issuable:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,396</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>RSUs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 40px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total excluded potentially dilutive shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,456</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.2in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>Three months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div> (in thousands except per share data)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Numerator: net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(3,384)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,881</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Vested RSUs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 40px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Basic weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,837</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS - basic</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>(0.28)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS  assuming dilution</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Numerator: net income (loss)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(3,384)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,881</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>11,832</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>RSUs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 40px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Diluted weighted average shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>12,083</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,837</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>EPS - diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>(0.28)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Excluded securities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common stock issuable:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,396</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Common stock warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>RSUs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 40px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total excluded potentially dilutive shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,456</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Inventories at December 31, 2016 are summarized as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Raw and packaging materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>243</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Less: reserve for finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(32)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Net inventories</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>309</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

60000

66000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Property, plant and equipment at March 31, 2017 and December 31, 2016 are summarized as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Building and improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,273</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,273</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Scientific equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>598</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Computer hardware and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Machinery and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>415</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>568</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Land and improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>162</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>162</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Other personal property</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,654</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,807</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: impairment reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(82)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(82)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Less: accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,833)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,858)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Net property, plant and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>739</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>867</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2654000

2807000

-82000 Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Accrued expenses at March 31, 2017 and December 31, 2016 are summarized as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Cost sharing expenses under license agreement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>269</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Advanced expense reimbursements under license agreements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Other fees and services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>51</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Payroll, payroll taxes and benefits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>173</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>116</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Professional services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>173</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>232</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Clinical, non-clinical and regulatory services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>136</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Marketing, advertising, and promotion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Property taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Franchise taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

P9Y8M12D

207000

2500000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our debt at March 31, 2017 is summarized below (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.75in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Current Debt</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Current</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Long-term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Balance at Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,979</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">5,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Principal payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">(445)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">(445)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Classification</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">722</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">(722)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Balance at Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,798</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">5,055</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Debt Discount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Current</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Long-term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="42%"> <div>Balance at Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(98)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(98)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Amortization expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Classification</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Balance at Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Deferred Debt Issuance Costs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Current</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Long-term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="42%"> <div>Balance at Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Amortization expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Classification</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Balance at Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(37)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(37)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Current Debt, net at Mar 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>2,798</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>2,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>4,940</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our interest expense for the three months ended March 31, 2017 and 2016 consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Term Loan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Debt issue costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Total interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">178</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">249</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The annual principal payments of the debt outstanding at March 31, 2017 are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 3.5in; WIDTH: 30%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Annual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Principal Payments</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="4%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="3%"> <div style="CLEAR:both;CLEAR: both">2,077</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="3%"> <div style="CLEAR:both;CLEAR: both">2,978</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="3%"> <div style="CLEAR:both;CLEAR: both">5,055</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.075

2000

50000

100000

50000

1200000

200000

2017 2036

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">NOTE 11 - SHARE-BASED COMPENSATION</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Share-based Compensation</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">  </font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We have four share-based compensation plans covering stock options and RSUs for our employees and directors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.2in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our share-based compensation expense recognized in the Company’s results of operations from all types of issued instruments comprised the following (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%" colspan="5"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development expense:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restricted stock units</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Subtotal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative expense:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restricted stock units</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Subtotal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>107</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Stock Option Award Plans</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We maintain various stock option plans. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of our stock option plan activity during the three month periods ending March 31, 2017 and 2016 is shown below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.2in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%" colspan="11"> <div>Three Months Ended<br/> March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number<br/> of<br/> Options<br/> (000’s)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number<br/> of<br/> Options<br/> (000’s)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Jan. 1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>13.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>15.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(0.92)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Mar. 31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,396</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>13.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>15.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Options exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>16.52</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>20.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.2in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes information about nonvested stock options outstanding at March 31, 2017 (in thousands except price data):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> Options Not<br/> Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Weighted<br/> Average<br/> Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding, Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(64)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding, Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The assumptions used in the Black-Scholes model to determine fair value for the 2016 stock option grant were:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Risk-free interest rates</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Average expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Weighted average grant date fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The intrinsic value of the option awards which were vested and outstanding at March 31, 2017 and 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> thousand and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70</font> thousand, respectively. The total remaining unrecognized compensation cost on unvested option awards outstanding at March 31, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">309</font> thousand, and is expected to be recognized in operating expense in varying amounts over the 20 months remaining in the requisite service period.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Restricted Stock Unit Award Plan</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">  </font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We have a Restricted Stock Unit Award Plan (the “2014 RSU Plan”) for our employees and non-employee directors. Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the grants under the RSU Plans consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%" colspan="11"> <div>Three months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%" colspan="11"> <div>(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number<br/> of RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> Vested<br/> RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> Vested<br/> RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Jan. 1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Distributed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(67)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(67)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(42)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(42)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Mar. 31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>262</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400</font> thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of March 31, 2017, three thousand shares are available for award under the 2014 RSU Plan.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Information about the awards under the 2014 RSU Plan is as follows:</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="12"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">⋅</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 2, 2015, we awarded approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> thousand RSUs to each of our four non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% at the end of each calendar quarter in 2015. The RSU awards subject to cash settlement are subject to marked-to market accounting. Distributions of stock under the January 2, 2015 award cannot be deferred until a later date and the stock under such awards were distributed on January 4, 2016.</font></div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="12"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">⋅</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 4, 2016, we awarded approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22</font> thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% at the end of each calendar quarter in 2016. The portion of the RSU awards which are subject to cash settlement are also subject to marked-to market accounting and the liability recorded in the Company’s balance sheet as an estimate for such cash settlement was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27</font> thousand at December 31, 2016. Distributions of stock under the January 4, 2016 award are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.</font></div> </div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="DISPLAY: none; FONT-SIZE: 10pt"></font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 9pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="12"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">⋅</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 3, 2017, we awarded approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60</font> thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% at the end of each calendar quarter in 2017. The portion of the RSU awards which are subject to cash settlement are also subject to marked-to market accounting and the liability recorded in the Company’s balance sheet as an estimate for such cash settlement was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19</font> thousand at March 31, 2017. Distributions of stock under the January 3, 2017 award are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 27pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -9pt; MARGIN: 0in 0in 0pt 9pt" align="justify"><font style="FONT-SIZE: 10pt">Information about the distribution of shares under the 2014 RSU Plan is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -9pt; MARGIN: 0pt 0px 0pt 9pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18pt"></td> <td style="WIDTH: 9pt"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">On January 4, 2016, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> thousand RSUs from the May 1, 2014 award and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41</font> thousand RSUs from the January 2, 2015 award were distributed. There are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> thousand RSUs from the May 1, 2014 award which remain deferred until a future distribution date. Of the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42</font> thousand RSUs distributed, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33</font> thousand RSUs were distributed in common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font> thousand RSUs were settled in cash.</font></font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18pt"></td> <td style="WIDTH: 9pt"> <div><font style="FONT-FAMILY:Symbol">⋅</font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt">On January 3, 2017, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> thousand RSUs from the May 1, 2014 award and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">66</font> thousand RSUs from the January 4, 2016 award were distributed. There are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> thousand RSUs from the May 1, 2014 award and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22</font> thousand RSUs from the January 4, 2016 award which remain deferred until a future distribution date. Of the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">67</font> thousand RSUs distributed, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">49</font> thousand RSUs were distributed in common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18</font> thousand RSUs were settled in cash.</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our share-based compensation expense recognized in the Company’s results of operations from all types of issued instruments comprised the following (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%" colspan="5"> <div>Three Months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development expense:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restricted stock units</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Subtotal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative expense:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>53</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restricted stock units</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Subtotal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>107</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 39px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A summary of our stock option plan activity during the three month periods ending March 31, 2017 and 2016 is shown below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.2in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%" colspan="11"> <div>Three Months Ended<br/> March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number<br/> of<br/> Options<br/> (000’s)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number<br/> of<br/> Options<br/> (000’s)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Jan. 1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>13.57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>15.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(0.92)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>--</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Mar. 31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,396</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>13.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>15.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Options exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>16.52</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>20.64</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A summary of the grants under the RSU Plans consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%" colspan="11"> <div>Three months Ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="19%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%" colspan="11"> <div>(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number<br/> of RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> Vested<br/> RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> Vested<br/> RSUs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Jan. 1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>238</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Distributed</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(67)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(67)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(42)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(42)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="39%"> <div>Outstanding, Mar. 31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>262</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

47200000

138800000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.2in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes information about nonvested stock options outstanding at March 31, 2017 (in thousands except price data):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Number of<br/> Options Not<br/> Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div>Weighted<br/> Average<br/> Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding, Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(64)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding, Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.34

2100000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The assumptions used in the Black-Scholes model to determine fair value for the 2016 stock option grant were:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Expected dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Risk-free interest rates</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Average expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Weighted average grant date fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

34000

43000

53000

30000

83000

77000

30000

107000

117000 150000

70000

309000

60000

0.25

19000

1000

66000 1000

67000

49000

18000

stock, for up to 40%

6343000 3282000 5181000 2485000

60000

2.52

0.92

-0

782000

2500000

1000

In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing pseudoephedrine (“PSE”) and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.

3000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">NOTE 9  DEBT</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.0</font> million (the “Term Loan”). The Term Loan accrues interest at a fixed rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.35</font>% per annum (with a default rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13.35</font>% per annum). The Company was required to make monthly interest<font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 11pt"> </font>only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">260</font> thousand sufficient to amortize the Term Loan through the maturity date of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 1, 2018</font>. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As security for its obligations under the initial Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after<font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 11pt"> </font>acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60</font> thousand shares of our common stock at an exercise price equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.98</font> per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400</font> thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 27, 2020</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the warrants was lowered from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.98</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.52</font> per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33</font> thousand representing the fair value of the warrant modification, (ii) we agreed to maintain $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million cash reserves until such time as we have repaid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 13, 2016, we and Oxford entered into a second amendment to the Loan Agreement (the “Second Amendment”). Pursuant to the Second Amendment, (i) the requirement that we maintain a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million cash balance reserve until such time as $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million in principal was repaid under the Term Loan has been modified so that the $2.5 million cash balance reserve remains in place until we raise an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.0</font> million (excluding payments received under the KemPharm Agreement) through the issuance of equity securities and from upfront payments under license, joint venture, collaboration or other partnering transactions, provided that at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million of such amount must be raised through the issuance and sale of our equity securities, and (ii) the Lender consented to the terms of our Agreement with KemPharm.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 16, 2017, we and Oxford entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment (i) we granted Oxford a lien on our intellectual property, (ii) Oxford provided a waiver of compliance with the Unqualified Audit Opinion Covenant in connection with our receipt of our auditor’s going concern opinion for our 2016 financial statements and (iii) Oxford consented to the terms of the MainPointe Agreement. Under the Loan Agreement, an audit opinion with an explanatory paragraph noting substantial doubt about the Company’s ability to continue in business is deemed to violate the Unqualified Audit Opinion Covenant.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font>% of the principal prepaid. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">795</font> thousand. We are accruing additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate. As of March 31, 2017 and December 31, 2016, we have accumulated and accrued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">598</font> thousand and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">559</font> thousand, respectively, of additional interest.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50</font> thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font> thousand consulting placement fee, the Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">231</font> thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10.16</font>%.</font></div> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non<font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 11pt"> </font>payment defaults, covenant defaults (including breach of the Unqualified Audit Opinion Covenant), a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Our debt at March 31, 2017 is summarized below (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.75in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Current Debt</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Current</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Long-term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Balance at Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,979</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">5,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Principal payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">(445)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">(445)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Classification</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">722</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">(722)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div style="CLEAR:both;CLEAR: both">Balance at Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,798</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">2,257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">5,055</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Debt Discount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Current</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Long-term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="42%"> <div>Balance at Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(98)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(98)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Amortization expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Classification</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Balance at Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(78)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Deferred Debt Issuance Costs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Current</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Long-term</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="42%"> <div>Balance at Jan. 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(47)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Amortization expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Classification</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Balance at Mar. 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(37)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>(37)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="42%"> <div>Current Debt, net at Mar 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>2,798</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>2,142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>4,940</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Our interest expense for the three months ended March 31, 2017 and 2016 consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%" colspan="5"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Term Loan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">148</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">209</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Debt discount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Debt issue costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Total interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">178</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div style="CLEAR:both;CLEAR: both">249</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The annual principal payments of the debt outstanding at March 31, 2017 are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 3.5in; WIDTH: 30%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Annual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="4%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Principal Payments</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="4%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(in thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="3%"> <div style="CLEAR:both;CLEAR: both">2,077</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="3%"> <div style="CLEAR:both;CLEAR: both">2,978</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="3%"> <div style="CLEAR:both;CLEAR: both">5,055</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

EX-101.SCH 8 acur-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - OPERATIONS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - REVENUE RECOGNITION link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - RESEARCH AND DEVELOPMENT ACTIVITIES link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - DEBT link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - COMMON STOCK WARRANTS link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - EARNINGS PER SHARE ("EPS") link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - INVENTORIES (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - DEBT (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - EARNINGS PER SHARE ("EPS") (Tables) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - OPERATIONS Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - REVENUE RECOGNITION - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - RESEARCH AND DEVELOPMENT ACTIVITIES - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - INVENTORIES - Schedule of Inventories (Detail) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Detail) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - ACCRUED EXPENSES (Detail) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - DEBT - Summary of Debt (Detail) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - DEBT - Interest Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - DEBT - Long-Term Debt (Detail) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - DEBT - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - COMMON STOCK WARRANTS - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - SHARE-BASED COMPENSATION -Recognition of Share-Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Award Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - SHARE-BASED COMPENSATION - Summary of Information about Non Vested Stock Options (Detail) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - SHARE-BASED COMPENSATION - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - SHARE-BASED COMPENSATION - Summary of RSU Plan (Detail) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - SHARE-BASED COMPENSATION - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - INCOME TAXES - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - EARNINGS PER SHARE ("EPS") - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 acur-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 acur-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 acur-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Research and Development Disclosure [Abstract] Research and Development Disclosure [Text Block] LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT Research And Development Disclosure. Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] INVENTORIES Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] PROPERTY, PLANT AND EQUIPMENT Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCRUED EXPENSES Debt Disclosure [Abstract] Debt Disclosure [Text Block] DEBT Stockholders Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] COMMON STOCK WARRANTS Statement Of Financial Position [Abstract] Statement [Table] Fair Value Of Warrants [Table] Legal Entity [Axis] Entity [Domain] Statement [Line Items] Assets [Abstract] Assets Assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents Restricted Cash and Cash Equivalents, Current Restricted cash equivalents (Note 9) Restricted cash equivalents Accounts Receivable, Net, Total Trade accounts receivable (net of allowances of $27 and $7) Collaboration Revenue Receivable Collaboration revenue receivable Amount due from clients within one year with respect to collaboration revenue. Royalty Receivable Royalty receivable Amount due from clients within one year with respect of use of copyrights, patents, trade names and technology. Inventory, Net, Total Inventories (net of allowances of $- and $32) (Note 6) Net inventories Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property, plant and equipment, net (Note 7) Net property, plant and equipment Finite-Lived Intangible Assets, Net, Total Intangible asset, net of accumulated amortization of $621 and $569 (Note 4) Assets, Total Total assets Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable Current Accounts payable Accrued Liabilities Current Accrued expenses (Note 8) Total Interest Payable, Current Accrued interest Other Liabilities, Current Other current liabilities Sales Returns Liability Current Sales returns liability Sales returns liability current. Long-term Debt, Current Maturities, Total Debt - current (Note 9) Liabilities, Current, Total Total current liabilities Liabilities [Abstract] Liabilities: Long-term Debt, Excluding Current Maturities, Total Debt - non-current portion, net of discounts (Note 9) Long-term Portion of Accrued Interest Accrued interest - non-current portion Long-term portion of accrued interest. Common Stock Value Common stock - $.01 par value per share; 100,000 shares authorized, 11,883 and 11,834 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively Additional Paid In Capital Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Stockholders Equity Attributable to Parent, Total Total stockholders' equity Balance Balance Liabilities, Total Total liabilities Income Tax Disclosure [Abstract] Income Tax Disclosure Text Block INCOME TAXES Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure Text Block COMMITMENTS AND CONTINGENCIES Schedule of Inventory, Current [Table Text Block] Inventories Schedule Of Property Plant And Equipment Net Carrying Value [Table Text Block] Property Plant and Equipment Tabular disclosure of gross value of each categories of plant property and equipment of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software, less accumulated depreciation and amortization and net value of long live property plant and equipment. Schedule Of Accrued Liabilities Table [Text Block] Accurued Expenses Schedule of Debt [Table Text Block] Schedule of Debt Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Interest Expense Schedule Of Long Term Debt Future Principal Payments Year [Table Text Block] Schedule Of Long Term Debt Future Principal Payments Year Schedule of long term debt future principal payments year. Allowance for Doubtful Accounts Receivable, Current Accounts receivable, net of allowances Finite-Lived Intangible Assets, Accumulated Amortization Finite-lived intangible assets accumulated amortization Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Non-Cash Share-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity Schedule of Nonvested Share Activity [Table Text Block] Schedule of Nonvested Share Activity Disclosure License Development and Commercialization Agreement Additional Information [Abstract] License Development and Commercialization Agreement [Table] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Range [Axis] Range [Domain] Minimum [Member] Minimum Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Pfizer Agreement [Member] Pfizer Agreement Pfizer Agreement Egalet Agreement [Member] Egalet Agreement Subsequent Event Type [Axis] Payment for Termination Represents the amount of one-time termination payment under the agreement. Minimum Net Sales Reaching Description Description of milestone payment to be made when worldwide net sales reached minimum level in a calendar year. Agreement Termination Notice Description Description of notice period of termination when the party breaches a payment obligation, or otherwise materially breaches the agreement. Income Statement [Abstract] Revenues [Abstract] Revenues: License and Services Revenue License fee revenue Other Revenue, Net Collaboration revenue Royalty Revenue, Total Royalty revenue Costs and Expenses [Abstract] Cost and expenses: Cost Of Sales Excluding Inventory Write Down Cost of sales Cost Of Sales Excluding Inventory Write Down Research and Development Expense, Total Research and development Research and development expense Selling, General and Administrative Expense, Total Sales, marketing, general and administrative Costs and Expenses, Total Total costs and expenses Operating expenses Operating Income (Loss), Total Operating income (loss) Operating loss Operating (loss) income Nonoperating Income (Expense) [Abstract] Non-Operating income (expense): Investment Income, Nonoperating, Total Investment income Interest Expense, Total Interest expense (Note 9) Total interest expense Other Nonoperating Income (Expense) Other income Nonoperating Income (Expense), Total Total other expense, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) before provision for income taxes Income Tax Expense (Benefit) Provision for income taxes Provision for income taxes Net Income (Loss) Attributable to Parent, Total Numerator: net loss Numerator: net loss Net income (loss) Net income Net (loss) income Net income (loss) Numerator: net income (loss) Numerator: net income (loss) Other Comprehensive Income (Loss), Net Of Tax [Abstract] Other comprehensive income: Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gains on securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total Comprehensive income (loss) Earnings Per Share [Abstract] Income (loss) per share: Earnings Per Share, Basic, Total EPS - basic and diluted Basic EPS - basic EPS - basic Basic (loss) income per share Earnings Per Share, Diluted, Total EPS - diluted Diluted Diluted loss per share Diluted (loss) income per share Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract] Denominator: Weighted average shares outstanding: Denominator: Weighted Average Number of Shares Outstanding, Basic, Total Basic and diluted weighted average shares outstanding Basic Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted Diluted weighted average shares outstanding Diluted Inventory, Current [Table] Inventory [Line Items] Inventory, Raw Materials and Supplies, Gross Raw and packaging materials Inventory, Finished Goods, Gross Finished goods Inventory, Gross Total Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Building Improvements [Member] Building and improvements Scientific Equipment [Member] Scientific equipment Computer Hardware and Software [Member] Computer hardware and software Machinery and Equipment [Member] Machinery and equipment Land Improvements [Member] Land and improvements Property, Plant and Equipment, Other Types [Member] Other personal property Office Equipment [Member] Office equipment Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Impairment Of Property, Plant and Equipment, Reserve Less: impairment reserve A impairment reserve for the amount of expected decrease in the value of nonmonetary assets which can physically measured. Class of Stock [Domain] Property, Plant and Equipment [Line Items] Disclosure Accrued Expenses [Abstract] Disclosure - Accrued Expenses [Abstract] Accounts Payable and Accrued Liabilities [Table] Accounts Payable and Accrued Liabilities [Table] Accounts Payable and Accrued Liabilities [Line Items] Accounts Payable and Accrued Liabilities [Line Items] Accounts Payable and Accrued Liabilities [Line Items] Accrued Cost Sharing Expenses Cost sharing expenses under license agreement Represents the accrued cost sharing expenses under license agreement. Advanced Expenses Reimbursement Advanced expense reimbursements under license agreements The advanced expenses reimbursement amount under license agreement. Other Accrued Liabilities Current Other fees and services Employee Related Liabilities Current Payroll, payroll taxes and benefits Accrued Professional Fees Current Professional services Accrued Other Professional Fees Current Clinical, non-clinical and regulatory services Accrued Other Professional Fees, Current Marketing Advertising And Promotion Marketing, advertising, and promotion Marketing Advertising And Promotion. Accrual For Taxes Other Than Income Taxes Current Property taxes Statement Of Stockholders Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Award Type [Axis] Equity Award [Domain] Shares, Outstanding, Beginning Balance Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Total Share-based compensation Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Net distribution of common stock pursuant to restricted stock unit award plan Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Net distribution of common stock pursuant to restricted stock unit award plan (in shares) Schedule of Long-term Debt Instruments [Table] Investment Type [Axis] Investments [Domain] Short-term Debt [Member] Current [Member] Financial Instrument [Axis] Financial Instruments [Domain] Long-term Debt [Member] Long-term [Member] Debt Instrument [Line Items] Debt Instruments [Abstract] Current Debt Long-term Debt, Gross Balance at Jan. 1, 2017 Balance at Mar. 31, 2017 Total Debt Instrument, Periodic Payment, Principal Principal payments Debt instrument, periodic payment, principal Debt Instrument Classification amount Classification This element refers our debt classifications. Debt Discount [Abstract] Debt Discount Debt Instrument, Unamortized Discount Long-term debt, net of debt discount Balance at Jan. 1, 2017 Debt instrument unamortized discount Balance at Mar. 31, 2017 Amortization of Debt Discount (Premium) Amortization expense Schedule Of Interest Expense [Table] Schedule Of Interest Expense [Line Items] Interest Expense, Debt Term Loan Interest Expense Debt Discount Debt discount The debt discount related to interest expense during the period. Debt Related Commitment Fees and Debt Issuance Costs Debt issue costs Debt related commitment fees and debt issuance costs Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2017 Long-term Debt, Maturities, Repayments of Principal in Year Two 2018 First Revenue Event Does Not Occurs [Member] First Revenue Event Occurs Warrant [Member] Common stock warrants Warrant Subsequent Event Type [Domain] Maximum [Member] Maximum Debt Instrument [Axis] Debt Instrument, Face Amount Debt instrument principal amount Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate, stated percentage Debt Default Long Term Debt Percentage Debt default long term debt percentage Debt default long term debt percentage. Debt Instrument, Maturity Date DebtInstrument PrePayment Percentage Debt instrument prepayment percentage Debt instrument prepayment percentage. Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Debt instrument periodic payment terms balloon payment to be paid Debt Instrument, Fee Amount Debt instrument, fee amount Debt Consulting Placement Fee Debt consulting placement fee Debt consulting placement fee. Class of Warrant or Right, Outstanding Warrants to purchase common stock Common stock warrant exercisable outstanding, shares Class of Warrant or Right, Exercise Price of Warrants or Rights Class Of Warrant Or Right Expiration Date Warrants, expiry date Common stock Warrant expiration date Class of warrant or right, expiration date. Debt instrument Cash Maintenance This represents the debt instrument cash maintenance amount. EX-101.PRE 12 acur-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2017	May 05, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		11,883,339

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 3,843	$ 2,681
Restricted cash equivalents (Note 9)	2,500	2,500
Trade accounts receivable (net of allowances of $27 and $7)	6	23
Collaboration revenue receivable	36	79
Royalty receivable	52	50
Inventories (net of allowances of $- and $32) (Note 6)	0	309
Prepaid expenses and other current assets	301	268
Total current assets	6,738	5,910
Property, plant and equipment, net (Note 7)	739	867
Intangible asset, net of accumulated amortization of $621 and $569 (Note 4)	1,379	1,431
Total assets	8,856	8,208
Liabilities:
Accounts payable	209	77
Accrued expenses (Note 8)	1,040	703
Accrued interest	35	0
Other current liabilities	19	27
Sales returns liability	302	304
Debt - current (Note 9)	2,798	2,376
Total current liabilities	4,403	3,487
Debt - non-current portion, net of discounts (Note 9)	2,142	2,979
Accrued interest - non-current portion	598	559
Total liabilities	7,143	7,025
Commitments and contingencies (Note 14)
Stockholders' equity:
Common stock - $.01 par value per share; 100,000 shares authorized, 11,883 and 11,834 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	119	118
Additional paid-in capital	375,887	375,763
Accumulated deficit	(374,293)	(374,698)
Total stockholders' equity	1,713	1,183
Total liabilities and stockholders' equity	$ 8,856	$ 8,208

XML 15 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accounts receivable, net of allowances	$ 27	$ 7
Finite-lived intangible assets accumulated amortization	$ 621	$ 569
Common stock, par value	$ 0.01	$ 10
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	11,883	11,834
Common stock, shares outstanding	11,883	11,834
Inventory Valuation Reserves	$ 0	$ 32

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
License fee revenue	$ 2,500	$ 0
Collaboration revenue	36	100
Royalty revenue	74	17
Product sales, net	107	107
Total revenues, net	2,717	224
Cost and expenses:
Cost of sales	128	102
Research and development	711	1,014
Sales, marketing, general and administrative	1,296	2,246
Total costs and expenses	2,135	3,362
Operating income (loss)	582	(3,138)
Non-Operating income (expense):
Investment income	1	27
Interest expense (Note 9)	(178)	(249)
Other income	0	(24)
Total other expense, net	(177)	(246)
Income (loss) before provision for income taxes	405	(3,384)
Provision for income taxes	0	0
Net income (loss)	405	(3,384)
Other comprehensive income:
Unrealized gains on securities	0	70
Comprehensive income (loss)	$ 405	$ (3,314)
Income (loss) per share:
Basic	$ 0.03	$ (0.28)
Diluted	$ 0.03	$ (0.28)
Weighted average shares outstanding:
Basic	11,907	11,837
Diluted	12,083	11,837

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 3 months ended Mar. 31, 2017 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2016	$ 1,183	$ 118	$ 375,763	$ (374,698)
Balance (in shares) at Dec. 31, 2016		11,834
Net income	405	$ 0	0	405
Share-based compensation	117	0	117	0
Net distribution of common stock pursuant to restricted stock unit award plan	8	$ 1	7	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		49
Balance at Mar. 31, 2017	$ 1,713	$ 119	$ 375,887	$ (374,293)
Balance (in shares) at Mar. 31, 2017		11,883

XML 18 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash Flows from Operating Activities:
Net income (loss)	$ 405	$ (3,384)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation	25	34
Provision for sales returns	49	39
Share-based compensation	117	150
Amortization of debt discount and deferred debt issue costs	30	40
Amortization of bond premium in marketable securities	0	19
Amortization of intangible asset	52	52
Loss on sales of marketable securities	0	24
Changes in assets and liabilities:
Trade accounts receivable	17	(57)
Collaboration revenue receivable	43	0
Royalty receivable	(2)	0
Accrued investment income	0	12
Inventories	103	74
Prepaid expenses and other current assets	(33)	121
Accounts payable	132	265
Accrued expenses	337	591
Accrued interest	74	99
Other current liabilities	0	1
Sales returns liability	(51)	(2)
Net cash provided by (used in) operating activities	1,298	(1,922)
Cash Flows from Investing Activities:
Proceeds from sales and maturities of marketable securities	0	3,177
Proceeds from transfer of equipment to licensee	103	0
Proceeds from transfer of inventory to licensee	206	0
Capital expenditures	0	(49)
Net cash provided by investing activities	309	3,128
Cash Flows from Financing Activities:
Principal payments on debt	(445)	(409)
Net cash (used in) financing activities	(445)	(409)
Net increase in cash, cash equivalents, and restricted cash	1,162	797
Cash, cash equivalents, and restricted cash at beginning of period	5,181	2,485
Cash, cash equivalents, and restricted cash at end of period	6,343	3,282
Cash paid during the year for:
Interest	75	110
Income taxes	0	0
Reconciliation of cash, cash equivalents, and restricted cash [Abstract]
Cash and cash equivalents	3,843	782
Restricted cash equivalents	2,500	2,500
Total cash, cash equivalents and restricted cash show in the consolidated statements of cash flows	$ 6,343	$ 3,282

XML 19 R7.htm IDEA: XBRL DOCUMENT

OPERATIONS

3 Months Ended

Mar. 31, 2017

Description Of Operation And Summary Of Significant Accounting Policies Disclosure [Abstract]

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – OPERATIONS

Principal Operations

Going Concern

XML 20 R8.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS

Revenue from Contracts with Customers

Inventories

Leases

Employee Share-Based

Intra-Entity Transfers of Assets Other Than Inventory

Statement of Cash Flows - Restricted Cash

XML 21 R9.htm IDEA: XBRL DOCUMENT

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

3 Months Ended

Mar. 31, 2017

Research and Development Disclosure [Abstract]

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT

NOTE 3 – LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

MainPointe Agreement

KemPharm Agreement

Bayer Agreement

Egalet Agreement

Terminated Pfizer Agreement

XML 22 R10.htm IDEA: XBRL DOCUMENT

REVENUE RECOGNITION

3 Months Ended

Mar. 31, 2017

Revenue Recognition [Abstract]

REVENUE RECOGNITION

NOTE 4 - REVENUE RECOGNITION

License Fee Revenue

Milestone Revenue

Collaboration Revenue

Royalty Revenue

Product Sales

Shipping and Handling Costs

XML 23 R11.htm IDEA: XBRL DOCUMENT

RESEARCH AND DEVELOPMENT ACTIVITIES

3 Months Ended

Mar. 31, 2017

Research and Development [Abstract]

RESEARCH AND DEVELOPMENT ACTIVITIES

NOTE 5 - RESEARCH AND DEVELOPMENT ACTIVITIES

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

XML 24 R12.htm IDEA: XBRL DOCUMENT

INVENTORIES

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 6 – INVENTORIES

Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.

Inventories at December 31, 2016 are summarized as follows:

	December 31,
	2016
	(in thousands)
Raw and packaging materials	$	98
Finished goods		243
Total		341
Less: reserve for finished goods		(32)
Net inventories	$	309

XML 25 R13.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT AND EQUIPMENT

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 7 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at March 31, 2017 and December 31, 2016 are summarized as follows:

	March 31,		December 31,
	2017		2016
	(in thousands)
Building and improvements	$	1,273	$	1,273
Scientific equipment		598		598
Computer hardware and software		109		109
Machinery and equipment		415		568
Land and improvements		162		162
Other personal property		70		70
Office equipment		27		27
Total		2,654		2,807
Less: impairment reserve		(82)		(82)
Less: accumulated depreciation		(1,833)		(1,858)
Net property, plant and equipment	$	739	$	867

XML 26 R14.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

ACCRUED EXPENSES

NOTE 8 - ACCRUED EXPENSES

Accrued expenses at March 31, 2017 and December 31, 2016 are summarized as follows:

	March 31,		December 31,
	2017		2016
	(in thousands)
Cost sharing expenses under license agreement	$	269	$	150
Advanced expense reimbursements under license agreements		209		-
Other fees and services		51		47
Payroll, payroll taxes and benefits		173		116
Professional services		173		232
Clinical, non-clinical and regulatory services		136		131
Marketing, advertising, and promotion		5		10
Property taxes		18		16
Franchise taxes		6		1
Total	$	1,040	$	703

XML 27 R15.htm IDEA: XBRL DOCUMENT

DEBT

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

DEBT

NOTE 9 – DEBT

On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest –only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As security for its obligations under the initial Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after –acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non –payment defaults, covenant defaults (including breach of the Unqualified Audit Opinion Covenant), a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.

Our debt at March 31, 2017 is summarized below (in thousands):

Current Debt	Current		Long-term		Total
Balance at Jan. 1, 2017	$	2,521	$	2,979	$	5,500
Principal payments		(445)		-		(445)
Classification		722		(722)		-
Balance at Mar. 31, 2017	$	2,798	$	2,257	$	5,055

Debt Discount	Current		Long-term		Total
Balance at Jan. 1, 2017	$	-	$	(98)	$	(98)
Amortization expense		-		20		20
Classification		-		-		-
Balance at Mar. 31, 2017	$	-	$	(78)	$	(78)

Deferred Debt Issuance Costs	Current		Long-term		Total
Balance at Jan. 1, 2017	$	-	$	(47)	$	(47)
Amortization expense		-		10		10
Classification		-		-		-
Balance at Mar. 31, 2017	$	-	$	(37)	$	(37)

Current Debt, net at Mar 31, 2017	$	2,798	$	2,142	$	4,940

Our interest expense for the three months ended March 31, 2017 and 2016 consisted of the following:

	March 31,		March 31,
	2017		2016
	(in thousands)
Term Loan	$	148	$	209
Debt discount		20		26
Debt issue costs		10		14
Total interest expense	$	178	$	249

The annual principal payments of the debt outstanding at March 31, 2017 are as follows:

	Annual
	Principal Payments
Year	(in thousands)
2017	$	2,077
2018		2,978
Total	$	5,055

XML 28 R16.htm IDEA: XBRL DOCUMENT

COMMON STOCK WARRANTS

3 Months Ended

Mar. 31, 2017

Stockholders Equity Note [Abstract]

COMMON STOCK WARRANTS

NOTE 10 - COMMON STOCK WARRANTS

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHARE-BASED COMPENSATION

NOTE 11 - SHARE-BASED COMPENSATION

Share-based Compensation

We have four share-based compensation plans covering stock options and RSUs for our employees and directors.

Our share-based compensation expense recognized in the Company’s results of operations from all types of issued instruments comprised the following (in thousands):

	Three Months Ended March 31,
	2017		2016
Research and development expense:
Stock options	$	34	$	43
Restricted stock units		-		-
Subtotal	$	34	$	43

General and administrative expense:
Stock options		53		77
Restricted stock units		30		30
Subtotal	$	83	$	107
Total	$	117	$	150

Stock Option Award Plans

We maintain various stock option plans. A summary of our stock option plan activity during the three month periods ending March 31, 2017 and 2016 is shown below:

	Three Months Ended March 31,
	2017				2016
	Number of Options (000’s)		Weighted Average Exercise Price		Number of Options (000’s)		Weighted Average Exercise Price
Outstanding, Jan. 1		1,397	$	13.57		1,198	$	15.67
Granted		-		-				--
Exercised		(1)		(0.92)				--
Forfeited or expired		-		-				--
Outstanding, Mar. 31		1,396	$	13.58		1,198	$	15.67
Options exercisable		1,125	$	16.52		876	$	20.64

The following table summarizes information about nonvested stock options outstanding at March 31, 2017 (in thousands except price data):

	Number of Options Not Exercisable		Weighted Average Fair Value

Outstanding, Jan. 1, 2017		335	$	1.18
Granted		-		-
Vested		(64)		1.36
Forfeited		-		-
Outstanding, Mar. 31, 2017		271	$	1.14

The assumptions used in the Black-Scholes model to determine fair value for the 2016 stock option grant were:

	2016
Expected dividend yield		0.0	%
Risk-free interest rates		2.3	%
Average expected volatility		85	%
Expected term (years)		10
Weighted average grant date fair value	$	0.77

Restricted Stock Unit Award Plan

A summary of the grants under the RSU Plans consisted of the following:

	Three months Ended March 31,
	2017				2016

	(in thousands)
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs
Outstanding, Jan. 1		91		91		45
Granted		238		-		88		-
Distributed		(67)		(67)		(42)		(42)
Vested		-		59		-		22
Forfeited or expired		-		-		-		-
Outstanding, Mar. 31		262		83		91		25

Information about the awards under the 2014 RSU Plan is as follows:

⋅

Information about the distribution of shares under the 2014 RSU Plan is as follows:

⋅

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 12 – INCOME TAXES

XML 31 R19.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE ("EPS")

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

EARNINGS PER SHARE ("EPS")

NOTE 13 – EARNINGS PER SHARE (“EPS”)

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Three months Ended March 31,
	2017		2016
	(in thousands except per share data)
EPS - basic
Numerator: net income (loss)	$	405	$	(3,384)
Denominator:
Common shares		11,881		11,832
Vested RSUs		26		5
Basic weighted average shares outstanding		11,907		11,837
EPS - basic	$	0.03	$	(0.28)

EPS – assuming dilution
Numerator: net income (loss)	$	405	$	(3,384)
Denominator:
Common shares		11,881		11,832
RSUs		202		5
Stock options		-		-
Common stock warrants		-		-
Diluted weighted average shares outstanding		12,083		11,837
EPS - diluted	$	0.03	$	(0.28)

Excluded securities:
Common stock issuable:
Stock options		1,396		1,198
Common stock warrants		60		60
RSUs		-		66
Total excluded potentially dilutive shares		1,456		1,324

XML 32 R20.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Reglan®/Metoclopramide Litigation

In Pennsylvania, and California, Generic Defendants, including us, also filed dispositive motions based on the Mensing decision.

Purdue Pharma Settlement

The Settlement Agreement specifically excludes our patents related to our Impede® and Limitx™ technologies from the scope of the Acura/Egalet Patents under the Settlement Agreement.

Egalet Agreement

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Egalet will pay a substantial majority of the expenses and we will pay for the remaining fees and expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Egalet will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. At March 31, 2017 and December 31, 2016, we have accrued approximately $269 thousand and $150 thousand, respectively, of these cost sharing expenses under the Egalet Agreement.

Facility Lease

XML 33 R21.htm IDEA: XBRL DOCUMENT

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories

Inventories at December 31, 2016 are summarized as follows:

	December 31,
	2016
	(in thousands)
Raw and packaging materials	$	98
Finished goods		243
Total		341
Less: reserve for finished goods		(32)
Net inventories	$	309

XML 34 R22.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment [Abstract]

Property Plant and Equipment

Property, plant and equipment at March 31, 2017 and December 31, 2016 are summarized as follows:

	March 31,		December 31,
	2017		2016
	(in thousands)
Building and improvements	$	1,273	$	1,273
Scientific equipment		598		598
Computer hardware and software		109		109
Machinery and equipment		415		568
Land and improvements		162		162
Other personal property		70		70
Office equipment		27		27
Total		2,654		2,807
Less: impairment reserve		(82)		(82)
Less: accumulated depreciation		(1,833)		(1,858)
Net property, plant and equipment	$	739	$	867

XML 35 R23.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Tables)

3 Months Ended

Mar. 31, 2017

Payables and Accruals [Abstract]

Accurued Expenses

Accrued expenses at March 31, 2017 and December 31, 2016 are summarized as follows:

	March 31,		December 31,
	2017		2016
	(in thousands)
Cost sharing expenses under license agreement	$	269	$	150
Advanced expense reimbursements under license agreements		209		-
Other fees and services		51		47
Payroll, payroll taxes and benefits		173		116
Professional services		173		232
Clinical, non-clinical and regulatory services		136		131
Marketing, advertising, and promotion		5		10
Property taxes		18		16
Franchise taxes		6		1
Total	$	1,040	$	703

XML 36 R24.htm IDEA: XBRL DOCUMENT

DEBT (Tables)

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Schedule of Debt

Our debt at March 31, 2017 is summarized below (in thousands):

Current Debt	Current		Long-term		Total
Balance at Jan. 1, 2017	$	2,521	$	2,979	$	5,500
Principal payments		(445)		-		(445)
Classification		722		(722)		-
Balance at Mar. 31, 2017	$	2,798	$	2,257	$	5,055

Debt Discount	Current		Long-term		Total
Balance at Jan. 1, 2017	$	-	$	(98)	$	(98)
Amortization expense		-		20		20
Classification		-		-		-
Balance at Mar. 31, 2017	$	-	$	(78)	$	(78)

Deferred Debt Issuance Costs	Current		Long-term		Total
Balance at Jan. 1, 2017	$	-	$	(47)	$	(47)
Amortization expense		-		10		10
Classification		-		-		-
Balance at Mar. 31, 2017	$	-	$	(37)	$	(37)

Current Debt, net at Mar 31, 2017	$	2,798	$	2,142	$	4,940

Schedule of Interest Expense

Our interest expense for the three months ended March 31, 2017 and 2016 consisted of the following:

	March 31,		March 31,
	2017		2016
	(in thousands)
Term Loan	$	148	$	209
Debt discount		20		26
Debt issue costs		10		14
Total interest expense	$	178	$	249

Schedule Of Long Term Debt Future Principal Payments Year

The annual principal payments of the debt outstanding at March 31, 2017 are as follows:

	Annual
	Principal Payments
Year	(in thousands)
2017	$	2,077
2018		2,978
Total	$	5,055

XML 37 R25.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2017

Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Our share-based compensation expense recognized in the Company’s results of operations from all types of issued instruments comprised the following (in thousands):

	Three Months Ended March 31,
	2017		2016
Research and development expense:
Stock options	$	34	$	43
Restricted stock units		-		-
Subtotal	$	34	$	43

General and administrative expense:
Stock options		53		77
Restricted stock units		30		30
Subtotal	$	83	$	107
Total	$	117	$	150

Schedule of Share-based Compensation, Stock Options, Activity

A summary of our stock option plan activity during the three month periods ending March 31, 2017 and 2016 is shown below:

	Three Months Ended March 31,
	2017				2016
	Number of Options (000’s)		Weighted Average Exercise Price		Number of Options (000’s)		Weighted Average Exercise Price
Outstanding, Jan. 1		1,397	$	13.57		1,198	$	15.67
Granted		-		-				--
Exercised		(1)		(0.92)				--
Forfeited or expired		-		-				--
Outstanding, Mar. 31		1,396	$	13.58		1,198	$	15.67
Options exercisable		1,125	$	16.52		876	$	20.64

Schedule of Nonvested Share Activity

The following table summarizes information about nonvested stock options outstanding at March 31, 2017 (in thousands except price data):

	Number of Options Not Exercisable		Weighted Average Fair Value

Outstanding, Jan. 1, 2017		335	$	1.18
Granted		-		-
Vested		(64)		1.36
Forfeited		-		-
Outstanding, Mar. 31, 2017		271	$	1.14

Schedule of fair value of the warrants

The assumptions used in the Black-Scholes model to determine fair value for the 2016 stock option grant were:

	2016
Expected dividend yield		0.0	%
Risk-free interest rates		2.3	%
Average expected volatility		85	%
Expected term (years)		10
Weighted average grant date fair value	$	0.77

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans consisted of the following:

	Three months Ended March 31,
	2017				2016

	(in thousands)
	Number of RSUs		Number of Vested RSUs		Number of RSUs		Number of Vested RSUs
Outstanding, Jan. 1		91		91		45
Granted		238		-		88		-
Distributed		(67)		(67)		(42)		(42)
Vested		-		59		-		22
Forfeited or expired		-		-		-		-
Outstanding, Mar. 31		262		83		91		25

XML 38 R26.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE ("EPS") (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following:

	Three months Ended March 31,
	2017		2016
	(in thousands except per share data)
EPS - basic
Numerator: net income (loss)	$	405	$	(3,384)
Denominator:
Common shares		11,881		11,832
Vested RSUs		26		5
Basic weighted average shares outstanding		11,907		11,837
EPS - basic	$	0.03	$	(0.28)

EPS – assuming dilution
Numerator: net income (loss)	$	405	$	(3,384)
Denominator:
Common shares		11,881		11,832
RSUs		202		5
Stock options		-		-
Common stock warrants		-		-
Diluted weighted average shares outstanding		12,083		11,837
EPS - diluted	$	0.03	$	(0.28)

Excluded securities:
Common stock issuable:
Stock options		1,396		1,198
Common stock warrants		60		60
RSUs		-		66
Total excluded potentially dilutive shares		1,456		1,324

XML 39 R27.htm IDEA: XBRL DOCUMENT

OPERATIONS Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Cash, Cash Equivalent And Marketable Securities	$ 3,800
Working Capital Deficit	200
Retained Earnings (Accumulated Deficit), Total	(374,293)		$ (374,698)
Operating Income (Loss), Total	582	$ (3,138)
Net Income (Loss) Attributable to Parent, Total	405	$ (3,384)
Debt Instrument, Debt Default, Amount	2,500
Oxford Term Loan Agreement [Member]
Debt Instrument, Debt Default, Amount	$ 2,500

XML 40 R28.htm IDEA: XBRL DOCUMENT

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended
	Oct. 09, 2015	Mar. 16, 2017	Oct. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
License Development and Commercialization Agreement [Line Items]
Agreement Termination Notice Description				Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.
Amortization of Intangible Assets				$ 52	$ 52
License Agreement Option Products Description		In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing pseudoephedrine (“PSE”) and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
Pfizer Agreement
License Development and Commercialization Agreement [Line Items]
Payment for Termination				$ 2,000
Finite-Lived Intangible Asset, Useful Life				9 years 8 months 12 days
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months				$ 207
Finite-Lived Intangible Assets, Amortization Expense, Year Two				207
Finite-Lived Intangible Assets, Amortization Expense, Year Three				207
Finite-Lived Intangible Assets, Amortization Expense, Year Four				$ 207
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Minimum Net Sales Reaching Description				one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Licenses Revenue	$ 5,000
Proceeds from Milestone Payment On Agreement	$ 2,500
Main Pointe Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 2,500		$ 2,500
Asset Transferred, License Agreement		$ 309
Licensing Agreement, Royalty Percentage		7.50%		7.50%
Main Pointe Agreement [Member] \| Nexafed inventory [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 117
Main Pointe Agreement [Member] \| UNITED KINGDOM
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		1,000
Main Pointe Agreement [Member] \| JAPAN
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		500
Main Pointe Agreement [Member] \| South Korea [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received		$ 250
Kempharm Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from License Fees Received			$ 3,500
Kempharm Agreement [Member] \| Minimum
License Development and Commercialization Agreement [Line Items]
Additional Upfront Payment Receivable			$ 1,000

XML 41 R29.htm IDEA: XBRL DOCUMENT

REVENUE RECOGNITION - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 16, 2017	Mar. 31, 2017	Mar. 31, 2016
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Other Revenue, Net		$ 36	$ 100
Royalty Revenue, Total		74	$ 17
Main Pointe Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Royalty Revenue, Total		2
Proceeds from License Fees Received	$ 2,500	$ 2,500
Licensing Agreement, Royalty Percentage	7.50%	7.50%

XML 42 R30.htm IDEA: XBRL DOCUMENT

RESEARCH AND DEVELOPMENT ACTIVITIES - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross	$ 50	$ 50
Professional and Contract Services Expense	$ 100

XML 43 R31.htm IDEA: XBRL DOCUMENT

INVENTORIES - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Raw and packaging materials		$ 98
Finished goods		243
Total		341
Less: reserve for finished goods	$ 0	(32)
Net inventories	$ 0	$ 309

XML 44 R32.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT AND EQUIPMENT (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,654	$ 2,807
Less: impairment reserve	(82)	(82)
Less: accumulated depreciation	(1,833)	(1,858)
Net property, plant and equipment	739	867
Building and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,273	1,273
Scientific equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	598	598
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	109	109
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	415	568
Land and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	70	70
Office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 27	$ 27

XML 45 R33.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT AND EQUIPMENT - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Impairment Of Property, Plant and Equipment, Reserve	$ (82)	$ (82)

XML 46 R34.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accounts Payable and Accrued Liabilities [Line Items]
Cost sharing expenses under license agreement	$ 269	$ 150
Advanced expense reimbursements under license agreements	209	0
Other fees and services	51	47
Payroll, payroll taxes and benefits	173	116
Professional services	173	232
Clinical, non-clinical and regulatory services	136	131
Marketing, advertising, and promotion	5	10
Property taxes	18	16
Franchise taxes	6	1
Total	$ 1,040	$ 703

XML 47 R35.htm IDEA: XBRL DOCUMENT

DEBT - Summary of Debt (Detail) $ in Thousands	3 Months Ended
DEBT - Summary of Debt (Detail) $ in Thousands	Mar. 31, 2017 USD ($)
Current Debt
Balance at Jan. 1, 2017	$ 5,500
Principal payments	(445)
Classification	0
Balance at Mar. 31, 2017	5,055
Debt Discount
Balance at Jan. 1, 2017	(98)
Amortization expense	20
Classification	0
Balance at Mar. 31, 2017	(78)
Deferred Debt Issuance Costs
Balance at Jan. 1, 2017	(47)
Amortization expense	10
Classification	0
Balance at Mar. 31, 2017	(37)
Current Debt, net at Mar 31, 2017	4,940
Long-term [Member]
Current Debt
Balance at Jan. 1, 2017	2,979
Principal payments	0
Classification	(722)
Balance at Mar. 31, 2017	2,257
Debt Discount
Balance at Jan. 1, 2017	(98)
Amortization expense	20
Classification	0
Balance at Mar. 31, 2017	(78)
Deferred Debt Issuance Costs
Balance at Jan. 1, 2017	(47)
Amortization expense	10
Classification	0
Balance at Mar. 31, 2017	(37)
Current Debt, net at Mar 31, 2017	2,142
Current [Member]
Current Debt
Balance at Jan. 1, 2017	2,521
Principal payments	(445)
Classification	722
Balance at Mar. 31, 2017	2,798
Debt Discount
Balance at Jan. 1, 2017	0
Amortization expense	0
Classification	0
Balance at Mar. 31, 2017	0
Deferred Debt Issuance Costs
Balance at Jan. 1, 2017	0
Amortization expense	0
Classification	0
Balance at Mar. 31, 2017	0
Current Debt, net at Mar 31, 2017	$ 2,798

XML 48 R36.htm IDEA: XBRL DOCUMENT

DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Schedule Of Interest Expense [Line Items]
Term Loan	$ 148	$ 209
Debt discount	20	26
Debt issue costs	10	14
Total interest expense	$ 178	$ 249

XML 49 R37.htm IDEA: XBRL DOCUMENT

DEBT - Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2017	$ 2,077
2018	2,978
Total	$ 5,055	$ 5,500

XML 50 R38.htm IDEA: XBRL DOCUMENT

DEBT - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		1 Months Ended	3 Months Ended
	Jan. 07, 2015	Oct. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2013	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount							$ 10,000
Debt default long term debt percentage							13.35%
Debt Instrument, Maturity Date			Dec. 01, 2018
Debt instrument, fee amount			$ 50
Debt consulting placement fee			100
Debt related commitment fees and debt issuance costs			10	$ 14
Debt instrument unamortized discount			78		$ 98
Debt instrument Cash Maintenance	$ 2,500
Repayments of Debt			445	$ 409
Debt Instrument, Periodic Payment			$ 260
Debt Instrument, Interest Rate, Effective Percentage			10.16%
Proceeds from Issuance or Sale of Equity		$ 6,000
Interest Payable, Current			$ 35		0
Term Loan [Member]
Debt Instrument [Line Items]
Debt related commitment fees and debt issuance costs			231
Interest Payable, Current			598		$ 559
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage							8.35%
Repayments of Debt	$ 5,000	5,000
Proceeds from Issuance or Sale of Equity		2,500
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52
Proceeds from Issuance or Sale of Equity		$ 3,000
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount			$ 400
Warrants to purchase common stock			60	60
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.98	$ 2.52		$ 2.52
Warrants, expiry date			December 27, 2020
Additions To Debt Instrument Unamortized Discount	$ 33
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid			$ 795
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage			1.00%

XML 51 R39.htm IDEA: XBRL DOCUMENT

COMMON STOCK WARRANTS - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Secured Debt			$ 10.0
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60	60
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98	$ 2.52	$ 2.52

XML 52 R40.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION -Recognition of Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	$ 711	$ 1,014
Total	117	150
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	34	43
Research and Development Expense [Member] \| Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	34	43
Research and Development Expense [Member] \| Restricted Stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	0	0
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	83	107
General and Administrative Expense [Member] \| Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	53	77
General and Administrative Expense [Member] \| Restricted Stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	$ 30	$ 30

XML 53 R41.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION - Stock Option Award Activity (Detail) - Stock Option Plan [Member] - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	1,397	1,198
Number of Options, Granted	0
Number of Options, Exercised	(1)
Number of Options, Forfeited or expired	0
Number of Options Outstanding, ending	1,396	1,198
Number of Options exercisable	1,125	876
Weighted Average Exercise Price, beginning	$ 13.57	$ 15.67
Weighted Average Exercise Price, Granted	0	0
Weighted Average Exercise Price, Exercised	(0.92)	0
Weighted Average Exercise Price, Forfeited or expired	0	0
Weighted Average Exercise Price, ending	13.58	15.67
Weighted Average Exercise Price, Options exercisable	$ 16.52	$ 20.64

XML 54 R42.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION - Summary of Information about Non Vested Stock Options (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2017 $ / shares shares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning \| shares	335
Granted \| shares	0
Vested \| shares	(64)
Forfeited \| shares	0
Outstanding, ending \| shares	271
Outstanding beginning, Weighted Average Fair Value \| $ / shares	$ 1.18
Granted, Weighted Average Fair Value \| $ / shares	0
Vested, Weighted Average Fair Value \| $ / shares	1.36
Forfeited, Weighted Average Fair Value \| $ / shares	0
Outstanding ending, Weighted Average Fair Value \| $ / shares	$ 1.14

XML 55 R43.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) - Stock Option [Member]	12 Months Ended
	Dec. 31, 2016 $ / shares
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Risk-free interest rates	2.30%
Average expected volatility	85.00%
Expected term (years)	10 years
Weighted average grant date fair value	$ 0.77

XML 56 R44.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION - Summary of RSU Plan (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	335
Granted	0
Vested	64
Forfeited or expired	0
Outstanding, ending	271
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	91	45
Granted	238	88
Distributed	(67)	(42)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	262	91
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	91	0
Granted	0	0
Distributed	(67)	(42)
Vested	59	22
Forfeited or expired	0	0
Outstanding, ending	83	25

XML 57 R45.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands		1 Months Ended		3 Months Ended	8 Months Ended
	Jan. 03, 2017	Jan. 04, 2016	May 01, 2014	Mar. 31, 2017	Jan. 02, 2015	Dec. 31, 2016	Mar. 31, 2016
Employee Benefit Plans Disclosure [Line Items]
Aggregate intrinsic value of the option awards vested				$ 0			$ 70
Unrecognized compensation cost on unvested option awards outstanding				$ 309
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1	1
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution	66	41	1
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award				3
2014 Restricted Stock Unit Award Plan [Member] \| Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	18	9
2014 Restricted Stock Unit Award Plan [Member] \| Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	67	42
2014 Restricted Stock Unit Award Plan [Member] \| Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	49	33
2014 Restricted Stock Unit Award Plan [Member] \| Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	60	22			10
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%	25.00%			25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description	stock, for up to 40%	stock, for up to 40%			stock, for up to 40%
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution		2
Deferred Compensation Arrangement with Individual, Recorded Liability	$ 19					$ 27

XML 58 R46.htm IDEA: XBRL DOCUMENT

INCOME TAXES - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)
Income Tax Disclosure [Line Items]
Federal income tax benefits	$ 47.2
Federal NOLs	$ 138.8
U.S. statutory tax rate	34.00%
State income tax benefits	$ 2.1
Federal Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	1.2
Indiana State Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$ 0.2
Maximum
Income Tax Disclosure [Line Items]
NOL expiration year	2036
Minimum
Income Tax Disclosure [Line Items]
NOL expiration year	2017

XML 59 R47.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE ("EPS") - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
EPS - basic
Numerator: net income (loss)	$ 405	$ (3,384)
Denominator:
Common shares	11,881	11,832
Vested RSUs	26	5
Basic weighted average shares outstanding	11,907	11,837
EPS - basic	$ 0.03	$ (0.28)
EPS - assuming dilution
Numerator: net income (loss)	$ 405	$ (3,384)
Denominator:
Common shares	11,881	11,832
RSUs	202	5
Stock options	0	0
Common stock warrants	0	0
Diluted weighted average shares outstanding	12,083	11,837
EPS - diluted	$ 0.03	$ (0.28)
Common stock issuable:
Total excluded potentially dilutive shares	1,456	1,324
Employee Stock Option [Member]
Common stock issuable:
Total excluded potentially dilutive shares	1,396	1,198
Warrant [Member]
Common stock issuable:
Total excluded potentially dilutive shares	60	60
Restricted Stock Units (RSUs) [Member]
Common stock issuable:
Total excluded potentially dilutive shares	0	66

XML 60 R48.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jun. 30, 2015 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Line Items]
Accrued Cost Sharing Expenses Clinical Studies		$ 269		$ 150
Purdue Pharma [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Expense	$ 250		$ 500
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		150
Number of lawsuits served		50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint		445
Palatine Illinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space		$ 25
Lease expiring date		March 31, 2017

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %N"K$H?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 6X*L2F;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !;@JQ*;R7=,.X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!3L,P#(9?!>7>NNG$0%&7"X@32$A, G&+'&^+:-HH,6KW]J1E MZX3@ 3C&_O/YL^0&@\(^TG/L T5VE*Y&WW9)8=B( W-0 D/Y$TJ'\C'L(!C_,GJ"NJC5X8F,-&YB 15B(0C<6%48RW,<3WN*"#Y^QG6$6@5KR MU'$"64H0>IH8CF/;P 4PP9BB3]\%L@MQKOZ)G3L@3LDQN24U#$,YK.9?)KZN[^^V#T'4E;XKJNI#U5JZ5O%55_3ZY M_O"["/O>NIW[Q\9G0=W K[O07U!+ P04 " !;@JQ*F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( %N"K$H#J@N\90( !0( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q W_D:A7-5BY-2SK1L"[@Y+H-=^#Y !)-,(@? M#1G$8A[H4$Z,O>K%Y\LVC+5'A)*SU":P&A[D0"C5EI0?OR:CX:RIBA"JX]41IG1H7Y M#]:>[.G*EHA=I]5'$9/;29";$?$7"! #,B4K9G M >@3V$.'#O\5.+@(Y!= W@B0H:,%/?'3$R\],?1D04^M"W 1F5\@]0JD#CVW M!%Q$X1?(O *90]]8 BX"Q'Z%W*N0NWQ@28R0U$"Z\3/'(/>+%%Z1PA6Q,F4_ M0K(E9"55-EZ)C2N16!(>2.J7 +&_H&+70F:75.S<5EYDFV3EOL!*Z0)7R4XM M'V8EN8"W?G< NA;L_/)@X$J" 7\1 ^1:L%/,AX$K*OY:!VXI0V2]1A-F^6T M* J$T,;2BA9O;$OXS;0C$9S9O3.]<+$[M[P=-&_T7_C8+[]B?FLZ$9R85"^] M>8^OC$FB'(J?E"NU:M'S@I*KU--<9^QC8_!J\OOOO6GYP;5M^;NNTWT6D8S@]QW.]/KBG[#_[LVO&? MH^^:X/W>N/,Q!31UCDJ1Q4U9MM%W/]QZ[[=J_#'75NL=NU;\T3=G] M*%SM+YL(HK<;7ZOGTS#=B+?K<_GL_G+#W^?';KR*;ZT7;5>>.F^@C M/.S4'# K_JG";I9712E-^OQZK=CY>EO;?PN0 7 +P%@#Z MEP%J"5 D(+XZFU/]5 [E=MWYRZJ[SM:YG!8%/*AQ,/?3S7GLYO_&;/OQ[NL6 M]3I^G=I9),55@O>2]XJ=H# W23SV?S.!H@FS?'Z/MZ2)*X2 M.TO:6:(RK4@>7(1I!K(3+3K1W$E&G%PEYKX3DR3$R?^(WCDQHA/#G>3$B6&= MI,0&5Z"23:2BB9294"33(F5=*.J"2VPNN["B"\M= '%A61>&+G)!$IB03'21 M<1>DBR)C7=!UP14J"8Q%+KK(N0OR%!2YT <9KQW7C$^*[ ,2&3P)=\+(D_ 5 M:E5&Z<-5)H? W$ @\#=&.H&^#I4.37#15EJ UYD&@)R+RGU@JP;4):9$51: M!8 &,EN!PU51N"Z:=TEGAC[&D@J3T*J1^0J:O2I4J 69B\#!2">Q (%["1M< M+K*AB9;I"!R/FN(1./P@H:J=H+))@-0@0Q(X)36E)' &TJ=D)VA"CZ+,2>"@ MU!24P#D(;'ZX!D/S([,2."QIR5" 1$M6'TDB+7M!&9?(<:DI+I&#$&U.<2FI ME W46RCC$CDN-<4EFIL!$CD($NJYVDBH/%1LH M Q,Y,#4%)G(4&CY1@LB$O,BX1%Z/:EJ/(J\U+;#26%(EP2I?1B]R]&J*7D%C M*.U^K7GO1"8OINPU8@*O191QB1R7M&(LD*,0&*9$4>"5AC(QD1/34$ZA4#E: MDV66VA%U-@V\3% F)W)R&D8K#L7?E-68LZ4G"],\,$I*)JCB!#6468JS$2RP MST1!!5E@A)1,4,4)2@NF8M'-Y=]T9N5X,_KSL^L2WK:?M3U!+ P04 M " !;@JQ*]1KX#"$" #%!@ & 'AL+W=O[N8@]PS\SWX U+@?*7G@-(+S7EG1\X]="]&N$^+&&%O,5[:&33\Z4M5A( MDUT0[QG@DPYJ"8J"($,M;CJ_*K5OSZJ27@5I.M@SCU_;%K,_6R!TV/BA?W<\ M-Y=:* >JRAY?X#N('_V>20O-64Y-"QUO:.92\'S&%' MR:_F).J-7_C>"<[X2L0S'3[#U$_J>U/S7^$&1,H5B:QQI(3K?^]XY8*V4Q:) MTN+7<6TZO0Y3_GN8.R": J(Y($S^&Q!/ ;$1@$8RW>I'+'!5,CIX;/Q8/59G M(ES'\F4>E5._._U,=LNE]U:E>8EN*L\DV8Z2:"&)'A4[AR*=)4C6GR$B)T2D MXY,E1&% C))<2[JQA,&YLR6Y&R)V0L0VQ),!$5L5LB@T*&Q-FCVY.1(G1V)Q M9('!,4J*18U@%9@@B042!FZ.U,F1VAQ&B>TH21]*J)]!\J;L@29STF0VC7$* MMYE=)BR*V(!QJN+$S9([67*;Q:BRS=_%XE3]BZ5PLA0V2V*P%-9!,#^0K8@C M P(M!HH:\-\PNS0=]PY4R-FD)\B94@$R7;"2'=7R3ID- F>AMKG&PO=V]R M:W-H965T&ULA9A=CYLZ$(;_"N(^"Q[S859)I$VJZASI5%JU M:GO-)DZ""C@'R*;]]S4?F[(SX_0F@/..__-KHTUY4O_+>&S\7QU/4-P7IYSH_ZB^Z^GI\;>Q7< M>MD7E:[;PM1>HP\K_TD\;N40,"B^%?K:SLZ]/I478W[T%__N5W[8.]*EWG5] M%[D]O.JM+LN^)^OC_ZE3_S9F'S@_?^O]XY"\3>8E;_76E-^+?7=:^$8M^;LO]/O^K2RGLG=HR=*=OAU]M=VLY44R_62I7_'(]%/1RO M4_]O87P 3 %P"[!CWPN04X#\$Q -R8_.AE0_Y%V^7C;FZC7CW3KG_4,A'J4M MYJYO'&HW_&>S;6WKZSJ)E\%KW\\DV8P2F$G$31'8SF\C #?"!D@XO!]@2Q5) MPH\@V1SD$"_G\2D?'['QT1 ?S>,5JL$H20=)/281AR'*@XI"WD;,VHBIC0S9 M&"7Q; 29(!-4(D*'C82UD1 ;*4ITDY QT@C9H!+AN"",9:R0C#WDJ^7@1\C,]I*E$>*J'M%Z MYL*6$X7@\.*@CJ!>"'8$?$:TD$(JAQN> MD"*FDR!S],##35"Z*4PWP; +9T,EX,"*X/DF*. 4!IR@]%H(7/XMIX+(51:> M& " M7?XIQUP$'G) (:6$?0HD3HJI%^ ".UP?PE -*N0Q3;M+\S0Y5W;/# MHP[HDBYS+.DDCR=)\43J*YG5FLC(0IF5*>F82)('E*2 (@66S(H-0LSX+2=C M_ 2S[]Q*-\=A2Z#U=N92=_TGY:SUMNWP!/UW,FK?B,?MN'GPIYMQ+^-3WAR+ MNO5>3&>_PH=OY8,QG;8NPP?K[Z3S_>VBU(>N/TWM>3/N(8P7G3E/^R/!;9-F M_1M02P,$% @ 6X*L2DR78ZM_ @ \P@ !@ !X;"]W;W)K^4-QL)YZTC/EVXCQ+#P/+YK<(?X$QUP M+[\<*.N0D%UV]/C ,-KKH(YXH>^G7H?:WJU*/?;,JI*>!&E[_,P!5Y8".^#L6/X9G)GO>[+)O.]SSEO8.PX>E^S%8; JE MUX*?+;[PF[:C2+:4OJK.E_W2]=6$,,$[H1R0?)UQC0E11G(:OR=/=TZI F_; M5_=/FEVR;!''-26_VKUHEF[N.GM\0"9X+_B,R92KF8B<^PH MX?KI[$Y*B/)GTTZX/H84 \!<1S M0)@]#$BF@.1?@$;P1G2]EFLD4%4R>G'86 T#4D47+!+YMW9J4/\<_4TN)Y>C MYZJ(2^^L?";):I2$MY+D7E(#DO1>L@8DV;UD TCR6>))C)DE!%E"'1_?QA<& MRRC)M*37DB#((X,&%!DXMB;*DBPUK#:V[$.4Q>E[7!'(%5E<@>\;S>F@K@/?$#NV/7>V5,B#1A\'!TH%EH[^DS1KY UD[A!\ M$*J9R38;S^&Q(^@P73&\^9Y3_0502P,$% @ 6X*L2@^2KZ*K! ?!@ M !@ !X;"]W;W)K78S/U?U MMV;G7#OY7A:'YG&Z:]OC0Q TZYTK\^9+=72'[I?7JB[SMKNLMT%SK%V^&1J5 M14!A& =EOC],%_/AWG.]F%>GMM@?W',]:4YEF=?_+EU1G1^G9OI^X^M^NVO[ M&\%B?LRW[@_7_GE\KKNKX!IELR_=H=E7ATGM7A^G3^9A96W?8%#\M7?GYN;[ MI$_EI:J^]1>_;AZG8>_(%6[=]B'R[N/-K5Q1])$Z'_^,0:?7/ON&M]_?H_\\ M)-\E\Y(W;E45?^\W[>YQFDXG&_>:GXKV:W7^Q8T)1=/)F/UO[LT5G;QWTO6Q MKHIF^#M9GYJV*LO/6! M1LWRHJ%;S541=-&O71#J8DFJ.=UWL-**.,8],$R"A_9\ET2* U@8P X![$V M-!:#<)$D@^0P2&P8B3RT9L:<6NPD@DXBD$J& \0P0*Q2,284N5PTT8U/DJEH M"7OR2*"-!-@PPD:B^K"9L*$E[!F-%-I(M8U0S+YEJOHP1BR!%=!$(3:202,9 M& ]I)-/)BB>WTA+KL6%"O-Y#8(3E@@]5-]((D!C/DS$>\AC@Q$HG1G4327I\ MK+FW @GU9 A8B:05^GQ0M(0\J\9@DAF ,N-AH<$L,QIF:CXO1]'=XY-S'FAF M4>+Q@FEF(N5%3NGEJ+F;TRRM:(UOVF,J&HU%EC@RFGDS-=>TQF<$<]$@,*;2 MB<:>FFI:8GR3'J/1 #::3#H!X O5T]&BQ#?M,1V-QB,K*&GVS:1H!42&?-4* M)B1I0K(<%@+T8U75:!'%D<<+9B0!1I)<0*3YQRP7,Q!%F6]@,"5)4]+*-42: M@(F55K0F\[PZ"%.26#N1+]-1\]$: A+?BDD:M1->2$$6-= )$GM5,F+2D M27L[\4>C &'8,-MVR M'%BR+ATCD\HW 5"133U5 V-P,@"G*J=84S%F57@#%5/JX3AC=G*J%X/O,($Q M\Q@PCR7S6.,L47,/U(?& SV+H6"B'@2P%8?^8%5 M!%1@%04W9[:EJ[?#\78S65>G0]N?CM[[@_-Y*5JVZH%>VW[KTGWO;Z&PO=V]R M:W-H965T&UL=5-ACYLP#/TK47[ A:;<-E6 =+W3M$F;5-VT M[7,*!J)+,$M"N?W[)8$RKF-?B&W\GI\=)QO1O-@6P)%7K3J;T]:Y_L"8+5O0 MPMYA#YW_4Z/1PGG7-,SV!D0505HQGB3OF!:RHT468R=39#@X)3LX&6('K87Y M?02%8TYW]!IXEDWK0H 562\:^ ;N>W\RWF,+2R4U=%9B1PS4.7W8'8YIR(\) M/R2,=F63T,D9\24XGZN<)D$0*"A=8!#^N, C*!6(O(Q?,R==2@;@VKZR?XR] M^U[.PL(CJI^R4S,U_@0LHGQZ4^!HE*AN_I!RL M0SVS>"E:O$ZG[.(YSOQ7V#: SP!^ V!3H:C\23A19 9'8J;9]R)<\>[ _6S* M$(RCB/^\>.NCEV*7)AF[!*(YYSCE\'7.DL$\^U*";Y4X\G_@?!N^WU2XC_#] M&X7_J9]N$J21('U#P&]:W,K9WQ1AJYEJ,$W<)DM*'+JXR:OHLK //-[)W_1I MV[\*T\C.DC,Z?[-Q_C6B R\EN?,KU/H'MC@*:A?,]]XVTYI-CL-^?D%L><;% M'U!+ P04 " !;@JQ*) 5RN+ ! #2 P & 'AL+W=O5-2VYRVSG5[QFS9@N+V"CO0_D^- M1G'G7=,PVQG@500IR9+-YH8I+C0MLA@[FB+#WDFAX6B([97BYOT $H><;NDE M\"2:UH4 *[*.-_ 3W*_N:+S'9I9**-!6H"8&ZIS>;?>'-.3'A-\"!KNP2>CD MA/@2G&]53C=!$$@H76#@_CC#/4@9B+R,UXF3SB4#<&E?V!]B[[Z7$[=PC_)9 M5*[-Z2TE%=2\E^X)AT>8^KFF9&K^.YQ!^O2@Q-+U.D*X2 MI)$@_6^+:SDWGXJPQ4P5F"9NDR4E]CIN\B(Z+^Q=$N_D(WW<]A_<-$);Y B"U;D,Q>Z0Z4OZFUD *3@;97DIFWH\@])#C#?YP//&F=<%!BJQC M#?P"][L[&6^1F:7B$I3E6B$#=8YO-X=C&N)CP#.'P2[.*%1RUOHE&#^J'"=! M$ @H76!@?KO '0@1B+R,UXD3SRD#<'G^8+^/M?M:SLS"G19_>.7:'.\QJJ!F MO7!/>GB J9X=1E/Q/^$"PH<')3Y'J86-*RI[Z[2<6+P4R=[&G:NX#^/-;C?! MU@%T M 9L(]YR)@H*O_.'"LRHP=DQMYW+#SQYD!];\K@C*V(=UZ\]=Y+L4EO M,G()1%/,<8RARY@Y@GCV.05=2W&D_\'I.GR[JG ;X=M/"O?K!.DJ01H)TD\$ MW[Z4N!*S2[XD(8N>2C!-G":+2MVK.,D+[SRPMS2^R;_P<=H?F6FXLNBLG7_9 MV/]::P=>2G+E1ZCU'VPV!-0N'&_\V8QC-AI.=],/(O,W+OX"4$L#!!0 ( M %N"K$H+H&PO=V]R:W-H965TO&G5N9RVWO<'QES9@A;NRO30X4UMK!8>3=LPUUL0 M501IQ?AN=\.TD!TMLN@[V2(S@U>R@Y,E;M!:V!]'4&;,:4+?'4^R:7UPL"+K M10-?P7_K3Q8MMK!44D/GI.F(A3JG=\GAN _Q,>"[A-&MSB14)MVF47]W&Z29,9 MM@W@,X O@-N8ATV)HO*/PHLBLV8D=NI]+\(3)P>.O2F#,[8BWJ%XA]Y+D5PG M&;L$HCGF.,7P=U,8J[M&T#7.=!5Y%D)(L MV6P.3'&A:9%%W]D6F>F]%!K.EKA>*6Y?3R#-D-,M?7,\BJ;UP<&*K.,-_ #_ MLSM;M-C,4@D%V@FCB84ZIW?;XRD-\3'@EX#!+7YC_Q)KQUHNW,&]D4^B\FU.;RFIH.:]](]F M^ I3/7M*IN*_PQ4DA@+,[3+!U0#(! MDAEP&_.P,5%4_IE[7F36#,2.O>]X>.+M,<'>E,$96Q'O4+Q#[[78[M.,70/1 M%',:8Y)ES!S!D'U.D:RE."7_P)-U^&Y5X2["=^\4[M<)TE6"-!*D_RUQ+>;P M(0E;]%2!;>(T.5*:7L=)7GCG@;U+XIO\#1^G_8';1FA'+L;CR\;^U\9X0"F; M&QRA%C_8;$BH?3A^PK,=QVPTO.FF'\3F;US\ 5!+ P04 " !;@JQ*:,4A M@K4! #2 P &0 'AL+W=O_(M0"#/6AF?TS:$[LB8+UO0PM_8#@S>U-9I$=!T#?.= U$ED%:,;S;O MF!;2T")+OK,K,ML')0V<'?&]UL+]/H&R0TZW],7Q*)LV1 0*E(A#)^39QT3AF!R_,+^\=4.]9R$1X>K/HIJ]#F]$!)!;7H57BTPR>8 MZKFE9"K^"UQ!87A4@CE*JWQ:2=G[8/7$@E*T>!YW:=(^C#<[/L'6 7P"\!EP M2'G8F"@I_R""*#)G!^+&WGRVVMW<9NT:B*>8T MQO!ES!S!D'U.P==2G/@;.%^'[U85[A)\]X_"PSK!?I5@GPCV_RUQ+>;]JR1L MT5,-KDG3Y$EI>Y,F>>&=!_8^/2+[&SY.^U?A&FD\N=B +YOZ7UL; *5L;G"$ M6OQ@LZ&@#O%XAVM>EO0SKGAR)BM.M#"WN O;]IT&CAO&E:9@<#HHX@K1A/DENFA>QI MF4??V90YCD[)'LZ&V%%K87Z<0.%4T)2^.AYEV[G@8&4^B!:^@/LZG(VWV,I2 M2PV]E=@3 TU![]/C*0OQ,>";A,ENSB144 ;@]O[*_C[7[6B["P@.J)UF[KJ!WE-30B%&Y1YP^P%+/&TJ6 MXC_!%90/#TI\C@J5C2NI1NM0+RQ>BA8O\R[[N$_S398NL'T 7P!\!=S%/&Q. M%)6_$TZ4N<&)F+GW@PA/G!ZY[TT5G+$5\<[\,/NPH/$7[X3>$_\F>[!%DDR/Y;XE[,GRK9IJ<:3!NG MR9(*QSY.\L:[#NP]CV_R*WR>]L_"M+*WY(+.OVSL?X/HP$M);OP(=?Z#K8:" MQH7C6W\V\YC-AL-A^4%L_<;E3U!+ P04 " !;@JQ*I=H\0;0! #2 P M&0 'AL+W=OX4]=/ZF1J.%\Z9IF.T-B"J"M&)\M[MA6LB.%EGTG4R1 MX>"4[.!DB!VT%N;U" K'G.[IF^-1-JT+#E9DO6C@![B?_RN[*CU#K/]AB**A=.'[R M9S.-V60X[.&PO=V]R:W-H965T<"CKM_/\"NZW;6O@!WW'OW[CB2'LVSK0$<>=6JL2FM MG6N/C-F\!BWL#;;0^)L2C1;.FZ9BMC4@B@C2BO'5:L>TD W-DN@[FRS!SBG9 MP-D0VVDMS)\3*.Q3NJ9OCD=9U2XX6):THH*?X'ZU9^,M-K$44D-C)3;$0)G2 MV_7QM WQ,>"WA-[.SB14QLO(2:>4 M 3@_O[%_C;7[6B["PAVJ)UFX.J4'2@HH1:?<(_8/,-;SA9*Q^.]P!>7#@Q*? M(T=EXTKRSCK4(XN7HL7KL,LF[OUPP_8APV)HO)[X426&.R) M&7K?BO#$ZR/WO2"SK]L['^)Z,!+6=WX$:K]!YL,!:4+Q[T_FV', M!L-A._X@-GWC["]02P,$% @ 6X*L2J%DH(BU 0 T@, !D !X;"]W M;W)K&UL?5/M;ML@%'T5Q ,4Q\F2+K(M-9VF35JE MJ-/:W\2^ME&!ZP&.V[U-FM_@'LYY]P/+MF YL6V (Z\*JEM3EOGNB-C MMFQ!<7N#'6A_4Z-1W'G3-,QV!G@524JR-$GV3'&A:9%%W]D4&?9."@UG0VRO M%#=O)Y XY'1#WQV/HFE=<+ BZW@#/\']ZL[&6VQ6J80";05J8J#.Z=WF>-H% M? 0\"1CLXDQ")1?$EV!\KW*:A(1 0NF" O?;%>Y!RB#DT_@]:=(Y9" NS^_J M7V/MOI8+MW"/\EE4KLWI+245U+R7[A&';S#5\XF2J?@?< 7IX2$3'Z-$:>-* MRMXZ5).*3T7QUW$7.N[#>+/=3[1U0CH1TIEP&^.P,5#,_ MWO,@,#L2,O>]X M>.+-,?6]*8,SMB+>^>2M]UZ+S?YSQJY!:,*<1DRZQ,P(YM7G$.E:B%/Z#SU= MIV]7,]Q&^G89_9"L"^Q6!7918/??$E*C!-G"9+2NQUG.2%=Q[8 MNS2^R0=\G/8';AJA+;F@\R\;^U\C.O"I)#=^A%K_P69#0NW"\>#/9ARST7#8 M33^(S=^X^ -02P,$% @ 6X*L2CA]K$JT 0 T@, !D !X;"]W;W)K M&UL?5/;CM,P$/T5RQ^P;MU 5U42:;L(@012M0AX M=I-)8JTOP7::Y>\9.]D0(.+%]HSGG#DS'N>C=<^^ PCD12OC"]J%T)\8\U4' M6O@[VX/!F\8Z+0*:KF6^=R#J!-**\=WN+=-"&EKFR7=Q96Z'H*2!BR-^T%JX MGV=0=BSHGKXZGF3;A>A@9=Z+%KY ^-I?'%IL8:FE!N.E-<1!4]"'_>F\IJ:$1@PI/=OP E6".RBJ?5E(- M/E@]LZ 4+5ZF79JTC]/-,9MAVP ^ _@"N$]YV)0H*7\G@BAS9T?BIM[W(C[Q M_L2Q-U5TIE:D.Q3OT7LK]T>>LULDFF/.4PQ?QRP1#-F7%'PKQ9G_ ^?;\,.F MPD."'_Y0>-@FR#8)LD20_;?$K9CLKR1LU5,-KDW3Y$EE!Y,F>>5=!O:!IS?Y M'3Y-^V?A6FD\N=J +YOZWU@; *7L[G"$.OQ@BZ&@"?%XQ+.;QFPR@NWG'\26 M;US^ E!+ P04 " !;@JQ*I)RFRK0! #2 P &0 'AL+W=O:%EGTG4R18>^DT' RQ/9*/P!%,]UY1,Q7^%"T@?'I3X'"5*&U=2]M:AFEB\ M%,7?QUWHN _C39I.L'5 ,@&2&7 ;\[ Q453^P!TO,H,#,6/O.QZ>>'M(?&_* MX(RMB'=>O/7>2['=7V?L$HBFF.,8DRQCY@CFV><4R5J*8_(//%F'IZL*TPA/ M_U!XLTZP6R7818+=?TMJK -'&:+"FQUW&2%]YY8.^2^":_P\=I M_\9-([0E9W3^96/_:T0'7LKFRH]0ZS_8;$BH73CN_=F,8S8:#KOI!['Y&Q&PO=V]R:W-H965T5-2VYRVSG4'QFS9@N+V!CO0_J9& MH[CSIFF8[0SP*H*49&F2?&2*"TV++/I.ILBP=U)H.!EB>Z6X^74$B4-.-_3J M>!1-ZX*#%5G'&_@![F=W,MYB,TLE%&@K4!,#=4[O-H?C+L3'@"8ZOE R53\-[B ].%!B<]1HK1Q)65O':J)Q4M1_&W< MA8[[,-YLK[!U0#H!TAFPCP V)HK*/W/'B\S@0,S8^XZ')]X<4M^;,CAC*^*= M%V^]]U)L;O<9NP2B*>8XQJ3+F#F">?8Y1;J6XIC^ T_7X=M5A=L(W_ZA\-,Z MP6Z58!<)=O\M<25FG_R5A"UZJL T<9HL*;'7<9(7WGE@[]+X)N_AX[1_YZ81 MVI(S.O^RL?\UH@,O);GQ(]3Z#S8;$FH7CK?^;,8Q&PV'W?2#V/R-B]]02P,$ M% @ 6X*L2HP%*06T 0 T@, !D !X;"]W;W)K&UL?5/;;MLP#/T501]0Q4K:!8%MH.DP=, &!!VV/BLV?4%U\20Y[OY^ ME.RZ;N?U11(IGL-#BDH'8Y]< ^#)LY+:9;3QOCLPYHH&E'!7I@.--Y6Q2G@T M; M@O&US.@F" ()A0\, K<+W(&4@0AE_)XXZ9PR )?G%_8OL7:LY2PB>DA(JT4O_8(9[F.JYIF0J_AM<0&)X4((Y"B-=7$G1.V_4Q()2E'@>]U;' M?1AOKOD$6P?P" MH?>2)_LD99= -,4,T.5*87L=)7GCG@;V-C\A>P\=I_RYLW6I'SL;C MR\;^5\9X0"F;*QRA!C_8;$BH?#A^PK,=QVPTO.FF'\3F;YS_!5!+ P04 M" !;@JQ*W\BUI+V$ *[Y0VRS)W]-\U.;5=@ .O4FA;($[Y_HC(;;J0#)[HWM0_J;11C+G3=,2VQM@ M=21)0>AN]X5(QA4N\^@[FS+7@Q-TH"/@%\<1KLZHU#)1>O78'RO"[P+ M"8& R@4%YKRR1+ M;&>XC?;^.?LBV!=)-@30*I&N! MY.NG$C%3$++JJ033QFFRJ-*#BI.\\BX#>QQN_ AU_H,MAH#&A>.M/YMIS";#Z7[^063YQN5?4$L#!!0 ( M %N"K$H>K#/UMP$ -(# 9 >&PO=V]R:W-H965T.J:U@4'*[)> M-/ 5W+?^8KS%%I:J4Z!MAYH8J'/ZD)S.:8B/ =\[&.WJ3$(E5\3G8'RJY-J='2BJH MQ2#=$XX?8:[G'25S\9_A!M*'ATR\1HG2QI64@W6H9A:?BA(OT][IN(_339K, ML&T GP%\ 1RC#IN$8N;OA1-%9G D9NI]+\(3)R?N>U,&9VQ%O//)6^^]%;!&DD2/\J M\?Y-B5LQQSV 0 T@, !D !X;"]W;W)K&UL M;5/;;IPP$/T5RQ\0LX:FFQ4@91-%K91(JU1-GKTP@!5?J&V6].]K&T)0RHOM M&9]SYN)Q/FKS9CL A]ZE4+; G7/]@1!;=2"9O=(]*'_3:".9\Z9IB>T-L#J2 MI" T2:Z)9%SA,H^^DRES/3C!%9P,LH.4S/P]@M!C@7?XP_',V\X%!RGSGK7P M"]SO_F2\11:5FDM0EFN%##0%OMT=CEG 1\ +A]&NSBA4.6UZPJ\QZB&A@W" M/>OQ!\SU?,-H+OX1+B \/&3B8U1:V+BB:K!.RUG%IR+9^[1S%?=QNDG3F;9- MH#.!+H1]C$.F0#'S>^98F1L](C/UOF?AB7<'ZGM3!6=L1;SSR5OOO92[_4U. M+D%HQAPG#%UC%@3QZDL(NA7B2/^CTVUZNIEA&NGI.OIUMBV0;0ID42!;"]PD M7TK3*CU#G/]AB"&A<.'[W9S.-V60XW<\_B"S?N/P'4$L#!!0 ( %N" MK$JE$;-[T@$ )P$ 9 >&PO=V]R:W-H965TGTF]MI&!\8%'%__OH!]KIOR8MAE M=F87[Y*-2K^:%L"B-RDZD^/6VOY$B"E;D,P\J!XZ=U(K+9EUIFZ(Z36P*@1) M0>AFDQ+)>(>++/@NNLC48 7OX**1&:1D^O<9A!ISO,7OCF?>M-8[2)'UK('O M8'_T%^TLLK!47$)GN.J0ACK'C]O3.?7X 'CA,)K5'OE*KDJ]>N-+E>.-3P@$ ME-8S,+?!Z_\[^*=3N:KDR T]*_.25;7-\Q*B"F@W" M/JOQ,\SU)!C-Q7^%&P@']YDXC5()$[ZH'(Q5 M0.< N@0<@PZ9A$+F'YEE1:;5B/1T]SWSOWA[HNYN2N\,5Q'.7/+&>6_%]@/- MR,T3S9CSA*%KS((@CGV1H#&),_TOG,;#=]$,=R%\MU9/#W&"?91@'PCV_Y2X MNRLQAMG'19*H2!(A2.Y$8I@T+I)&1=((P>%.)(8YWHF057=(T$V8"X-*-71A M)E?>9?0>:>BNO_!I;K\QW?#.H*NRKD=#)]5*67"I;!YAJ8R;"JG]\"LCQ(Q1]02P,$% @ 6X*L2@NBV)+H 0 9@4 !D !X M;"]W;W)K&UL=53;CIPP#/T5E _8 '/=$2#M;%6U M4BN-MNKV.0/FHDT(3<*P_?LF@:&4NB\D=H[/L1/L9)#J3=< )G@7O-4IJ8WI M3I3JO ;!](/LH+4GI52"&6NJBNI. 2M\D. T#L,]%:QI299XWT5EB>P-;UJX MJ$#W0C#UZPQ<#BF)R-WQTE2U<0Z:)1VKX!N8[]U%68O.+$4CH-6-; ,%94J> MHM/YZ/ >\-K H!?[P%5RE?+-&9^+E(0N(>"0&\? ['*#9^#<$=DT?DZ<9)9T M@VVDF%AL*H*]CVO3^G68^.]A>$ \!<2K #H*^&;97@8X@1;E&#K";9_$42K$C',?[+C:T_&D9VTU2C\VC-?@-02P,$% @ 6X*L2D4 _L:V 0 T@, !D M !X;"]W;W)K&UL;5/;;MP@$/T5Q >$-;MITI5M M*9NJ:J146B5*^LS:8QL%C MXG?Y]!^QUW-0OP SGG+DPI(.Q;ZX!\.1=J]9E MM/&^VS/FB@:T<%>F@Q9O*F.U\&C:FKG.@B@C22O&-YLO3 O9TCR-OJ/-4]-[ M)5LX6N)ZK87] ;_TATM6FQ6*:6&UDG3$@M5 M1N^2_6$7\!'P*F%PBS,)E9R,>0O&0YG134@(%!0^* C^2)*BMYYHR<53$6+]W&7;=R'\>;Z0ELG$G 9$M)+ Q4,S\F_ B3ZT9 MB!U[WXGPQ,F>8V^*X(RMB'>8O$/O.>=)DK)S$)HPAQ'#%Y@/!$/U.01?"W'@ M_]'Y.GV[FN$VTK?+Z#=?UP5VJP*[*+#[IT3^J<0US/93$+;HJ09;QVERI#!] M&R=YX9T']H['-_F C]/^4]A:MHZ7C?VOC/& J6RN<(0:_&"SH:#RX7B# M9SN.V6AXTTT_B,W?./\+4$L#!!0 ( %N"K$JBV9\470( &\' 9 M>&PO=V]R:W-H965TV$Z[^O;3@N 2?J2VRO9W9F';/..L9?10D@G;>:-F+E MEE*V2X1$44)-Q!-KH5$[1\9K(M62GY!H.9"#(=448<^+44VJQLTS$]OQ/&-G M2:L&=MP1Y[HF_.\:*.M6KN^^!UZJ4REU .592T[P ^3/=L?5"HU9#E4-C:A8 MXW XKMQG?[GU/4TPB%\5=.)J[NA2]HR]ZL77P\KUM".@4$B=@JCA AN@5&=2 M/OX,2=U14Q.OY^_9/YOB53%[(F##Z._J(,N5F[K. 8[D3.4+Z[[ 4%#D.D/U MW^ "5,&U$Z51,"K,KU."4K[$2$8 M",$'(7Q(" ="."&@OA1S-ELB29YQUCF\_WM;HF^1OPS5Z19U<)K2JA1652R;K'1%I'9#L=50;#&43@S%,T-1.KT&L<6,']RQDEBM)!8KBXF5 M9&8E]"9789-8K 1I:+>26JVDIVK.U WC_ M870 )8^=HJNN4P,_F8XNG(*=&ZD_WJOH^&H\8]VU)O&UO]STO?\C3?\4?2?\ M5#7"V3.I>J+I7$?&)"B3WI,ZR%*]?N."PE'J::+FO'\"^H5D[?"\H?&-S?\! M4$L#!!0 ( %N"K$HFN/]3>0, .81 9 >&PO=V]R:W-H965TJT[3=-G 05< 9. MT]W]S$>C8EZWY$\"Y#WG/Z[V4VGLM\K)>^'NM#]=!4*_WLDCK M*W60I?EEJZHBU>:TV@7UH9+II@TJ\H"&8104:5;ZRWE[[:%:SM51YUDI'RJO M/A9%6OV[D;DZ+7SBOUUXS'9[W5P(EO-#NI,_I?YU>*C,67#.LLD*6=:9*KU* M;A?^%W)]S]N 5O$[DZ?ZW;'7M/*DU'-S\FVS\,.F(IG+M6Y2I.;K1:YDGC>9 M3!U_^Z3^V;,)?'_\EOV^;=XT\Y36:Y77[:>W/M9:%7T64TJ1OG;?6=E^G_K\;V$X@/8!]!Q M^(ER7JF35W4+Z) VZY1< M1V9^U\W%=CK;W\P$U.;JRY)2.@]>FD2]YJ;3T(&"KI.%#S2W2B*'F#FB& MBONQ(HK.DL T>^Z8PHYI&\\&53@2,)B M0GX($%LM8$T"3;AT(2#!#/+I-/$ MK:9L-<(>K \E@S($+$.,RV"A-?5(0[!)!$TBD,!190P3Q-.G-($)$E"!M<+O MDM%0FOMWB%UFT&4&7"Q&[I!&8!,28J)#D"*R,0M!-['#QW'G(,#'YJ 7B4D^ MF%="@4]B^] +?##6!##+;.1ZT;1QPV03@#9WK"."J21B^H(GF#D"H./$[A:) M'&02C":)00IF;S#Q^#;E9(M@A E@F'/;"$ LG$:88@(0Y0Y$*4:4AM/GCV+Z M**"/6Y2O>I&SW6Z6/U,-RW%LJ@!2'MOET)$1"V<.'PPI!9#RQ/9!(IOD3T3# M8C#)%) L7..&2:87D$PQR11!.EH)T6CH"7'DP#2P"YXY&::!H1W+ZO:6C7&ULC57;;J,P$/T5Q >4^RTB2$VB:E?:E:*NMOOLD$E -9C:3NC^ M_?I"*0&KFQ=LC\^<.3/&X[PG])55 -QZ;W#+UG;%>;=R'%96T"#V0#IHQPIQ:[- VB?S> 2;^V M/?O#\%R?*RX-3I%WZ R_@/_N]E2LG)'E6#?0LIJT%H73VG[T5CO/E0X*\5)# MSR9S2Z9R(.15+KX?U[8K%0&&DDL*)(8K; %CR21TO VD]AA3.D[G'^Q/*GF1 MS $QV!+\IS[R:FVGMG6$$[I@_DSZ;S D%-G6D/T/N (6<*E$Q"@)9NIKE1?& M23.P""D->M=CW:JQUSM)-KB9'?S!P1\=1.RO'(+!(;C7(1P*A35+Z51%5OMB?(P8;T6?I3DSE42#9B-QO@WF/06 MLUUBO!'A" 6C#-\D8^,O0_CA+(0!6AL8D"M,J3!#/\EA"/-9M<@)IU?9Q,HF]_GKT%:C#/I,@W0L^K@S"K)I>7R'DZLXROQZ,LN M-;-OY>NANMNW&!X<3E-!%S MJEN^7G#2#<^9,[ZIQ3]02P,$% @ 6X*L2K3UE.CE 0 T00 !D !X M;"]W;W)K&UL?53;CILP$/T5RQ^PYA+8*@*D3:K5 M5FJE:*NVSPX,%ZV-J6W"]N]K&\(2@O8E]@QGSISCC)T,0KZI&D"C=\Y:E>): MZVY/B,IKX%0]B Y:\Z44DE-M0ED1U4F@A2OBC 2>%Q-.FQ9GBFJK5-D"SI: 4_0?_J3M)$9&8I&@ZM:D2+))0I M?O+WQ\CB'>!W X-:[)%U%R?V5_=MZ-ES-5J:99(,2 Y_ED=M3/A[T-SF+E-NK-SWXQ;9;*7+(B#A%PLT80YC)A@@?%O M$<=[1!"',X88!;.,8$O&(;@G6+780$3;'<)-HZ&K#V\D[K8)=IL$.T>PNR&( M5B9&=[^M3X";L SY>]A]45DVKT%EH,Z=NFDHA-!@IWH/14IOW90X8E-IN'\U> MCK=L#+3HI@>$S*]8]A]02P,$% @ 6X*L2I.F5&/W 0 @@4 !D !X M;"]W;W)K&ULA51=CYLP$/PKB/>>P7Q=(D!J4E6M MU$K156V?'5@".H.I[83KOZ]M.$3 O7O!WO7LS*RQG0Z,/XL:0#HO+>U$YM92 M]GN$1%%#2\0#ZZ%3*Q7C+9$JY!@ZD-$4M1=CS8M22IG/SU.1./$_95=*F M@Q-WQ+5M"?][ ,J&S/7=U\13@*<"/!?XX9L%P500K K0 MZ,RT^HE(DJ><#0X??U9/])GP]X':S$(GS=Z9-=6M4-E;CN,D13=--&$.(P8O M,?>(HP41S1"D#,PNL-4%-O7!G8M'.T%@)0@,07A'L%N9'#&)P70&L_N/1FC5 M"+<:B;?2&#'10@.'@5TDLHI$&Y%=M-*(-AI!Z-LU8JM&;&G$7_WS>+-9ZU;C MC8T/ ;;;2*PV$HN-U<$Z)._:V"(";[>R@1:W0;].WPF_-)UPSDRJBV6.?\68 M!,7G/:B.:O4@S@&%2NIIHN9\?!;&0+)^>O'0_.SF_P!02P,$% @ 6X*L M2D0A"E+G @ [0P !D !X;"]W;W)K&ULE5== M;YLP%/TKB/<5;#[L5$FD-=.T29L4=>KV["9.@@J882?I_OULH"C8EX2\!&S. MO3[WQ,HQ".3FP LF'T3%2_UE)^J"*=VL]X&L M:LZV35"1!S@,TZ!@6>DOYTW?NE[.Q5'E6/1<'J?T\\%^>%C_R/CN=L M?U"F(UC.*[;GO[AZJ=:U;@5]EFU6\%)FHO1JOEOXG]'C"A,3T"!^9_PL+]X] M4\JK$&^F\7V[\$/#B.=\HTP*IA\GON)Y;C)I'G^[I'X_I@F\?/_(_K4I7A?S MRB1?B?Q/ME6'A4]];\MW[)BK9W'^QKN"$M_KJO_!3SS7<,-$C[$1N6Q^O(RWFQG0VVC7?=+52]YZ6F$3SX&02=9BG%H,O,4/$"D D/230 M!'H6&&2!F_AHP"*&$T1@@JA)$ \2)%89+88TF++%I$EL50* :$A@*C%()0:H MI!:5%I-QPR()""1!"!"+"*).PBBD34!5B JH3"9%"23 F2H129U MAB'1S*+B8F@Z\O<0D @!B,S@!!1,0*?/U1F88#9AKLZ<,I'CR]4-T( *"F'[ MARX9&HZD&%E!T'1!$&Q_A"=(TH$NRTUFU%Z(KH.&9."E! %K"44C*> E ,5W M2 *;%T'N=21QC8E"VS$W0$,RL'D1X-ZQM0C!MD/D#DE@XR$Z11+J5!NCQ);$ M!27IV"R!38P %],1[V'8>SB<+@F&O8?1!$DZT& "I/9N(0CL/ SM>(X@ MQ#WW$%N0JYB62G!Q[C07@9^LWF>E]%Z%TD?8YJ"Y$T)QG2]\T/(<]-VC;^1\ MI\PKT>]U>P!O&TI4W>4BZ&\XR_]02P,$% @ 6X*L2I.P; &M 0 T , M !D !X;"]W;W)K&UL?5-=;^,@$/PK%N]7$CMM MHLBVU*:J>M*=%/5T[3.QUS$J'RZ0N/?O;\'$R-[D#A2J.-9 Y+Y/8DY3,_'L H?N"+,FE\<*/K?,-6N8=.\(?<'^[O<&*CBHUEZ L MURHQT!3D?KG=91X? *\<>CN9)S[)0>MW7_RL"[+PAD! Y;P"P^$,.Q#""Z&- MCZA)QBT]<3J_J#^%[)CEP"SLM'CCM6L+LB%)#0T["?>B^V>(>6Y)$L/_@C,( MA'LGN$>EA0W?I#I9IV5402N2?0XC5V'LH_Z%-D]((R$="&PO=V]R M:W-H965TTDV[>O;5A$[$G5&WSZ9^8;;(U=WAA_%0VETGOKNT%L_$;*\3D( MQ*&A/1%/;*2#6CDQWA.IAOP$"*5!3]K!KTHSM^-5R2ZR:P>Z MXYZX]#WA?[:T8[>-C_WWB9?VW$@]$53E2,[T.Y4_QAU7HV#QQZGLZE3UCKWKPY;CQD2:B'3U([8*HYDIKVG7:D^+X M/3OUEYC:<-U_]_[))*^2V1-!:];]:H^RV?BY[QWIB5PZ^<)NG^F<4.)[<_9? MZ95V2JY)5(P#ZX3Y>H>+D*R?O2B4GKQ-;3N8]C:M)-EL!AN$LT&X&.#XGP;1 M;!!9!L%$9E+]2"2I2LYN'I]V:R3Z4.#G2/W,@YXT_\ZLJ6R%FKU689Z7P54[ MFC7;21.N-?>*&E DBR10 M%"%*$QCZZHRA@!Q'H(#(.XK6# EEI3)K,:(9) MDQ96(JX&)P@&B4&0& #!%LBD2=8@R 9Q-0\P$A C 3"L3=LF3HC$(JU=29S! M&"F(D0(8D861.C%P9FEJ0(-3&"0#03( )+9 LO\ <35A%,(@.0B2 R")!9*[ M(%%J@4 :#(,4($@!@%A!MH5[0BP,5X$?G%.,X/J# ([,+D#(#9/;)0C0/#@B M^$$IQ "*4PNQ$\;>&D#R8&R;5M6,NAQ-CDBJ'Z$EEU:CWPC+HZ$GJ;J;Z?+HTIX%DX_P@")97 M2?474$L#!!0 ( %N"K$JRXHE=]@, ,$5 9 >&PO=V]R:W-H965T MO3G%MS3\%;RR)'L[/X?#C2%Q?J_I[=ELPE/;GI^B MJ-F=7)$V'ZNS*[M_#E5=I&WW6!^CYER[=#]T*O*(XG@1%6E6AMOUT/9:;]?5 MI&K[AFB[/J=']X=KOYU?Z^XINGG9 M9X4KFZPJ@]H=-N&S>GJQU'<8+/[,W+6YNP_Z4-ZJZGO_\.M^$\;]B%SN=FWO M(NTN[^Z3R_/>4S>.OR>GX4VS[WA__]/[ER'X+IBWM'&?JORO;-^>-N$R#/;N MD%[R]FMU_<5- =DPF*+_S;V[O#/O1])I[*J\&7Z#W:5IJV+RT@VE2'^,UZP< MKM?Q'Y-,W7 'FCK0K0.-L8Q"P\@_IVVZ7=?5-:C'R3^G?8[5$W5SL^L;AZD8 M_NL&WW2M[UM:K=;1>^]HLGD9;>C.1MTLHL[[38*0Q NQ[CJ.L0,-QZ@'!_K! M@3 " QV8P8%Y<$"S($>;9+ I!QMKI6%:J&*!BIZIC#;V3N6#,1:K+*#* JB8 MF65WQ^5XML8B*,2 Q MD%G,"8F9#@E3K@0.E4=>)R./Q"J(XK,BC]1.1@^3EDB3AHE5"-E$<(&953[0 M3D://$DZF%J%L&7YY=PJ:>8QMLJ'6^4-KL+D*A]T%6?W@Y8F#;.KEB":Y5QG MR73,RD@!8<85@GPE5!\,,,7^Y8,PG(3@G*]%XG#2*I'&BODDSB>O(<3Y%":5 M,)VD/=;B9/2X"Q )0IAAX@SSY4B<82(KK$?"$)/U+R:$ 24$*,LQ!U2L)X01 M)8XHWV^((RK5$\*$$B*4Y9@3*JE@/(GC"1(,BK!43S1F6".&A26B,SB>?A^/)Z#_S\7#S][0^9F43O%5M6Q7#:=NA MJEK7#2;^V 5[WV7U!+ P04 M" !;@JQ*Y+$*Q!D" #Y!0 &0 'AL+W=O0:M/SEPPHK0I+DAV M LC)!C&*\&J5(4::-BP+ZSN(LN!719L6#B*05\:(^+,#ROMM&(7OCI?F4BOC M0&71D0M\!_6C.PAMH9'EU#!H93O:!J>3(^:LQ MOIRVXM:CD3"GM-?S4G5 MVW =!BG:3K( ^!Z0V.*=,EOJ1Z)(60C>!\)=5D?,/Q%M M8MW,RCAM[^R9KE9J[ZV,HZA -T,T8'8.@R>8.P)I]C$%]J78X44X?DRP7R*R MS)\A]A81V_CXH0CL)TB\!(DE2!X(XED7'":WF-9U(5G/"EEB\.J#7TCJ%9)Z MA"0S(0Z3/B29Z?! _M'0S"LC\\A(9S*R18YH+L,#2?PR2 MSZ]EB<')_%K0Y,4P$!<[7&10\6NKS+\Y\8[SZQF;%S?S[_1<"S>-G*%X-PQ:-$[[\B]0 M2P,$% @ 6X*L2D5-[)75 0 GP0 !D !X;"]W;W)K&UL?53M;ILP%'T5Y >H^8A+&@%22S5MTB9%G;;]=N 24&W,;"=T M;S_;4$2HMS^Q?7W.N> ?XV<&H5O/ M)CD)\6H77^HE2"*?<;5!>E!9]5C!5. MWZ:QZ]TX3COD?J;Y"?%,B!="M/LO(9D)R8: )V[] XA5(G !Q OUD(/R08P*E-Z T];?9>=OL?&WVFS8>T$/ZCS3$VX8X MA=WJ.![(I@GYD(6$9 ,J/2 2AALG>'55[*?[CYN-$)H,(+A MG5%LS6NQ+!@TVDY3,Y?3-S,MM!CFYP O;U+Q%U!+ P04 " !;@JQ*%7S> M=!T$ R%0 &0 'AL+W=OG?:9V.,8%1@72-S^_>$R<6%F34KR$ ->^SJS MUAZS.JOZ1W.4LO5^E475K/UCVYZN@Z#9'669-5?J)*ONFX.JRZSM;NNGH#G5 M,ML/1F41T#",@C++*W^S&IX]U)N5>FZ+O)(/M=<\EV56_[Z1A3JO?>*_/OB: M/QW;_D&P69VR)_FO;/\[/=3=77#QLL]+636YJKQ:'M;^!W)]SWEO,""^Y?+< M3*Z]OI1'I7[T-Y_W:S_L,Y*%W+6]BZS[>)&WLBAZ3UT>/[53_Q*S-YQ>OWJ_ M&XKOBGG,&GFKBN_YOCVN_<3W]O*0/1?M5W6^E[H@X7NZ^B_R118=O,^DB[%3 M13/\]W;/3:M*[:5+IM?]7,VQ M0&]&!#^I@'3!FRI =<&_(]! M\J:!T 9B:81(&T1+#6)M$"\U2+1!8A@$XW(,Z[O-VFRSJM79J\LIZ)I#K MI-M!N_[AL&&&[[HE;KJG+QM&TE7PTCO2F)L10Z<8&LXQMS:&4C''; %FCOAH M(Z)H#KD#3HPXGU"^9(ZY1Y@_V01=SRZ-H[!Q='# 9HU+L ,&';#! 9]EP(PL M1TP\8*H!0\+N#X?A, P'8;@1!F$$#B)@$ $<& NW19@8!XE@D @X2(P@D=4P MX>A6#&/$((9!A^V($?-%P4$2&"2Q@S"#3]L$!#'(DMB;@^,T4IA&"M(P:+)- MK31BH^5WJ95&ZN !";$$A2 1:FI0:(6APM5VXM Z @(Q4Z2(53+GPM0I8F7# MP]21#-8/0D$RW$R&VE5'KJ*QS!"@,\Q29@2*''&PSA @(BR>Q[G5H&D]D5// M"-8: H2$F3J@0=- 9M%W&C-=:55JT+1<>B4T=?,6L88HUY MWF+V@.3.:C%I&")-;,:Q9U]DGB_?QLQ3P>1C8$":6VFK04[FZ&1LU&S#C;_\ M_H::)XWISA#=S3D'08X1QC#;&6"["$V>V8=\YA! AA6!@;$M').?8T7@X?+- MSS'7.>"ZN7I;;G,]3AWZQS'5.:"Z<#2,8ZKS=U"=.WYS ZH+<]]#D%EM,'F/ MT[]-_">KG_*J\1Y5VZIR>'%S4*J5G&ULC53;CILP$/T5Q ?$W,E&@-1-5+52*T5; MM7UV8 AH;4QM)VS_OK8AB!!KNR_X=LZ9,V,\V<#XJV@ I/-&22=RMY&RWR$D MR@8H%AO60Z=.:L8IEFK)STCT''!E2)2@P/,21'';N45F]HZ\R-A%DK:#(W?$ MA5+,_SX#84/N^NYMXZ4]-U)OH"+K\1E^@/S9'[E:H5FE:BETHF6=PZ'.W4_^ M[I!JO '\:F$0B[FC,SDQ]JH77ZO<];0A(%!*K8#5<(4]$**%E(T_DZ8[A]3$ MY?RF_MGDKG(Y80%[1GZWE6QR=^LZ%=3X0N0+&[[ E$_L.E/RW^ *1,&U$Q6C M9$28KU->A&1T4E%6*'X;Q[8SXS#IWVAV0C 1@IG@1^\2PHD0?I00381H14!C M*J8V!RQQD7$V.'R\W1[KG\C?1:KZI=XTQ39GJCQ"[5Z+,$XR=-5"$^9YQ 0+ M3'"/V#\BDI7(X1$2!OZ,096 422Y9/JPL=,?$BR\1;W>B[D#L;J=5& M:BE$M+(Q8K:+&.GF:74C^T=0L(E7_]_A/Z#1+UJ\"=W4OF-^;COAG)A4S\L\ M@IHQ"4K0VZC,&]5'YP6!6NIIJN9\[";C0K)^:I1H[M;%/U!+ P04 " !; M@JQ*14_;F,(" !'"P &0 'AL+W=OOUMP$!T29S:!JYO7]L)N9!L4/AS MB'9\ YM?)W8GE5+[PDA7ZDP,7.55Z*8Z> M+ 6C>UN49Q[V_5I07;"$>>\YR*?RN6\>O<1>YMXS4] MGI39\!9)28_L%U._RXW0*Z]AV:PP]Q=HMD:$U-@$6\IN\K6NV-: MV7+^;A;?]W/7-XI8QG;*4%#]N+ URS+#I'7\K4G=YDQ3V'Z_L7^US>MFME2R M-<_^I'MUFKL3U]FS SUGZI5?O[&ZH=!UZNY_L O+--PHT6?L>";M7V=WEHKG M-8N6DM./ZID6]GFM^6]E< &N"W!3H,]^5$#J O)9$-CF*V6VU2]4T44B^-41 MU6V5U/Q3H!G19N[,IO7.?J:[E7KWLB"1GW@70U1C5A4&MS"H07B:O3D"0T>L M<*\"O00$K1"#-JT$,W ,R0'0A,\Q)A M0$HX0 ''%3V15P0'%HU); UJ-^MW_7@$N1<"YQ7U TN&OKP0'#44/6$''#84 M RKBKAUQK]<)Z?K1QR _'M "YQ9!P9T,4,"90]/QCF X=-@?X4@-:G<;=AT! M,/& (1@.+X;".QV@@$.'\1.&P*'#9(PAI/<#1KJ1>8RII'BM\2-GXF@G->GL M^+E0YH>^M=M,@TMLQI?._DI/B=5,]TE3C9@_J3BFA72V7.GAR(XP!\X5TQ+] M%WU;)SW5-HN,'91YC?6[J$:[:J%X68^M7C,[+_X#4$L#!!0 ( %N"K$H@ M#$'[MP( /8) 9 >&PO=V]R:W-H965TTDV[^O;1P6S)#N2["=,W/. M#,-X%C?*7OF9$.&\567-E^Y9B&;N^WQ_)A7F'FU(+?\Y4E9A(;?LY/.&$7S0 M1E7IAT&0^!4N:G>UT&=/;+6@%U$6-7EB#K]4%69_-Z2DMZ6+W/O!E0/V.!5PM&;PYKWU:# M55&@>223N5>'.G?Z/QDMEZ?7590&"_^J'!G,IL6$/0SJ$+[TWE&$$,4F')F' M0X+M&)$D,$,$!A%I^V@0Q(3$&>A@IAW,!@XLD9L6$VM,W68ARE,K$@"$\@R6 M$H-28D!*9$F)1RP!3)& % E ,;,HDA'%IXF,IB!'"G#$%D?ZT3 RD"(#*!*+ M(H->F@7: J#)EY:#4G) BE4:FQQ@":V4;,>@+)WX%% ?] !H"6SO^@6E WR MXL5V-4.PV$O2"4$3'08!@G);$'I0"T;,(\A0"-B'UB@<"\E&O:X%Y?W"#[S< M[E@&]A$Q<,M"$2 &V6*B_V?E$60H!&Y]".A]F=W[#"BWZB6SQ0"P!_4"-T $ M=,#,[H &-*C,Q(M'KVD,"P,OF5F"_-YM61%VTH,%=_;T4@MU+_5.N^%E':K; MUCK?J*%&W\+O;MJ)Z =FIZ+FSHX*>9?K&_=(J2!29>!)E6&PO=V]R:W-H965TC8K7< MN(52S1HAF1>T(G+!&UKK-R1[7H0J4M9NEMJ]O./)2543\W5'&VXV+W=O&:WDNE-E 6=J0,_U)U5NS%WJ%!I5C6=%: MEKQV!#UMW"U>[W!@'*S%KY*VW]2_V.1U,@B(7IEYY^Y7V"86N MTV?_G5XIT^8F$LW(.9/VZ>07J7C5J^A0*O+1C65MQ[;7O[G!#G[OX \.@75 M';]BCL.QV\U+O7+$B6*;H:H=YFU]GX M(QL\6""M/B!\"+'S9^Y!$L(" 1AC8 6".X$(%EB" DLKL+P3B"=)=C:AM:D[ MF^!!E"$("0%(,H&$,X@'(R(0$0&(U001S1"?HB4,B4%(/(>LO DD?C:/!$0D M )/$,D,X<<\>&'Y0IAB@ MS.JT,UK=I1,\J!0,%NL6^P HG(+\I].!*QH' "6:4@+HZTS_933J=!459]OC MI9/S2VTOF-'N<(]L?=LI_YMWE] /(LYE+9T#5[K?VJYXXEQ1'8RWT,D6^MX; M%HR>E)G&>BZZYM\M%&_ZBPT-MVOV#U!+ P04 " !;@JQ*%')#KO7[/3K#S7JHW70.8 MX%WP5A=A;4RW)T17-0BF5[*#UIYX4L+,/$IS0*-H2P9HV+'/O M.ZHRES?#FQ:.*M W(9CZ
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end XML 62 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 135 250 1 false 51 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://acurapharm.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://acurapharm.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://acurapharm.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://acurapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 105 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://acurapharm.com/role/ConsolidatedStatementOfStockholdersEquity CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://acurapharm.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 107 - Disclosure - OPERATIONS Sheet http://acurapharm.com/role/Operations OPERATIONS Notes 7 false false R8.htm 108 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://acurapharm.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 8 false false R9.htm 109 - Disclosure - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS Sheet http://acurapharm.com/role/LicenseDevelopmentAndCommercializationAgreements LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS Notes 9 false false R10.htm 110 - Disclosure - REVENUE RECOGNITION Sheet http://acurapharm.com/role/RevenueRecognition REVENUE RECOGNITION Notes 10 false false R11.htm 111 - Disclosure - RESEARCH AND DEVELOPMENT ACTIVITIES Sheet http://acurapharm.com/role/ResearchAndDevelopmentActivities RESEARCH AND DEVELOPMENT ACTIVITIES Notes 11 false false R12.htm 112 - Disclosure - INVENTORIES Sheet http://acurapharm.com/role/Inventories INVENTORIES Notes 12 false false R13.htm 113 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://acurapharm.com/role/PropertyPlantAndEquipment PROPERTY, PLANT AND EQUIPMENT Notes 13 false false R14.htm 114 - Disclosure - ACCRUED EXPENSES Sheet http://acurapharm.com/role/AccruedExpenses ACCRUED EXPENSES Notes 14 false false R15.htm 115 - Disclosure - DEBT Sheet http://acurapharm.com/role/Debt DEBT Notes 15 false false R16.htm 116 - Disclosure - COMMON STOCK WARRANTS Sheet http://acurapharm.com/role/CommonStockWarrants COMMON STOCK WARRANTS Notes 16 false false R17.htm 117 - Disclosure - SHARE-BASED COMPENSATION Sheet http://acurapharm.com/role/SharebasedCompensation SHARE-BASED COMPENSATION Notes 17 false false R18.htm 118 - Disclosure - INCOME TAXES Sheet http://acurapharm.com/role/IncomeTaxes INCOME TAXES Notes 18 false false R19.htm 119 - Disclosure - EARNINGS PER SHARE ("EPS") Sheet http://acurapharm.com/role/EarningsPerShareEps EARNINGS PER SHARE ("EPS") Notes 19 false false R20.htm 120 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://acurapharm.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 121 - Disclosure - INVENTORIES (Tables) Sheet http://acurapharm.com/role/InventoriesTables INVENTORIES (Tables) Tables http://acurapharm.com/role/Inventories 21 false false R22.htm 122 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://acurapharm.com/role/PropertyPlantAndEquipmentTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://acurapharm.com/role/PropertyPlantAndEquipment 22 false false R23.htm 123 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://acurapharm.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://acurapharm.com/role/AccruedExpenses 23 false false R24.htm 124 - Disclosure - DEBT (Tables) Sheet http://acurapharm.com/role/DebtTables DEBT (Tables) Tables http://acurapharm.com/role/Debt 24 false false R25.htm 125 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://acurapharm.com/role/SharebasedCompensationTables SHARE-BASED COMPENSATION (Tables) Tables http://acurapharm.com/role/SharebasedCompensation 25 false false R26.htm 126 - Disclosure - EARNINGS PER SHARE ("EPS") (Tables) Sheet http://acurapharm.com/role/EarningsPerShareEpsTables EARNINGS PER SHARE ("EPS") (Tables) Tables http://acurapharm.com/role/EarningsPerShareEps 26 false false R27.htm 127 - Disclosure - OPERATIONS Additional Information (Detail) Sheet http://acurapharm.com/role/OperationsAdditionalInformationDetail OPERATIONS Additional Information (Detail) Details 27 false false R28.htm 128 - Disclosure - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) Sheet http://acurapharm.com/role/LicenseDevelopmentAndCommercializationAgreementsAdditionalInformationDetail LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) Details 28 false false R29.htm 129 - Disclosure - REVENUE RECOGNITION - Additional Information (Detail) Sheet http://acurapharm.com/role/RevenueRecognitionAdditionalInformationDetail REVENUE RECOGNITION - Additional Information (Detail) Details 29 false false R30.htm 130 - Disclosure - RESEARCH AND DEVELOPMENT ACTIVITIES - Additional Information (Detail) Sheet http://acurapharm.com/role/ResearchAndDevelopmentActivitiesAdditionalInformationDetail RESEARCH AND DEVELOPMENT ACTIVITIES - Additional Information (Detail) Details 30 false false R31.htm 131 - Disclosure - INVENTORIES - Schedule of Inventories (Detail) Sheet http://acurapharm.com/role/InventoriesScheduleOfInventoriesDetail INVENTORIES - Schedule of Inventories (Detail) Details 31 false false R32.htm 132 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Detail) Sheet http://acurapharm.com/role/PropertyPlantAndEquipmentDetail PROPERTY, PLANT AND EQUIPMENT (Detail) Details http://acurapharm.com/role/PropertyPlantAndEquipmentTables 32 false false R33.htm 133 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Additional Information (Detail) Sheet http://acurapharm.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail PROPERTY, PLANT AND EQUIPMENT - Additional Information (Detail) Details 33 false false R34.htm 134 - Disclosure - ACCRUED EXPENSES (Detail) Sheet http://acurapharm.com/role/AccruedExpensesDetail ACCRUED EXPENSES (Detail) Details http://acurapharm.com/role/AccruedExpensesTables 34 false false R35.htm 135 - Disclosure - DEBT - Summary of Debt (Detail) Sheet http://acurapharm.com/role/DebtSummaryOfDebtDetail DEBT - Summary of Debt (Detail) Details 35 false false R36.htm 136 - Disclosure - DEBT - Interest Expense (Detail) Sheet http://acurapharm.com/role/DebtInterestExpenseDetail DEBT - Interest Expense (Detail) Details 36 false false R37.htm 137 - Disclosure - DEBT - Long-Term Debt (Detail) Sheet http://acurapharm.com/role/DebtLongtermDebtDetail DEBT - Long-Term Debt (Detail) Details 37 false false R38.htm 138 - Disclosure - DEBT - Additional Information (Detail) Sheet http://acurapharm.com/role/DebtAdditionalInformationDetail DEBT - Additional Information (Detail) Details 38 false false R39.htm 139 - Disclosure - COMMON STOCK WARRANTS - Additional Information (Detail) Sheet http://acurapharm.com/role/CommonStockWarrantsAdditionalInformationDetail COMMON STOCK WARRANTS - Additional Information (Detail) Details 39 false false R40.htm 140 - Disclosure - SHARE-BASED COMPENSATION -Recognition of Share-Based Compensation Expense (Detail) Sheet http://acurapharm.com/role/SharebasedCompensationRecognitionOfSharebasedCompensationExpenseDetail SHARE-BASED COMPENSATION -Recognition of Share-Based Compensation Expense (Detail) Details 40 false false R41.htm 141 - Disclosure - SHARE-BASED COMPENSATION - Stock Option Award Activity (Detail) Sheet http://acurapharm.com/role/SharebasedCompensationStockOptionAwardActivityDetail SHARE-BASED COMPENSATION - Stock Option Award Activity (Detail) Details 41 false false R42.htm 142 - Disclosure - SHARE-BASED COMPENSATION - Summary of Information about Non Vested Stock Options (Detail) Sheet http://acurapharm.com/role/SharebasedCompensationSummaryOfInformationAboutNonVestedStockOptionsDetail SHARE-BASED COMPENSATION - Summary of Information about Non Vested Stock Options (Detail) Details 42 false false R43.htm 143 - Disclosure - SHARE-BASED COMPENSATION - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) Sheet http://acurapharm.com/role/SharebasedCompensationAssumptionsUsedInBlackscholesModelToDetermineFairValueForStockOptionAwardsGrantedDetail SHARE-BASED COMPENSATION - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) Details 43 false false R44.htm 144 - Disclosure - SHARE-BASED COMPENSATION - Summary of RSU Plan (Detail) Sheet http://acurapharm.com/role/SharebasedCompensationSummaryOfRsuPlanDetail SHARE-BASED COMPENSATION - Summary of RSU Plan (Detail) Details 44 false false R45.htm 145 - Disclosure - SHARE-BASED COMPENSATION - Additional Information (Detail) Sheet http://acurapharm.com/role/SharebasedCompensationAdditionalInformationDetail SHARE-BASED COMPENSATION - Additional Information (Detail) Details 45 false false R46.htm 146 - Disclosure - INCOME TAXES - Additional Information (Detail) Sheet http://acurapharm.com/role/IncomeTaxesAdditionalInformationDetail INCOME TAXES - Additional Information (Detail) Details 46 false false R47.htm 147 - Disclosure - EARNINGS PER SHARE ("EPS") - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) Sheet http://acurapharm.com/role/EarningsPerShareEpsReconciliationOfNumeratorsAndDenominatorsOfBasicAndDilutedEpsDetail EARNINGS PER SHARE ("EPS") - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) Details http://acurapharm.com/role/EarningsPerShareEpsTables 47 false false R48.htm 148 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) Sheet http://acurapharm.com/role/CommitmentsAndContingenciesAdditionalInformationDetail COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) Details 48 false false All Reports Book All Reports acur-20170331.xml acur-20170331.xsd acur-20170331_cal.xml acur-20170331_def.xml acur-20170331_lab.xml acur-20170331_pre.xml true true ZIP 67 0001144204-17-026909-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-026909-xbrl.zip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
N8[7+IXWSC?T_A>))>!:'0A1LO##.7^P<(&]$BLF_B"&U%I^^ Q$>6O.FS M6);V3H[=/PS8%8U5B+8"MMV;UXIW,]P6F7!="K;2ROK@K"<&E-M MZ8,A8!K1UG;TX_V!5>:G/*-7E"U?.+QE,@]L:3T04T\6D02V$,)S@YYL@"V8%@X\L MR\+20%Z.(]DJA-?B(N^))5AS 5)BM16!;/>X>#8>)SEW14TS[G0*^)>]3L^A M<.;FB\-]$K\%L/_XLOB6LLEU MM#X\G8VSX*V(ABXW9CG\;/E+GM1'O;C;^0 (G$2V"DP5Q(IC$[NEB!/W!]=F MB7A/3DG<+]MD%-69;=B6HEDFZ\.4ZR2]9Y/_RM/RQ,=S*(YC..R%; ,YSQVF M)6>-*:B+SP$S)*[-NU?([J1G*0:(@N7_@D&?QT')?C0YF\=)%ORK^*?4FHO6 M @F1>+6B._8QVZY")):BDCH)>REDP-,*7\7)HQ_RRXTL3R+44(>5]T:?:>R1 M=\6^CC1(Q#MUF>-!=HH25@!).@T =35'R*1!(>+*TB:I,O7=3:^""'9L("IN MWN9VV(S].+(K!D0"PEKZ4Y7J48RLA541F'QVA3 -= =S0*>:"]-F<%L MM%W1._U,(G6VVSE(+!5;T6H4U$N?\:9'ZH81'2;P0&( G#XZY5RU1" MMH+FW.^[Z\C/QN4V$,3.@C>%+X!.=1 9B?G*E&1=5<$0MPZ5VYR,[.ZAZS#. MXQ (CDM;Z0-[8U'.I#K0J!UO-#HF8>IKIPUML+<.J]NM7CS$"S_,%DU4H5;5 M&QWLD3A$=<(^!K=UG)X5PCM<+[@CXG7TQLHENURCFR\?\M: CP','ZT%T#KF MC[1. M6**TQC1K$ 1+PE+/SSK*N=SHB<9?9]6%G ZZM MJ$:BQV&^'M\$_G,08O<))M5!9"2<^SK>P-00#R?,4;080Z]@O[8<%?+X5YWJ M(+)!VTPPQ,.)6!1(CB^JYWF2% ZUS:83I T0WJ /15+8MN(:NWO!? -+Q=EG M!66A;U(1U?9&!S3\A3NQJD@0MXYI)+0K;>?:VEE( @PQ$L?HG;BBMY:3K0=6 MLQC&"D5U+,U2'4;*&'X Q$["*=!*I$PC[+:><:7@+0$"&3,V2?D3E'S:/XLF M7_V,7_4O[J::KEV-VP)QDKB:L*D<8O5K*!I;;\Q2U+2[*?P$A)@M^+MF&4B$ MI]-^Y2/:0,O7FJIV'I$MHN'(VI@5H9W=-,NJ<+WK23.]=UI M@:8($,J-W8M)3";E$XGI4WPV!LU.6*.Y1+L1[W2/A(EY!S.)H4P0I=*W0],_ M#VI*M[.--PCZ#[*,V9 3HI#F-F^JY\%U%$E7YT'##X#825C"K)P'&V%'5*Z' M%O0']KJ<_^^F%^Q9ICS;1?F^DH0>V&16K#L(=$0-](WB])="32%V-N=XI_N4 M]V$6=AXL$U8( M]B2U78AJEF[3)M_6],C?Q19>1$?ZE7M8?!H^R\[])%G 4/K5#W-S>\%6?2XP M]W.$!HL'4>&-5\_6;8,D'_/YW$\6 M=]/'8!8%TV#,/4'*H$2^'XW#8/,I)=5VS/J'O-.C?5>KQ)<\A?U8FE9 \;3" MM5X_ ;U?H!^_2]8)X[8 N%/?MB[I%"\>#45DZ7FA^HD'&>U__<1[_^RGK.#F M_P-02P$"% ,4 " !;@JQ*;3M84&7? L-0X $0 @ $ M 86-U&UL4$L! A0#% @ 6X*L2C02_)?U10 080$ !4 M ( !PO\ &%C=7(M,C Q-S S,S%?9&5F+GAM;%!+ 0(4 Q0 M ( %N"K$K%\M#@SVT '+K!0 5 " >I% 0!A8W5R+3(P M,3&UL4$L%!@ & - 8 B@$ !T! @ $! end